EP2619178A1 - Composés de benzamide substitués - Google Patents
Composés de benzamide substituésInfo
- Publication number
- EP2619178A1 EP2619178A1 EP11761012.1A EP11761012A EP2619178A1 EP 2619178 A1 EP2619178 A1 EP 2619178A1 EP 11761012 A EP11761012 A EP 11761012A EP 2619178 A1 EP2619178 A1 EP 2619178A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- methyl
- carboxylic acid
- dihydro
- acid amide
- piperidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003936 benzamides Chemical class 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 135
- 208000002193 Pain Diseases 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 19
- -1 benzamide compound Chemical class 0.000 claims description 526
- 125000003118 aryl group Chemical group 0.000 claims description 203
- 125000001072 heteroaryl group Chemical group 0.000 claims description 166
- 125000000217 alkyl group Chemical group 0.000 claims description 144
- 125000001424 substituent group Chemical group 0.000 claims description 122
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 114
- 229910052731 fluorine Inorganic materials 0.000 claims description 109
- 229910052801 chlorine Inorganic materials 0.000 claims description 93
- 125000000623 heterocyclic group Chemical group 0.000 claims description 78
- 125000003541 2-chlorobenzoyl group Chemical group ClC1=C(C(=O)*)C=CC=C1 0.000 claims description 73
- 125000004076 pyridyl group Chemical group 0.000 claims description 69
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 68
- 150000003254 radicals Chemical class 0.000 claims description 66
- 125000002947 alkylene group Chemical group 0.000 claims description 61
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 60
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 59
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 58
- 229910052799 carbon Inorganic materials 0.000 claims description 50
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 46
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 44
- 125000001544 thienyl group Chemical group 0.000 claims description 40
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 38
- 125000005842 heteroatom Chemical group 0.000 claims description 38
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 36
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 36
- 229910052717 sulfur Inorganic materials 0.000 claims description 36
- GBPWDYCNVWWKRQ-UHFFFAOYSA-N 2,3-dihydro-1h-indene-5-carboxamide Chemical compound NC(=O)C1=CC=C2CCCC2=C1 GBPWDYCNVWWKRQ-UHFFFAOYSA-N 0.000 claims description 35
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 34
- 229910052794 bromium Inorganic materials 0.000 claims description 33
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 33
- 229910052740 iodine Inorganic materials 0.000 claims description 32
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 30
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims description 28
- 229920006395 saturated elastomer Polymers 0.000 claims description 28
- 125000003386 piperidinyl group Chemical group 0.000 claims description 27
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 25
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 125000001624 naphthyl group Chemical group 0.000 claims description 23
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 claims description 21
- 125000002971 oxazolyl group Chemical group 0.000 claims description 20
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 19
- 125000002541 furyl group Chemical group 0.000 claims description 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 17
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 17
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 16
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 16
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 15
- 125000002883 imidazolyl group Chemical group 0.000 claims description 14
- 125000002393 azetidinyl group Chemical group 0.000 claims description 13
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 13
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 12
- MTPBUCCXRGSDCR-UHFFFAOYSA-N 4-piperidin-1-ylpyridine Chemical compound C1CCCCN1C1=CC=NC=C1 MTPBUCCXRGSDCR-UHFFFAOYSA-N 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 12
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 claims description 11
- 150000007513 acids Chemical class 0.000 claims description 11
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 11
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 11
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 10
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 10
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000003566 oxetanyl group Chemical group 0.000 claims description 10
- 230000036961 partial effect Effects 0.000 claims description 9
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 9
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 9
- 125000006591 (C2-C6) alkynylene group Chemical group 0.000 claims description 8
- 125000004450 alkenylene group Chemical group 0.000 claims description 8
- 150000001721 carbon Chemical group 0.000 claims description 8
- 125000004639 dihydroindenyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 8
- VTXNOVCTHUBABW-UHFFFAOYSA-N 3,4-dichlorobenzoyl chloride Chemical group ClC(=O)C1=CC=C(Cl)C(Cl)=C1 VTXNOVCTHUBABW-UHFFFAOYSA-N 0.000 claims description 7
- AHFINSWGYAZBOZ-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)benzaldehyde Chemical group FC(F)(F)C1=CC(Cl)=CC=C1C=O AHFINSWGYAZBOZ-UHFFFAOYSA-N 0.000 claims description 7
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000004296 neuralgia Diseases 0.000 claims description 6
- 208000021722 neuropathic pain Diseases 0.000 claims description 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 6
- 125000004306 triazinyl group Chemical group 0.000 claims description 6
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 claims description 5
- UAIUMFLFYLWSNO-UHFFFAOYSA-N 1h-indene-5-carboxamide Chemical compound NC(=O)C1=CC=C2CC=CC2=C1 UAIUMFLFYLWSNO-UHFFFAOYSA-N 0.000 claims description 5
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 5
- 208000000094 Chronic Pain Diseases 0.000 claims description 5
- SVSARCCKBMZNMR-UHFFFAOYSA-N [1-[2-[methyl-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethyl]amino]ethyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1CCN(C)CCN1C=CC(=C[NH+]=O)C=C1 SVSARCCKBMZNMR-UHFFFAOYSA-N 0.000 claims description 5
- 208000005298 acute pain Diseases 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 208000009935 visceral pain Diseases 0.000 claims description 5
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims description 4
- YUPOPBYNJTYUOI-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)CCC1CCCC1 YUPOPBYNJTYUOI-UHFFFAOYSA-N 0.000 claims description 4
- VPYJGTUJIVOFHA-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 VPYJGTUJIVOFHA-UHFFFAOYSA-N 0.000 claims description 4
- SGWCWWAMPTUFTG-UHFFFAOYSA-N 3-[(2-chloro-5-fluorobenzoyl)-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(F)=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 SGWCWWAMPTUFTG-UHFFFAOYSA-N 0.000 claims description 4
- QTTNOSISMSVCTH-UHFFFAOYSA-N 3-[(2-chloro-5-fluorobenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(F)=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QTTNOSISMSVCTH-UHFFFAOYSA-N 0.000 claims description 4
- SMDMKGOJQWGIAJ-UHFFFAOYSA-N 3-[(2-chloro-5-fluorobenzoyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=C(F)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 SMDMKGOJQWGIAJ-UHFFFAOYSA-N 0.000 claims description 4
- YJYKJHVFMAYIEV-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)NC1C2=CC(C(=O)NCCC3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 YJYKJHVFMAYIEV-UHFFFAOYSA-N 0.000 claims description 4
- ZYCGURFIKOWOQS-UHFFFAOYSA-N 3-[3-cyclopentylpropanoyl(methyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CCCC1CCC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 ZYCGURFIKOWOQS-UHFFFAOYSA-N 0.000 claims description 4
- CCBRGKKCNSPDOY-UHFFFAOYSA-N 3-[[(2-chlorophenyl)-methylcarbamoyl]amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)N(C)C=3C(=CC=CC=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CCBRGKKCNSPDOY-UHFFFAOYSA-N 0.000 claims description 4
- KOYPFWMYQMTJCU-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 KOYPFWMYQMTJCU-UHFFFAOYSA-N 0.000 claims description 4
- GNFULHUTXRGZMM-UHFFFAOYSA-N 3-[cyclohexanecarbonyl(methyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CCCCC1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GNFULHUTXRGZMM-UHFFFAOYSA-N 0.000 claims description 4
- HJOYCKSREQBCRX-UHFFFAOYSA-N 4-[[(2-chlorophenyl)-methylcarbamoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)N(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HJOYCKSREQBCRX-UHFFFAOYSA-N 0.000 claims description 4
- UHESWPDHELSNPU-UHFFFAOYSA-N 8-[[(2-chlorophenyl)-methylcarbamoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)N(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 UHESWPDHELSNPU-UHFFFAOYSA-N 0.000 claims description 4
- MZTIJRCVZQISLM-UHFFFAOYSA-N 8-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MZTIJRCVZQISLM-UHFFFAOYSA-N 0.000 claims description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- 208000008589 Obesity Diseases 0.000 claims description 4
- 206010040070 Septic Shock Diseases 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000005872 benzooxazolyl group Chemical group 0.000 claims description 4
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- DCUKGWQCEQHVRY-UHFFFAOYSA-N n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-3-(3-methylbutanoylamino)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC=CC2=CC(N3CCC(CC3)N(C)C(=O)C3=CC=C4CCC(C4=C3)NC(=O)CC(C)C)=CC=C21 DCUKGWQCEQHVRY-UHFFFAOYSA-N 0.000 claims description 4
- FWOSBZWYYKOLCM-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 FWOSBZWYYKOLCM-UHFFFAOYSA-N 0.000 claims description 4
- HJEGKMAPRDTTJT-UHFFFAOYSA-N n-methyl-4-(3-methylbutanoylamino)-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C1=C2C(NC(=O)CC(C)C)CCOC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HJEGKMAPRDTTJT-UHFFFAOYSA-N 0.000 claims description 4
- KHBCJGVLHXOIPO-UHFFFAOYSA-N n-methyl-8-(3-methylbutanoylamino)-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C1=C2C(NC(=O)CC(C)C)CCCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 KHBCJGVLHXOIPO-UHFFFAOYSA-N 0.000 claims description 4
- 235000020824 obesity Nutrition 0.000 claims description 4
- 230000036303 septic shock Effects 0.000 claims description 4
- 125000006564 (C4-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 125000006128 2-methylpropyl sulfonyl group Chemical group 0.000 claims description 3
- DOXKTPUCPBPEGS-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 DOXKTPUCPBPEGS-UHFFFAOYSA-N 0.000 claims description 3
- MZKYTVKTDBUKEM-UHFFFAOYSA-N 3-[cyclohexanecarbonyl(methyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CCCCC1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 MZKYTVKTDBUKEM-UHFFFAOYSA-N 0.000 claims description 3
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 208000025747 Rheumatic disease Diseases 0.000 claims description 3
- 125000005509 dibenzothiophenyl group Chemical group 0.000 claims description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 3
- WSOGLQYSJSVTIC-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-[methyl(3-methylbutanoyl)amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)CC(C)C)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 WSOGLQYSJSVTIC-UHFFFAOYSA-N 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 3
- YGMFENDCWBRPJM-AREMUKBSSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C)CCC1N1CCC(NC(=O)C=2C=C3CC[C@H](C3=CC=2)N2C(C3=C(Cl)C=CC=C3C2)=O)CC1 YGMFENDCWBRPJM-AREMUKBSSA-N 0.000 claims description 2
- JBCMXSGHBZCVKM-CLCZQPDDSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-[(1s,3r)-3-(4-methylpiperazin-1-yl)cyclohexyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound N1([C@@H]2CCC[C@@H](C2)N(C)C(=O)C=2C=C3CC[C@H](C3=CC=2)N2C(C3=C(Cl)C=CC=C3C2)=O)CCN(C)CC1 JBCMXSGHBZCVKM-CLCZQPDDSA-N 0.000 claims description 2
- ZMPVPUXGKKLFCZ-HHHXNRCGSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-[1-(pyridin-4-ylmethyl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2)N3C(C4=C(Cl)C=CC=C4C3)=O)CC1=CC=2C(=O)N(C)C(CC1)CCN1CC1=CC=NC=C1 ZMPVPUXGKKLFCZ-HHHXNRCGSA-N 0.000 claims description 2
- FAZLPVJAKFZIEW-SSEXGKCCSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-[1-[(2-pyrrolidin-1-ylpyridin-4-yl)methyl]piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2)N3C(C4=C(Cl)C=CC=C4C3)=O)CC1=CC=2C(=O)N(C)C(CC1)CCN1CC(C=1)=CC=NC=1N1CCCC1 FAZLPVJAKFZIEW-SSEXGKCCSA-N 0.000 claims description 2
- CVPMJNWXMJDPCY-MUUNZHRXSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-[[1-(2-methylpyridin-4-yl)piperidin-4-yl]methyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2)N3C(C4=C(Cl)C=CC=C4C3)=O)CC1=CC=2C(=O)N(C)CC(CC1)CCN1C1=CC=NC(C)=C1 CVPMJNWXMJDPCY-MUUNZHRXSA-N 0.000 claims description 2
- IOMREKYGIJDXTB-RUZDIDTESA-N (1r)-1-[(2-chlorobenzoyl)amino]-6-fluoro-n-methyl-n-[1-(6-methylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC=1C=1)C=C(F)C=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC=N1 IOMREKYGIJDXTB-RUZDIDTESA-N 0.000 claims description 2
- WXUXAZLZDOXVIG-RUZDIDTESA-N (1r)-1-[(2-chlorophenyl)sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2)NS(=O)(=O)C=3C(=CC=CC=3)Cl)CC1=CC=2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WXUXAZLZDOXVIG-RUZDIDTESA-N 0.000 claims description 2
- SDTIOKXOVKYFKW-HSZRJFAPSA-N (3r)-3-(2,2-dimethylpropanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C(C)(C)C)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SDTIOKXOVKYFKW-HSZRJFAPSA-N 0.000 claims description 2
- XILDCBHYRWOWIA-ZBAATNBSSA-N (3r)-3-(2,3-dihydro-1h-indene-1-carbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C2C3=CC=CC=C3CC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XILDCBHYRWOWIA-ZBAATNBSSA-N 0.000 claims description 2
- YPVBCWPGFKGGRI-COTLDPOVSA-N (3r)-3-(3,4-dimethylpentanoylamino)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)NC(=O)CC(C)C(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 YPVBCWPGFKGGRI-COTLDPOVSA-N 0.000 claims description 2
- XBBCOBUBBVBGBA-HHHXNRCGSA-N (3r)-3-(3-cyclopentylpropanoylamino)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)CCC2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 XBBCOBUBBVBGBA-HHHXNRCGSA-N 0.000 claims description 2
- IGWJHRDGFZYQBE-RUZDIDTESA-N (3r)-3-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-[1-(2-methylpyridin-4-yl)azetidin-3-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](N2C(C3=C(Cl)C=CC=C3C2)=O)CCC1=CC=1)=CC=1C(=O)N(C)C(C1)CN1C1=CC=NC(C)=C1 IGWJHRDGFZYQBE-RUZDIDTESA-N 0.000 claims description 2
- NAPGGHMSWVTCEX-RUZDIDTESA-N (3r)-3-(cyclopentanecarbonylamino)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 NAPGGHMSWVTCEX-RUZDIDTESA-N 0.000 claims description 2
- OBCLUSKGPQIHIF-XMMPIXPASA-N (3r)-3-(cyclopentanecarbonylamino)-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C4CCCC4)CCC3=CC=2)=N1 OBCLUSKGPQIHIF-XMMPIXPASA-N 0.000 claims description 2
- FAOOCCGRNQBTNP-AREMUKBSSA-N (3r)-3-(cyclopentanecarbonylamino)-n-methyl-n-[1-(2-methylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C)=C1 FAOOCCGRNQBTNP-AREMUKBSSA-N 0.000 claims description 2
- YWTOWCNFOUDNOQ-HHHXNRCGSA-N (3r)-3-[(2-chloro-3-fluorobenzoyl)-ethylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=C(F)C=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YWTOWCNFOUDNOQ-HHHXNRCGSA-N 0.000 claims description 2
- VZIQYNCENZXXTP-AREMUKBSSA-N (3r)-3-[(2-chloro-3-fluorobenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C=3C(=C(F)C=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VZIQYNCENZXXTP-AREMUKBSSA-N 0.000 claims description 2
- AUBBPYCBMBZRQR-MUUNZHRXSA-N (3r)-3-[(2-chloro-3-fluorobenzoyl)-propan-2-ylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=C(F)C=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 AUBBPYCBMBZRQR-MUUNZHRXSA-N 0.000 claims description 2
- MBRNHVUHOUNENR-GDLZYMKVSA-N (3r)-3-[(2-chloro-4-fluorobenzoyl)-propan-2-ylamino]-6-fluoro-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC(F)=CC=3)Cl)CC1=CC(F)=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MBRNHVUHOUNENR-GDLZYMKVSA-N 0.000 claims description 2
- JGCAHZBUDRXQDQ-GDLZYMKVSA-N (3r)-3-[(2-chloro-4-fluorobenzoyl)-propan-2-ylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-6-fluoro-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC(F)=CC=3)Cl)CC1=CC(F)=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 JGCAHZBUDRXQDQ-GDLZYMKVSA-N 0.000 claims description 2
- ZAKJGNNZPPJCRN-GDLZYMKVSA-N (3r)-3-[(2-chloro-4-fluorobenzoyl)-propan-2-ylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC(F)=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 ZAKJGNNZPPJCRN-GDLZYMKVSA-N 0.000 claims description 2
- RUNCOXJTIUVHQS-GDLZYMKVSA-N (3r)-3-[(2-chloro-4-fluorobenzoyl)-propan-2-ylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC(F)=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 RUNCOXJTIUVHQS-GDLZYMKVSA-N 0.000 claims description 2
- NRDVXPJDWGLPIX-AREMUKBSSA-N (3r)-3-[(2-chloro-4-fluorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC(F)=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 NRDVXPJDWGLPIX-AREMUKBSSA-N 0.000 claims description 2
- IZPJAAQJUGGBIS-MUUNZHRXSA-N (3r)-3-[(2-chloro-5-fluorobenzoyl)-ethylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=CC=C(F)C=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IZPJAAQJUGGBIS-MUUNZHRXSA-N 0.000 claims description 2
- JXPSDNVFILTNPP-GDLZYMKVSA-N (3r)-3-[(2-chloro-5-fluorobenzoyl)-propan-2-ylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC=C(F)C=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 JXPSDNVFILTNPP-GDLZYMKVSA-N 0.000 claims description 2
- RJDIKVHIECKYTH-AREMUKBSSA-N (3r)-3-[(2-chloro-5-fluorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=C(F)C=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 RJDIKVHIECKYTH-AREMUKBSSA-N 0.000 claims description 2
- NIMUOJKPDCSQNW-HHHXNRCGSA-N (3r)-3-[(2-chloro-6-fluorobenzoyl)-ethylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=CC=CC=3F)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NIMUOJKPDCSQNW-HHHXNRCGSA-N 0.000 claims description 2
- ZORAESJGTNPMAU-RUZDIDTESA-N (3r)-3-[(2-chloro-6-fluorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2F)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 ZORAESJGTNPMAU-RUZDIDTESA-N 0.000 claims description 2
- QNSVLWWQVLLTOZ-RUZDIDTESA-N (3r)-3-[(2-chloro-6-fluorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2F)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QNSVLWWQVLLTOZ-RUZDIDTESA-N 0.000 claims description 2
- CRGJOHJHTQQNNS-SSEXGKCCSA-N (3r)-3-[(2-chlorobenzoyl)-(2-methylpropyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC(C)C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CRGJOHJHTQQNNS-SSEXGKCCSA-N 0.000 claims description 2
- CEKGUYVLPGPZNS-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)-ethylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 CEKGUYVLPGPZNS-MUUNZHRXSA-N 0.000 claims description 2
- CUEPQNONSPRHED-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)-methylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 CUEPQNONSPRHED-HHHXNRCGSA-N 0.000 claims description 2
- FLVUYGCNEUXWIW-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)-methylamino]-n-methyl-n-(1-pyrimidin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=N1 FLVUYGCNEUXWIW-RUZDIDTESA-N 0.000 claims description 2
- CXZVJQQLACUASO-GDLZYMKVSA-N (3r)-3-[(2-chlorobenzoyl)-propan-2-ylamino]-6-fluoro-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC(F)=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CXZVJQQLACUASO-GDLZYMKVSA-N 0.000 claims description 2
- TXBHFHAFXZISRN-GDLZYMKVSA-N (3r)-3-[(2-chlorobenzoyl)-propan-2-ylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 TXBHFHAFXZISRN-GDLZYMKVSA-N 0.000 claims description 2
- YDCXSLDCAAQOQL-SSEXGKCCSA-N (3r)-3-[(2-chlorobenzoyl)-propan-2-ylamino]-n-methyl-n-[1-(6-methyl-2-propan-2-ylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C(C)C)=N1 YDCXSLDCAAQOQL-SSEXGKCCSA-N 0.000 claims description 2
- GLNJCUZTCVOGHP-KDYSTLNUSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[(3s)-1-(1-cyclopropylpiperidin-4-yl)pyrrolidin-3-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N[C@H]1C2=CC(C(=O)N[C@@H]3CN(CC3)C3CCN(CC3)C3CC3)=CC=C2CC1 GLNJCUZTCVOGHP-KDYSTLNUSA-N 0.000 claims description 2
- IGUJXOHPYFTYKV-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-6-fluoro-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C=1C=2)NC(=O)C=3C(=CC=CC=3)Cl)CC=1C=C(F)C=2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 IGUJXOHPYFTYKV-AREMUKBSSA-N 0.000 claims description 2
- KVAKHQNKTYFAHK-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-ethyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(CC)C(CC1)CCN1C1=CC(C)=NC(C)=N1 KVAKHQNKTYFAHK-HHHXNRCGSA-N 0.000 claims description 2
- YUOFLMHFSAZWKM-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 YUOFLMHFSAZWKM-AREMUKBSSA-N 0.000 claims description 2
- JREFXCSIWVUICS-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(4-methoxyphenyl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=CC(OC)=CC=C1N1CCC(N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)CC1 JREFXCSIWVUICS-MUUNZHRXSA-N 0.000 claims description 2
- KJEKSDHNEQINBD-MVXOQVLLSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[2,2-dimethyl-4-(4-methylpiperazin-1-yl)cyclohexyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C)CCN1C1CC(C)(C)C(NC(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)CC1 KJEKSDHNEQINBD-MVXOQVLLSA-N 0.000 claims description 2
- YJYKJHVFMAYIEV-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N[C@H]1C2=CC(C(=O)NCCC3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 YJYKJHVFMAYIEV-HHHXNRCGSA-N 0.000 claims description 2
- LCUBQYZAWPVDEX-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[2-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CC1=NC(C)=CC(N2CCC(CCNC(=O)C=3C=C4[C@H](NC(=O)C=5C(=CC=CC=5)Cl)CCC4=CC=3)CC2)=N1 LCUBQYZAWPVDEX-HHHXNRCGSA-N 0.000 claims description 2
- JOGOSWVURULNFB-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[2-[1-(2-methylpyridin-4-yl)piperidin-4-yl]ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC(C)=CC(N2CCC(CCNC(=O)C=3C=C4[C@H](NC(=O)C=5C(=CC=CC=5)Cl)CCC4=CC=3)CC2)=C1 JOGOSWVURULNFB-MUUNZHRXSA-N 0.000 claims description 2
- BIVICOMQAULCOZ-RDMIVRQXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-(4-pyridin-4-ylcyclohexyl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCC1C1=CC=NC=C1 BIVICOMQAULCOZ-RDMIVRQXSA-N 0.000 claims description 2
- KFFBDCCEZPMRTC-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[(1-pyridin-4-ylpiperidin-4-yl)methyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)CC(CC1)CCN1C1=CC=NC=C1 KFFBDCCEZPMRTC-HHHXNRCGSA-N 0.000 claims description 2
- DGXQZVXRJRIJIE-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[(1-pyrimidin-4-ylpiperidin-4-yl)methyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)CC(CC1)CCN1C1=CC=NC=N1 DGXQZVXRJRIJIE-RUZDIDTESA-N 0.000 claims description 2
- LWVNINPKIMSXTI-QHWMMSMNSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[(1s,3r)-3-(4-methylpiperazin-1-yl)cyclohexyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound N1([C@@H]2CCC[C@@H](C2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)CCN(C)CC1 LWVNINPKIMSXTI-QHWMMSMNSA-N 0.000 claims description 2
- QYJAWPLQLDGIJN-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1CCN(C)CC1 QYJAWPLQLDGIJN-HHHXNRCGSA-N 0.000 claims description 2
- PJWXRCQDDJZVEJ-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(1-oxidopyridin-1-ium-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=[N+]([O-])C=C1 PJWXRCQDDJZVEJ-AREMUKBSSA-N 0.000 claims description 2
- HRMPJZSNZUKRKG-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-methylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C)=C1 HRMPJZSNZUKRKG-HHHXNRCGSA-N 0.000 claims description 2
- SOXUGFTUKCCIJX-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-oxo-1h-pyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C=1C=CNC(=O)C=1 SOXUGFTUKCCIJX-RUZDIDTESA-N 0.000 claims description 2
- JDITXETTYLABRD-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-oxo-2-pyrrolidin-1-ylethyl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1CC(=O)N1CCCC1 JDITXETTYLABRD-AREMUKBSSA-N 0.000 claims description 2
- NRGCESYAYKNMRU-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(3-piperidin-1-ylpropanoyl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C(=O)CCN1CCCCC1 NRGCESYAYKNMRU-MUUNZHRXSA-N 0.000 claims description 2
- VINQEWAGBMJDBL-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(6-methyl-2-propan-2-ylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CC(C)C1=NC(C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 VINQEWAGBMJDBL-HHHXNRCGSA-N 0.000 claims description 2
- WBJWKIFWYZZNHB-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(6-methylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC=N1 WBJWKIFWYZZNHB-RUZDIDTESA-N 0.000 claims description 2
- YTZUULFYOUJQSB-SSEXGKCCSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-[(2-pyrrolidin-1-ylpyridin-4-yl)methyl]piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1CC(C=1)=CC=NC=1N1CCCC1 YTZUULFYOUJQSB-SSEXGKCCSA-N 0.000 claims description 2
- VHLVGPUGTSKGHA-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-[(3-methyl-1,2-oxazol-5-yl)methyl]piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1CC1=CC(C)=NO1 VHLVGPUGTSKGHA-AREMUKBSSA-N 0.000 claims description 2
- RQNRCSUXXLLDMI-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1CC(=O)N1CCN(C)CC1 RQNRCSUXXLLDMI-HHHXNRCGSA-N 0.000 claims description 2
- IUEYNZLDACOHBA-XMMPIXPASA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-[2-(methylamino)pyrimidin-4-yl]piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CNC1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 IUEYNZLDACOHBA-XMMPIXPASA-N 0.000 claims description 2
- KCYXBPNWTOMXGS-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)CCC(CC1)CCN1C1=CC=NC=C1 KCYXBPNWTOMXGS-MUUNZHRXSA-N 0.000 claims description 2
- YPKRFPPNXCXECP-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[[1-(2-methylpyridin-4-yl)piperidin-4-yl]methyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)CC(CC1)CCN1C1=CC=NC(C)=C1 YPKRFPPNXCXECP-MUUNZHRXSA-N 0.000 claims description 2
- VJCWFNLLOKXDOK-RUZDIDTESA-N (3r)-3-[(2-chlorophenyl)sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NS(=O)(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VJCWFNLLOKXDOK-RUZDIDTESA-N 0.000 claims description 2
- GBIAQGXVLLUOOK-PPJWLVRDSA-N (3r)-3-[(2-chlorophenyl)sulfonylamino]-n-methyl-n-[(1s,3r)-3-(4-methylpiperazin-1-yl)cyclohexyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound N1([C@@H]2CCC[C@@H](C2)N(C)C(=O)C=2C=C3[C@H](NS(=O)(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)CCN(C)CC1 GBIAQGXVLLUOOK-PPJWLVRDSA-N 0.000 claims description 2
- AEDKDNMOZSDWCI-HHHXNRCGSA-N (3r)-3-[(2-cyclopentylacetyl)-methylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)CC3CCCC3)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 AEDKDNMOZSDWCI-HHHXNRCGSA-N 0.000 claims description 2
- ACPPOISSFRWCOZ-AREMUKBSSA-N (3r)-3-[(2-cyclopentylacetyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)CC2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 ACPPOISSFRWCOZ-AREMUKBSSA-N 0.000 claims description 2
- ZQUZKEDEFRHYNM-AREMUKBSSA-N (3r)-3-[(4-fluorophenyl)sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NS(=O)(=O)C=2C=CC(F)=CC=2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZQUZKEDEFRHYNM-AREMUKBSSA-N 0.000 claims description 2
- CWZUZDSCMZJNMB-RUZDIDTESA-N (3r)-3-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=C(C=CC=2)C(F)(F)F)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CWZUZDSCMZJNMB-RUZDIDTESA-N 0.000 claims description 2
- YEERNSSOGJUTOY-GDLZYMKVSA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-3-[ethyl-(2-methylbenzoyl)amino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=CC=CC=3)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 YEERNSSOGJUTOY-GDLZYMKVSA-N 0.000 claims description 2
- SYDARKYDLCFVPW-XMMPIXPASA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-3-(3-methylbutanoylamino)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)NC(=O)CC(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 SYDARKYDLCFVPW-XMMPIXPASA-N 0.000 claims description 2
- PBNIKPCBHGACAF-SSEXGKCCSA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-3-[(2-methylbenzoyl)-propan-2-ylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)C=3C(=CC=CC=3)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 PBNIKPCBHGACAF-SSEXGKCCSA-N 0.000 claims description 2
- XPULISNZBCPQGF-MUUNZHRXSA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-3-[methyl-(2-methylbenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C=3C(=CC=CC=3)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 XPULISNZBCPQGF-MUUNZHRXSA-N 0.000 claims description 2
- WFVSGUVXNAXSEH-RUZDIDTESA-N (3r)-n-methyl-3-(3-methylbutanoylamino)-n-[1-(2-methylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)NC(=O)CC(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC(C)=C1 WFVSGUVXNAXSEH-RUZDIDTESA-N 0.000 claims description 2
- NAPXJQLCEBQVQK-OAQYLSRUSA-N (3r)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3-(3,3,3-trifluoropropanoylamino)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)CC(F)(F)F)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NAPXJQLCEBQVQK-OAQYLSRUSA-N 0.000 claims description 2
- YHFAQJLFUOTJOY-AREMUKBSSA-N (3r)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3-[[2-(trifluoromethyl)benzoyl]amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)C(F)(F)F)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YHFAQJLFUOTJOY-AREMUKBSSA-N 0.000 claims description 2
- IVQCLHLCXNASJY-RUZDIDTESA-N (4r)-4-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-7-carboxamide Chemical compound C([C@H](C1=CC=2)N3C(C4=C(Cl)C=CC=C4C3)=O)COC1=CC=2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IVQCLHLCXNASJY-RUZDIDTESA-N 0.000 claims description 2
- WGEKTHDIXFNKEX-RUZDIDTESA-N (4r)-4-[(2-chlorobenzoyl)amino]-8-fluoro-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCOC1=C(F)C=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WGEKTHDIXFNKEX-RUZDIDTESA-N 0.000 claims description 2
- PXPJMAHKXHHCJZ-RUZDIDTESA-N (4r)-4-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-8-fluoro-n-methyl-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCOC1=C(F)C=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 PXPJMAHKXHHCJZ-RUZDIDTESA-N 0.000 claims description 2
- MMUWNIOWDNXPGI-RUZDIDTESA-N (4r)-4-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCOC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MMUWNIOWDNXPGI-RUZDIDTESA-N 0.000 claims description 2
- MYBUHYORKDAWRS-RUZDIDTESA-N (4r)-4-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-7-carboxamide Chemical compound C([C@H](C1=CC=2)NC(=O)C=3C(=CC=CC=3)Cl)COC1=CC=2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MYBUHYORKDAWRS-RUZDIDTESA-N 0.000 claims description 2
- QQWJKHNOVUEAHZ-HHHXNRCGSA-N (8r)-8-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 QQWJKHNOVUEAHZ-HHHXNRCGSA-N 0.000 claims description 2
- JTCMBCBHIPZYQG-HHHXNRCGSA-N (8r)-8-[(2-chlorobenzoyl)amino]-n-[1-[2-(dimethylamino)-6-methylpyrimidin-4-yl]piperidin-4-yl]-n-methyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound CN(C)C1=NC(C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCCC3=CC=2)=N1 JTCMBCBHIPZYQG-HHHXNRCGSA-N 0.000 claims description 2
- PMRIEHNNYXNOFS-AREMUKBSSA-N (8r)-8-[(2-chlorobenzoyl)amino]-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCCC3=CC=2)=N1 PMRIEHNNYXNOFS-AREMUKBSSA-N 0.000 claims description 2
- LYTSJZDXZWOKGM-UHFFFAOYSA-N 1-(cyclohexanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C3CCCCC3)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LYTSJZDXZWOKGM-UHFFFAOYSA-N 0.000 claims description 2
- RXLUOTKCSZDRAK-UHFFFAOYSA-N 1-[(2,3-dichlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 RXLUOTKCSZDRAK-UHFFFAOYSA-N 0.000 claims description 2
- BBQHCVDMIBAKJG-UHFFFAOYSA-N 1-[(2,6-dimethylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C(=CC=CC=3C)C)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BBQHCVDMIBAKJG-UHFFFAOYSA-N 0.000 claims description 2
- LBHLGAKQYGMDEH-UHFFFAOYSA-N 1-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C(=CC=CC=3)Cl)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LBHLGAKQYGMDEH-UHFFFAOYSA-N 0.000 claims description 2
- BCMRXRCPKBMBIB-UHFFFAOYSA-N 1-[[(2-chlorophenyl)-methylcarbamoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)N(C)C=3C(=CC=CC=3)Cl)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BCMRXRCPKBMBIB-UHFFFAOYSA-N 0.000 claims description 2
- WGEIXRRBWYCNJR-UHFFFAOYSA-N 1-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WGEIXRRBWYCNJR-UHFFFAOYSA-N 0.000 claims description 2
- BTWANUBGRPGZJA-UHFFFAOYSA-N 1-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NS(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BTWANUBGRPGZJA-UHFFFAOYSA-N 0.000 claims description 2
- HTUMDWDLNDNCPQ-UHFFFAOYSA-N 3-(3,3-dimethylbutanoylamino)-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)CC(C)(C)C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HTUMDWDLNDNCPQ-UHFFFAOYSA-N 0.000 claims description 2
- DXRMFEKNRCYXTF-UHFFFAOYSA-N 3-(3,3-dimethylbutanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CC(C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 DXRMFEKNRCYXTF-UHFFFAOYSA-N 0.000 claims description 2
- OZNFJEYNFGFFPP-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-[1-(2-cyclopropylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1C1CC1 OZNFJEYNFGFFPP-UHFFFAOYSA-N 0.000 claims description 2
- RMVBKNULWXWVBT-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-methyl-n-(1-pyridazin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NN=C1 RMVBKNULWXWVBT-UHFFFAOYSA-N 0.000 claims description 2
- RAXMHDIPTMWEAQ-UHFFFAOYSA-N 3-(3-methylbutanoylamino)-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(NC(=O)CC(C)C)CCC2=CC=C1C(=O)NCCC(CC1)CCN1C1=CC=NC=C1 RAXMHDIPTMWEAQ-UHFFFAOYSA-N 0.000 claims description 2
- BSHQWCJRXSJWSJ-UHFFFAOYSA-N 3-(cyclohexanecarbonylamino)-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CCCCC1C(=O)NC(C1=C2)CCC1=CC=C2C(=O)NCCC(CC1)CCN1C1=CC=NC=C1 BSHQWCJRXSJWSJ-UHFFFAOYSA-N 0.000 claims description 2
- DGAARUMDSNSPNS-UHFFFAOYSA-N 3-(cyclopropanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C3CC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 DGAARUMDSNSPNS-UHFFFAOYSA-N 0.000 claims description 2
- HXYFGBICDIKFHC-UHFFFAOYSA-N 3-(ethylsulfonylamino)-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC=CC2=CC(N3CCC(CC3)N(C)C(=O)C3=CC=C4CCC(C4=C3)NS(=O)(=O)CC)=CC=C21 HXYFGBICDIKFHC-UHFFFAOYSA-N 0.000 claims description 2
- DNVRUENPIBFBHI-UHFFFAOYSA-N 3-[(2,3-dichlorobenzoyl)-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC(Cl)=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 DNVRUENPIBFBHI-UHFFFAOYSA-N 0.000 claims description 2
- YROAVGXIKNVBQB-UHFFFAOYSA-N 3-[(2,3-dichlorobenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC(Cl)=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YROAVGXIKNVBQB-UHFFFAOYSA-N 0.000 claims description 2
- FSRCMSDOSOEILL-UHFFFAOYSA-N 3-[(2,3-dichlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FSRCMSDOSOEILL-UHFFFAOYSA-N 0.000 claims description 2
- UMYMSEGNENNXJC-UHFFFAOYSA-N 3-[(2,3-dichlorophenyl)carbamoyl-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC(Cl)=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 UMYMSEGNENNXJC-UHFFFAOYSA-N 0.000 claims description 2
- UDGGQJVSBYGCPY-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=CC(Cl)=CC=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 UDGGQJVSBYGCPY-UHFFFAOYSA-N 0.000 claims description 2
- GGVRNTLDRRNHSY-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=CC(Cl)=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 GGVRNTLDRRNHSY-UHFFFAOYSA-N 0.000 claims description 2
- IPUKDTLLTHIYMU-UHFFFAOYSA-N 3-[(2,4-dimethylphenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C(C)C=C(C)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 IPUKDTLLTHIYMU-UHFFFAOYSA-N 0.000 claims description 2
- XCVIJFHJBAYFIU-UHFFFAOYSA-N 3-[(2,4-dimethylphenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=CC(C)=CC=3)C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XCVIJFHJBAYFIU-UHFFFAOYSA-N 0.000 claims description 2
- DGIUEHLUBIEGDI-UHFFFAOYSA-N 3-[(2,4-dimethylphenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC=C(C)C=C1C DGIUEHLUBIEGDI-UHFFFAOYSA-N 0.000 claims description 2
- WKHGXMQYLFODAL-UHFFFAOYSA-N 3-[(2,5-dichlorobenzoyl)-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(Cl)=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 WKHGXMQYLFODAL-UHFFFAOYSA-N 0.000 claims description 2
- VIJVBSRJUQGCJT-UHFFFAOYSA-N 3-[(2,5-dichlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=C(Cl)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VIJVBSRJUQGCJT-UHFFFAOYSA-N 0.000 claims description 2
- JYVKZIHZVKWEMK-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)carbamoyl-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(Cl)=CC=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 JYVKZIHZVKWEMK-UHFFFAOYSA-N 0.000 claims description 2
- ZOENQGSZCJWBBO-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=CC=C(Cl)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 ZOENQGSZCJWBBO-UHFFFAOYSA-N 0.000 claims description 2
- KVIGDAIYAVVNIO-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)carbamoyl-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC=1C=CC=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 KVIGDAIYAVVNIO-UHFFFAOYSA-N 0.000 claims description 2
- UKQWHSDIEYKHIK-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=CC=CC=3Cl)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 UKQWHSDIEYKHIK-UHFFFAOYSA-N 0.000 claims description 2
- VCOZYQLRGCMNHQ-UHFFFAOYSA-N 3-[(2,6-dimethylbenzoyl)-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CC=1C=CC=C(C)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 VCOZYQLRGCMNHQ-UHFFFAOYSA-N 0.000 claims description 2
- QBUSSHGXORUUDI-UHFFFAOYSA-N 3-[(2,6-dimethylbenzoyl)amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=CC=CC=3C)C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QBUSSHGXORUUDI-UHFFFAOYSA-N 0.000 claims description 2
- YPTCIESMPRFLJC-UHFFFAOYSA-N 3-[(2,6-dimethylbenzoyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 YPTCIESMPRFLJC-UHFFFAOYSA-N 0.000 claims description 2
- NXJQWPCXYZIFAA-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylbenzoyl)amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=C(C)C=CC=3F)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NXJQWPCXYZIFAA-UHFFFAOYSA-N 0.000 claims description 2
- SSKBHOBUFBGUAS-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylbenzoyl)amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=C(F)C=CC(C)=C1Cl SSKBHOBUFBGUAS-UHFFFAOYSA-N 0.000 claims description 2
- QXFPCPHAZLTXJB-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylbenzoyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=C(C)C=CC=3F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 QXFPCPHAZLTXJB-UHFFFAOYSA-N 0.000 claims description 2
- KQDBTGSDDAUBHW-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=C(C)C=CC=3F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 KQDBTGSDDAUBHW-UHFFFAOYSA-N 0.000 claims description 2
- JUCYBLXGQNUABV-UHFFFAOYSA-N 3-[(2-chloro-6-methylphenyl)sulfonyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C)S(=O)(=O)C=3C(=CC=CC=3C)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 JUCYBLXGQNUABV-UHFFFAOYSA-N 0.000 claims description 2
- IJVBHCDTVZCNIQ-UHFFFAOYSA-N 3-[(2-chloro-6-methylphenyl)sulfonylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NS(=O)(=O)C=3C(=CC=CC=3C)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IJVBHCDTVZCNIQ-UHFFFAOYSA-N 0.000 claims description 2
- XWADNZNAHMKKLR-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=CC=CC=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XWADNZNAHMKKLR-UHFFFAOYSA-N 0.000 claims description 2
- DEWLZBRVOVXTAU-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CC=CC=C1Cl DEWLZBRVOVXTAU-UHFFFAOYSA-N 0.000 claims description 2
- QBHXCCHATONVAZ-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 QBHXCCHATONVAZ-UHFFFAOYSA-N 0.000 claims description 2
- SKYHOTRXYGDJRR-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-[1-(5-fluoropyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=NC=NC=C1F SKYHOTRXYGDJRR-UHFFFAOYSA-N 0.000 claims description 2
- OCEACOIRABQYJZ-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-[1-[2-(dimethylamino)-6-methylpyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC(C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3C(NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 OCEACOIRABQYJZ-UHFFFAOYSA-N 0.000 claims description 2
- CXUXHRVRFNBWSO-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3C(NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 CXUXHRVRFNBWSO-UHFFFAOYSA-N 0.000 claims description 2
- ZPUMTCCTQGHZTL-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridazin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NN=C1 ZPUMTCCTQGHZTL-UHFFFAOYSA-N 0.000 claims description 2
- SQGHJEMHLJMOKM-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SQGHJEMHLJMOKM-UHFFFAOYSA-N 0.000 claims description 2
- WDILGMNJSZYLJC-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-pyrrolidin-1-ylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1N1CCCC1 WDILGMNJSZYLJC-UHFFFAOYSA-N 0.000 claims description 2
- MXINQRCSXRQWPV-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-methyl-n-[4-(3-methyl-5-oxo-7h-imidazo[1,5-c]imidazol-6-yl)cyclohexyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CC(N2C(N3C(C)=NC=C3C2)=O)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CC=CC=C1Cl MXINQRCSXRQWPV-UHFFFAOYSA-N 0.000 claims description 2
- IFFPEYWJLMNYRT-UHFFFAOYSA-N 3-[(2-chlorophenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 IFFPEYWJLMNYRT-UHFFFAOYSA-N 0.000 claims description 2
- UHQPYOARWDQPGU-UHFFFAOYSA-N 3-[(2-chlorophenyl)carbamoyl-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 UHQPYOARWDQPGU-UHFFFAOYSA-N 0.000 claims description 2
- BKZCFECGBJPADN-UHFFFAOYSA-N 3-[(2-chlorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=CC=CC=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BKZCFECGBJPADN-UHFFFAOYSA-N 0.000 claims description 2
- RPFBLIPHFDOBIV-UHFFFAOYSA-N 3-[(2-chlorophenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC=CC=C1Cl RPFBLIPHFDOBIV-UHFFFAOYSA-N 0.000 claims description 2
- LVWOLEXAGUWIPF-UHFFFAOYSA-N 3-[(2-chlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 LVWOLEXAGUWIPF-UHFFFAOYSA-N 0.000 claims description 2
- ZHFSNXQIPIZUKJ-UHFFFAOYSA-N 3-[(3,5-dichlorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZHFSNXQIPIZUKJ-UHFFFAOYSA-N 0.000 claims description 2
- OKZVEHQYVZYTDZ-UHFFFAOYSA-N 3-[(3,5-dichlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 OKZVEHQYVZYTDZ-UHFFFAOYSA-N 0.000 claims description 2
- LWESZKPIOPZRSK-UHFFFAOYSA-N 3-[(3-chloro-4-fluorophenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C(F)C(Cl)=CC=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 LWESZKPIOPZRSK-UHFFFAOYSA-N 0.000 claims description 2
- VFNUJAHBJRUQGD-UHFFFAOYSA-N 3-[(3-chloro-4-fluorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C=C(Cl)C(F)=CC=3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VFNUJAHBJRUQGD-UHFFFAOYSA-N 0.000 claims description 2
- IAYBOIJJAQMWBV-UHFFFAOYSA-N 3-[(3-chloro-4-fluorophenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC=C(F)C(Cl)=C1 IAYBOIJJAQMWBV-UHFFFAOYSA-N 0.000 claims description 2
- JDKWMDMKPCDYFN-UHFFFAOYSA-N 3-[(3-chloro-4-fluorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C=C(Cl)C(F)=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 JDKWMDMKPCDYFN-UHFFFAOYSA-N 0.000 claims description 2
- QGAGWMVDIFLPIT-UHFFFAOYSA-N 3-[(3-chloro-4-methylphenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C=C(Cl)C(C)=CC=3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QGAGWMVDIFLPIT-UHFFFAOYSA-N 0.000 claims description 2
- IMCNGDSKOXVCOT-UHFFFAOYSA-N 3-[(3-chloro-4-methylphenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C=C(Cl)C(C)=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 IMCNGDSKOXVCOT-UHFFFAOYSA-N 0.000 claims description 2
- CFFIKEUCMSDVGD-UHFFFAOYSA-N 3-[(3-chlorophenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC(Cl)=CC=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 CFFIKEUCMSDVGD-UHFFFAOYSA-N 0.000 claims description 2
- WUTWRRBREULMSO-UHFFFAOYSA-N 3-[(3-chlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C=C(Cl)C=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 WUTWRRBREULMSO-UHFFFAOYSA-N 0.000 claims description 2
- FCPGYNLCDFOANK-UHFFFAOYSA-N 3-[3,3-dimethylbutanoyl(methyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)CC(C)(C)C)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 FCPGYNLCDFOANK-UHFFFAOYSA-N 0.000 claims description 2
- BQFCYTRTLXXHBN-UHFFFAOYSA-N 3-[3-cyclopentylpropanoyl(methyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CCCC1CCC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BQFCYTRTLXXHBN-UHFFFAOYSA-N 0.000 claims description 2
- DHGZBDLOXQSXQI-UHFFFAOYSA-N 3-[[(2,4-dichlorophenyl)-methylcarbamoyl]-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1N(C)C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 DHGZBDLOXQSXQI-UHFFFAOYSA-N 0.000 claims description 2
- SYNQJLCEQZCNEL-UHFFFAOYSA-N 3-[[(2,4-dichlorophenyl)-methylcarbamoyl]amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)N(C)C1=CC=C(Cl)C=C1Cl SYNQJLCEQZCNEL-UHFFFAOYSA-N 0.000 claims description 2
- CUSZWRODOTXFMZ-UHFFFAOYSA-N 3-[[(2,4-dichlorophenyl)-methylcarbamoyl]amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)N(C)C=3C(=CC(Cl)=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 CUSZWRODOTXFMZ-UHFFFAOYSA-N 0.000 claims description 2
- GOHFNDHQVMEBHJ-UHFFFAOYSA-N 3-[[(2-chlorophenyl)-methylcarbamoyl]-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1N(C)C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 GOHFNDHQVMEBHJ-UHFFFAOYSA-N 0.000 claims description 2
- JXSFMJFMIRMQTL-UHFFFAOYSA-N 3-[[(2-chlorophenyl)-methylcarbamoyl]-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1N(C)C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 JXSFMJFMIRMQTL-UHFFFAOYSA-N 0.000 claims description 2
- QARVARLCOPCKMZ-UHFFFAOYSA-N 3-[[(2-chlorophenyl)-methylcarbamoyl]amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)N(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 QARVARLCOPCKMZ-UHFFFAOYSA-N 0.000 claims description 2
- JVOPLFYKWAUJOJ-UHFFFAOYSA-N 3-[[(2-chlorophenyl)-methylcarbamoyl]amino]-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1N(C)C(=O)NC(C1=C2)CCC1=CC=C2C(=O)NCCC(CC1)CCN1C1=CC=NC=C1 JVOPLFYKWAUJOJ-UHFFFAOYSA-N 0.000 claims description 2
- KBTMPCKGEFNGLC-UHFFFAOYSA-N 3-[[2-(2-chlorophenyl)-2-methylpropanoyl]amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C(C)(C)C1=CC=CC=C1Cl KBTMPCKGEFNGLC-UHFFFAOYSA-N 0.000 claims description 2
- JJKDYRDZGDAHSE-UHFFFAOYSA-N 3-[[2-(2-chlorophenyl)-2-methylpropanoyl]amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C(C)(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 JJKDYRDZGDAHSE-UHFFFAOYSA-N 0.000 claims description 2
- RYEGXVNDXYSNDV-UHFFFAOYSA-N 3-[[2-(2-chlorophenyl)-2-methylpropanoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C(C)(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 RYEGXVNDXYSNDV-UHFFFAOYSA-N 0.000 claims description 2
- YOTYANMDMYNYQE-UHFFFAOYSA-N 3-[[2-[2-chloro-3-(trifluoromethyl)phenyl]-2-oxoethyl]amino]-N-methyl-N-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1H-indene-5-carboxamide Chemical compound ClC1=C(C(=O)CNC2CCC3=CC=C(C=C23)C(=O)N(C2CCN(CC2)C2=CC=NC=C2)C)C=CC=C1C(F)(F)F YOTYANMDMYNYQE-UHFFFAOYSA-N 0.000 claims description 2
- LWRAEWIENSGCCY-UHFFFAOYSA-N 3-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=C(C=CC=3)C(F)(F)F)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LWRAEWIENSGCCY-UHFFFAOYSA-N 0.000 claims description 2
- CGNSCXNWJASEAU-UHFFFAOYSA-N 3-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CC=CC(C(F)(F)F)=C1Cl CGNSCXNWJASEAU-UHFFFAOYSA-N 0.000 claims description 2
- YJYPWLQNDPZFGD-UHFFFAOYSA-N 3-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=C(C=CC=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 YJYPWLQNDPZFGD-UHFFFAOYSA-N 0.000 claims description 2
- WJSUKPNBHIQLJB-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)benzoyl]-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(C(F)(F)F)=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 WJSUKPNBHIQLJB-UHFFFAOYSA-N 0.000 claims description 2
- LHGKRBPXACOVRM-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)benzoyl]amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=CC=C(C=3)C(F)(F)F)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LHGKRBPXACOVRM-UHFFFAOYSA-N 0.000 claims description 2
- BEQRPHPXYCDEAI-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)benzoyl]amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CC(C(F)(F)F)=CC=C1Cl BEQRPHPXYCDEAI-UHFFFAOYSA-N 0.000 claims description 2
- GXCWBCVLXVRWDI-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=C(C=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GXCWBCVLXVRWDI-UHFFFAOYSA-N 0.000 claims description 2
- BYCGWYLLRAEEGB-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=CC=C(C=3)C(F)(F)F)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BYCGWYLLRAEEGB-UHFFFAOYSA-N 0.000 claims description 2
- ASWBBQPMVLCHJM-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC(C(F)(F)F)=CC=C1Cl ASWBBQPMVLCHJM-UHFFFAOYSA-N 0.000 claims description 2
- OWWCAYPJMDRTNU-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)phenyl]carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=CC=C(C=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 OWWCAYPJMDRTNU-UHFFFAOYSA-N 0.000 claims description 2
- OUEGVCWMYLDDNG-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=C(Cl)C=CC=C1C(F)(F)F OUEGVCWMYLDDNG-UHFFFAOYSA-N 0.000 claims description 2
- ZNSCOBCDGHXJEI-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 ZNSCOBCDGHXJEI-UHFFFAOYSA-N 0.000 claims description 2
- ZXZVIXXECTYYAI-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC(Cl)=C1C(=O)NC1C2=CC(C(=O)NCCC3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 ZXZVIXXECTYYAI-UHFFFAOYSA-N 0.000 claims description 2
- VPCHNVKRXWYFJQ-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C)S(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 VPCHNVKRXWYFJQ-UHFFFAOYSA-N 0.000 claims description 2
- MUGUZTBMDCWVAQ-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NS(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MUGUZTBMDCWVAQ-UHFFFAOYSA-N 0.000 claims description 2
- ZCBSKUAVTVVRON-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 ZCBSKUAVTVVRON-UHFFFAOYSA-N 0.000 claims description 2
- ZCSJWBQYDHNSBR-UHFFFAOYSA-N 3-[[4-chloro-2-(trifluoromethyl)phenyl]carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC=C(Cl)C=C1C(F)(F)F ZCSJWBQYDHNSBR-UHFFFAOYSA-N 0.000 claims description 2
- OHLLRIHSBGYOHA-UHFFFAOYSA-N 3-[[4-chloro-2-(trifluoromethyl)phenyl]carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=CC(Cl)=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 OHLLRIHSBGYOHA-UHFFFAOYSA-N 0.000 claims description 2
- WGSVZYWFNNDXQN-UHFFFAOYSA-N 3-[cyclopropanecarbonyl(methyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CC1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 WGSVZYWFNNDXQN-UHFFFAOYSA-N 0.000 claims description 2
- CJMJCUFEEMYEON-UHFFFAOYSA-N 3-[cyclopropanecarbonyl(methyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CC1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CJMJCUFEEMYEON-UHFFFAOYSA-N 0.000 claims description 2
- VKOSAIXTDCSUAD-UHFFFAOYSA-N 3-[tert-butyl-(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C(=O)C=3C(=CC=CC=3)Cl)C(C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VKOSAIXTDCSUAD-UHFFFAOYSA-N 0.000 claims description 2
- SYWUMFVPKRISFA-UHFFFAOYSA-N 3-acetamido-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(C)=O)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SYWUMFVPKRISFA-UHFFFAOYSA-N 0.000 claims description 2
- YWMIJDNVKAGSEB-UHFFFAOYSA-N 3-acetamido-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(C)=O)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 YWMIJDNVKAGSEB-UHFFFAOYSA-N 0.000 claims description 2
- HUKDYHUMESLDRP-UHFFFAOYSA-N 3-chloro-n-[6-[2-(1-pyridin-4-ylpiperidin-4-yl)ethylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]thiophene-2-carboxamide Chemical compound C1=CSC(C(=O)NC2C3=CC(=CC=C3CC2)C(=O)NCCC2CCN(CC2)C=2C=CN=CC=2)=C1Cl HUKDYHUMESLDRP-UHFFFAOYSA-N 0.000 claims description 2
- TXLWUWFSLNRKKW-UHFFFAOYSA-N 3-chloro-n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]thiophene-2-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C3=C(C=CS3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 TXLWUWFSLNRKKW-UHFFFAOYSA-N 0.000 claims description 2
- HXBWZSQGGTUPEQ-UHFFFAOYSA-N 4-(cyclohexanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C3CCCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HXBWZSQGGTUPEQ-UHFFFAOYSA-N 0.000 claims description 2
- KHAIYQOYTWCITR-UHFFFAOYSA-N 4-(cyclopropanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C3CC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 KHAIYQOYTWCITR-UHFFFAOYSA-N 0.000 claims description 2
- NZNLQTAVJXWJIJ-UHFFFAOYSA-N 4-[(2,3-dichlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NZNLQTAVJXWJIJ-UHFFFAOYSA-N 0.000 claims description 2
- MLUJQKJSRFUHHN-UHFFFAOYSA-N 4-[(2,3-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C(=C(Cl)C=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MLUJQKJSRFUHHN-UHFFFAOYSA-N 0.000 claims description 2
- NTQGPTQSUDVPJN-UHFFFAOYSA-N 4-[(2,5-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C(=CC=C(Cl)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NTQGPTQSUDVPJN-UHFFFAOYSA-N 0.000 claims description 2
- NFSQQTQWHYMPHQ-UHFFFAOYSA-N 4-[(2-chloro-6-fluoro-3-methylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=C(C)C=CC=3F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NFSQQTQWHYMPHQ-UHFFFAOYSA-N 0.000 claims description 2
- INHLGGYCWAWXDW-UHFFFAOYSA-N 4-[(2-chloro-6-methylphenyl)sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NS(=O)(=O)C=3C(=CC=CC=3C)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 INHLGGYCWAWXDW-UHFFFAOYSA-N 0.000 claims description 2
- CYHANFMOTLJKPY-UHFFFAOYSA-N 4-[(2-chlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CYHANFMOTLJKPY-UHFFFAOYSA-N 0.000 claims description 2
- WDCYSKHLRRFORU-UHFFFAOYSA-N 4-[(2-methoxyacetyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C1=C2C(NC(=O)COC)CCOC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WDCYSKHLRRFORU-UHFFFAOYSA-N 0.000 claims description 2
- LKCGJIQLLYJIKJ-UHFFFAOYSA-N 4-[(3,5-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C=C(Cl)C=C(Cl)C=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LKCGJIQLLYJIKJ-UHFFFAOYSA-N 0.000 claims description 2
- QUWMRKSIBOZOKI-UHFFFAOYSA-N 4-[(3-chloro-4-fluorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C=C(Cl)C(F)=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QUWMRKSIBOZOKI-UHFFFAOYSA-N 0.000 claims description 2
- INIXGIPICSSZRB-UHFFFAOYSA-N 4-[(3-chloro-4-methylphenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C=C(Cl)C(C)=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 INIXGIPICSSZRB-UHFFFAOYSA-N 0.000 claims description 2
- BUWQRMVESLDZST-UHFFFAOYSA-N 4-[(3-chlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C=C(Cl)C=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BUWQRMVESLDZST-UHFFFAOYSA-N 0.000 claims description 2
- UKTVMPNLFPLPDJ-UHFFFAOYSA-N 4-[(3-chlorothiophene-2-carbonyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C3=C(C=CS3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 UKTVMPNLFPLPDJ-UHFFFAOYSA-N 0.000 claims description 2
- QUIXOHVLYCBAAX-UHFFFAOYSA-N 4-[(5-chloro-2-methoxyphenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound COC1=CC=C(Cl)C=C1NC(=O)NC1C2=CC(C(=O)N(C)C3CCN(CC3)C=3C=CN=CC=3)=CC=C2OCC1 QUIXOHVLYCBAAX-UHFFFAOYSA-N 0.000 claims description 2
- GPLQVSYDIWEQLA-UHFFFAOYSA-N 4-[4-[[3-(3-cyclopentylpropanoylamino)-2,3-dihydro-1h-indene-5-carbonyl]-methylamino]piperidin-1-yl]-n,n-dimethylpyridine-2-carboxamide Chemical compound C1=NC(C(=O)N(C)C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3C(NC(=O)CCC4CCCC4)CCC3=CC=2)=C1 GPLQVSYDIWEQLA-UHFFFAOYSA-N 0.000 claims description 2
- FKTOLKPGOFXHBN-UHFFFAOYSA-N 4-[[2-(2-chlorophenyl)-2-methylpropanoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C(C)(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FKTOLKPGOFXHBN-UHFFFAOYSA-N 0.000 claims description 2
- SEQQCKGEBCBWDF-UHFFFAOYSA-N 4-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=C(C=CC=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SEQQCKGEBCBWDF-UHFFFAOYSA-N 0.000 claims description 2
- BJSYPAVTTMFGPD-UHFFFAOYSA-N 4-[[2-chloro-5-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=CC=C(C=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BJSYPAVTTMFGPD-UHFFFAOYSA-N 0.000 claims description 2
- FSFXQHDRFVZSSY-UHFFFAOYSA-N 4-[[2-chloro-6-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FSFXQHDRFVZSSY-UHFFFAOYSA-N 0.000 claims description 2
- SQBYNNHGZDOSAX-UHFFFAOYSA-N 4-acetamido-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(C)=O)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SQBYNNHGZDOSAX-UHFFFAOYSA-N 0.000 claims description 2
- IGGMFJVQYJXHHW-UHFFFAOYSA-N 8-[(2,4-dimethylphenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C(=CC(C)=CC=3)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IGGMFJVQYJXHHW-UHFFFAOYSA-N 0.000 claims description 2
- XDVYXNLERZFGOO-UHFFFAOYSA-N 8-[(2,6-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C(=CC=CC=3Cl)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XDVYXNLERZFGOO-UHFFFAOYSA-N 0.000 claims description 2
- NOCLKPRTTOCYPW-UHFFFAOYSA-N 8-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NOCLKPRTTOCYPW-UHFFFAOYSA-N 0.000 claims description 2
- XQUWDIBLNBNJAT-UHFFFAOYSA-N 8-[(2-chlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XQUWDIBLNBNJAT-UHFFFAOYSA-N 0.000 claims description 2
- UYESUFHITYBHJG-UHFFFAOYSA-N 8-[(3-chloro-4-fluorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C=C(Cl)C(F)=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 UYESUFHITYBHJG-UHFFFAOYSA-N 0.000 claims description 2
- SSTIFRJNUGFRRC-UHFFFAOYSA-N 8-[(3-chloro-4-methylphenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C=C(Cl)C(C)=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SSTIFRJNUGFRRC-UHFFFAOYSA-N 0.000 claims description 2
- MQUAHVPNJIEUSH-UHFFFAOYSA-N 8-[(3-chlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C=C(Cl)C=CC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MQUAHVPNJIEUSH-UHFFFAOYSA-N 0.000 claims description 2
- WFCQZDLQXARGLS-UHFFFAOYSA-N 8-[[(2,4-dichlorophenyl)-methylcarbamoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)N(C)C=3C(=CC(Cl)=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WFCQZDLQXARGLS-UHFFFAOYSA-N 0.000 claims description 2
- PETBRTPTFVJTPB-UHFFFAOYSA-N 8-[[2-(2-chlorophenyl)-2-methylpropanoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C(C)(C)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 PETBRTPTFVJTPB-UHFFFAOYSA-N 0.000 claims description 2
- PRZODCNFJPQMCA-UHFFFAOYSA-N 8-[[2-chloro-5-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=CC=C(C=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 PRZODCNFJPQMCA-UHFFFAOYSA-N 0.000 claims description 2
- WRZOYKRTPZNGCQ-UHFFFAOYSA-N 8-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NS(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WRZOYKRTPZNGCQ-UHFFFAOYSA-N 0.000 claims description 2
- HHAQDYANJOTPOF-UHFFFAOYSA-N 8-acetamido-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(C)=O)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HHAQDYANJOTPOF-UHFFFAOYSA-N 0.000 claims description 2
- RBCDIYQBGXAWGV-UHFFFAOYSA-N C(C)(=O)CNC1CCC2=CC=C(C=C12)C(=O)N(C)C1CCN(CC1)C1=CC(=NC(=C1)C)C Chemical compound C(C)(=O)CNC1CCC2=CC=C(C=C12)C(=O)N(C)C1CCN(CC1)C1=CC(=NC(=C1)C)C RBCDIYQBGXAWGV-UHFFFAOYSA-N 0.000 claims description 2
- FLVNTUDQYUOYJI-UHFFFAOYSA-N C=1C=C2CCC(NC(=O)NCC=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 Chemical compound C=1C=C2CCC(NC(=O)NCC=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 FLVNTUDQYUOYJI-UHFFFAOYSA-N 0.000 claims description 2
- ZWVKHXPCTQEIEO-UHFFFAOYSA-N CS(=O)(=O)C1=NC=CC(=N1)N1CCC(CC1)C1CCC2=CC(=CC=C12)C(=O)N Chemical compound CS(=O)(=O)C1=NC=CC(=N1)N1CCC(CC1)C1CCC2=CC(=CC=C12)C(=O)N ZWVKHXPCTQEIEO-UHFFFAOYSA-N 0.000 claims description 2
- 108010011438 H 77 Proteins 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 2
- 230000003176 fibrotic effect Effects 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- PJYCUGCUXXCKCV-UHFFFAOYSA-N n,n-dimethyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-2-amine Chemical compound C1NCCC2=NC(N(C)C)=NC=C21 PJYCUGCUXXCKCV-UHFFFAOYSA-N 0.000 claims description 2
- LFFBJHJRTDLWHU-UHFFFAOYSA-N n-(1-isoquinolin-6-ylpiperidin-4-yl)-3-(methanesulfonamido)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2CCC(NS(C)(=O)=O)C2=CC(C(=O)N(C2CCN(CC2)C=2C=C3C=CN=CC3=CC=2)C)=C1 LFFBJHJRTDLWHU-UHFFFAOYSA-N 0.000 claims description 2
- ROPXKPMJUIFEDY-UHFFFAOYSA-N n-(1-isoquinolin-6-ylpiperidin-4-yl)-3-[(2-methoxyacetyl)amino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC=CC2=CC(N3CCC(CC3)N(C)C(=O)C3=CC=C4CCC(C4=C3)NC(=O)COC)=CC=C21 ROPXKPMJUIFEDY-UHFFFAOYSA-N 0.000 claims description 2
- HOMZLIABYBQZIA-UHFFFAOYSA-N n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-3-(propylsulfonylamino)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC=CC2=CC(N3CCC(CC3)N(C)C(=O)C3=CC=C4CCC(C4=C3)NS(=O)(=O)CCC)=CC=C21 HOMZLIABYBQZIA-UHFFFAOYSA-N 0.000 claims description 2
- RUDPTKYWIAUAAG-UHFFFAOYSA-N n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-3-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NS(=O)(=O)CC1=CC=CC=C1C(F)(F)F RUDPTKYWIAUAAG-UHFFFAOYSA-N 0.000 claims description 2
- HUTGICSLQWLHND-UHFFFAOYSA-N n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-3-[[3-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NS(=O)(=O)CC1=CC=CC(C(F)(F)F)=C1 HUTGICSLQWLHND-UHFFFAOYSA-N 0.000 claims description 2
- LHYPQPUJMKSLEZ-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-3-[(2-fluorophenyl)methylsulfonylamino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)CC=3C(=CC=CC=3)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 LHYPQPUJMKSLEZ-UHFFFAOYSA-N 0.000 claims description 2
- LEYVXBKGWMFCOS-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-3-[(2-methoxyacetyl)-methylamino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)COC)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 LEYVXBKGWMFCOS-UHFFFAOYSA-N 0.000 claims description 2
- DKPUIUXJPOLYNX-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-3-[(2-methoxyacetyl)amino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(NC(=O)COC)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 DKPUIUXJPOLYNX-UHFFFAOYSA-N 0.000 claims description 2
- QENBXLMMYWZIBA-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-(3-methylbutanoylamino)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(NC(=O)CC(C)C)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 QENBXLMMYWZIBA-UHFFFAOYSA-N 0.000 claims description 2
- JKARHSGIMDYYNM-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-[methyl(methylsulfonyl)amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C)S(C)(=O)=O)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 JKARHSGIMDYYNM-UHFFFAOYSA-N 0.000 claims description 2
- QTEVNAAEEZCPCC-UHFFFAOYSA-N n-[1-(2-tert-butylpyrimidin-4-yl)piperidin-4-yl]-3-[(2-chlorobenzoyl)amino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C(C)(C)C)=N1 QTEVNAAEEZCPCC-UHFFFAOYSA-N 0.000 claims description 2
- HLEZCPGMKWGRET-UHFFFAOYSA-N n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-3-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC=C1CS(=O)(=O)NC1C2=CC(C(=O)NCCC3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 HLEZCPGMKWGRET-UHFFFAOYSA-N 0.000 claims description 2
- SVQWVTLCHUJWGS-UHFFFAOYSA-N n-[3,3-dimethyl-6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-1,2-dihydroinden-1-yl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=CC=NC=3)C(F)(F)F)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SVQWVTLCHUJWGS-UHFFFAOYSA-N 0.000 claims description 2
- GRZLQJBBHQZATE-UHFFFAOYSA-N n-[3,3-dimethyl-6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-1,2-dihydroinden-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C=NC=NC=3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GRZLQJBBHQZATE-UHFFFAOYSA-N 0.000 claims description 2
- QXPPRIVBTUABLN-UHFFFAOYSA-N n-[5-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C(=CC=NC=3)C(F)(F)F)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QXPPRIVBTUABLN-UHFFFAOYSA-N 0.000 claims description 2
- ZJOYRCGPBCRRKR-UHFFFAOYSA-N n-[5-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C=NC=NC=3)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZJOYRCGPBCRRKR-UHFFFAOYSA-N 0.000 claims description 2
- NNMUCYDSPOPUMM-UHFFFAOYSA-N n-[6-[(1-isoquinolin-6-ylpiperidin-4-yl)-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CN=CC=C1C(F)(F)F NNMUCYDSPOPUMM-UHFFFAOYSA-N 0.000 claims description 2
- JGJPCJGEFRUYEC-UHFFFAOYSA-N n-[6-[(1-isoquinolin-6-ylpiperidin-4-yl)-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CN=CN=C1 JGJPCJGEFRUYEC-UHFFFAOYSA-N 0.000 claims description 2
- XWLKHIVNZJBAOL-UHFFFAOYSA-N n-[6-[2-(1-pyridin-4-ylpiperidin-4-yl)ethylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C=NC=NC=3)C2=CC=1C(=O)NCCC(CC1)CCN1C1=CC=NC=C1 XWLKHIVNZJBAOL-UHFFFAOYSA-N 0.000 claims description 2
- IDGCUVNOEPHETQ-UHFFFAOYSA-N n-[6-[[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-n-methyl-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1N=CC=C(C(F)(F)F)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 IDGCUVNOEPHETQ-UHFFFAOYSA-N 0.000 claims description 2
- XJHILUWQTPLEBV-UHFFFAOYSA-N n-[6-[[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C=NC=NC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 XJHILUWQTPLEBV-UHFFFAOYSA-N 0.000 claims description 2
- TZHXFQIKRNBHBK-UHFFFAOYSA-N n-[6-[[1-(2-cyclopropylpyrimidin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=NC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1C1CC1 TZHXFQIKRNBHBK-UHFFFAOYSA-N 0.000 claims description 2
- CJEONUFZJGKLGN-UHFFFAOYSA-N n-[6-[[1-[2-(dimethylamino)-6-methylpyrimidin-4-yl]piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound CN(C)C1=NC(C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3C(NC(=O)C=4C(=NC=CC=4)C(F)(F)F)CCC3=CC=2)=N1 CJEONUFZJGKLGN-UHFFFAOYSA-N 0.000 claims description 2
- GWOWPPZAABJSMY-UHFFFAOYSA-N n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-3,4-dihydro-2h-chromen-4-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C=NC=NC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GWOWPPZAABJSMY-UHFFFAOYSA-N 0.000 claims description 2
- LKCSUVAWCOOURL-UHFFFAOYSA-N n-[6-[methyl-[1-(2-pyrrolidin-1-ylpyrimidin-4-yl)piperidin-4-yl]carbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=NC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1N1CCCC1 LKCSUVAWCOOURL-UHFFFAOYSA-N 0.000 claims description 2
- UAVXOOQMIINCAJ-UHFFFAOYSA-N n-[6-[methyl-[4-(3-methyl-5-oxo-7h-imidazo[1,5-c]imidazol-6-yl)cyclohexyl]carbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1CC(N2C(N3C(C)=NC=C3C2)=O)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CC=CN=C1C(F)(F)F UAVXOOQMIINCAJ-UHFFFAOYSA-N 0.000 claims description 2
- GRPNXWNUHZLEGU-UHFFFAOYSA-N n-methyl-1-(3-methylbutanoylamino)-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)CC(C)C)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GRPNXWNUHZLEGU-UHFFFAOYSA-N 0.000 claims description 2
- OWCIQFJSSRTAPJ-UHFFFAOYSA-N n-methyl-3-(3-methylbutanoylamino)-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(NC(=O)CC(C)C)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 OWCIQFJSSRTAPJ-UHFFFAOYSA-N 0.000 claims description 2
- HFRALKMQPNQQLY-UHFFFAOYSA-N n-methyl-3-[methyl-[[2-(trifluoromethyl)phenyl]methylsulfonyl]amino]-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C)S(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HFRALKMQPNQQLY-UHFFFAOYSA-N 0.000 claims description 2
- LHPZODBZWFZMHE-UHFFFAOYSA-N n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-1-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NS(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LHPZODBZWFZMHE-UHFFFAOYSA-N 0.000 claims description 2
- TYXSDQYXWNHLQU-UHFFFAOYSA-N n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 TYXSDQYXWNHLQU-UHFFFAOYSA-N 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- IXTDBCCTUKVCGY-MQBBKVSDSA-N (3r)-3-[3,4-dimethylpentanoyl(methyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)CC(C)C(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 IXTDBCCTUKVCGY-MQBBKVSDSA-N 0.000 claims 19
- NKIDZPZAWSBDMY-UHFFFAOYSA-N 3-(cyclohexanecarbonylamino)-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1CCCCC1 NKIDZPZAWSBDMY-UHFFFAOYSA-N 0.000 claims 2
- KYCWKQROVUZNDQ-UHFFFAOYSA-N 3-(cyclohexanecarbonylamino)-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C3CCCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 KYCWKQROVUZNDQ-UHFFFAOYSA-N 0.000 claims 2
- CKXIQDYSZXQAAS-UHFFFAOYSA-N 3-[(2-chloro-5-fluorobenzoyl)amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=CC=C(F)C=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CKXIQDYSZXQAAS-UHFFFAOYSA-N 0.000 claims 2
- SLQAUNCCPNDFRJ-UHFFFAOYSA-N 3-[(2-chloro-5-fluorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=C(F)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SLQAUNCCPNDFRJ-UHFFFAOYSA-N 0.000 claims 2
- QKVZJJLVFSTJEA-UHFFFAOYSA-N 8-[(2-chloro-5-fluorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=CC=C(F)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QKVZJJLVFSTJEA-UHFFFAOYSA-N 0.000 claims 2
- BQPGRKDLTUNAAK-AREMUKBSSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-6-fluoro-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1([C@H](N2C(C3=C(Cl)C=CC=C3C2)=O)CCC=1C=1)C=C(F)C=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 BQPGRKDLTUNAAK-AREMUKBSSA-N 0.000 claims 1
- NEQKBYIQDOTZDC-AREMUKBSSA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2)N3C(C4=C(Cl)C=CC=C4C3)=O)CC1=CC=2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NEQKBYIQDOTZDC-AREMUKBSSA-N 0.000 claims 1
- GQDMJQOCDQGHQQ-GDLZYMKVSA-N (1r)-1-[(2-chlorobenzoyl)-propan-2-ylamino]-6-fluoro-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2F)N(C(C)C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GQDMJQOCDQGHQQ-GDLZYMKVSA-N 0.000 claims 1
- MFJHCDNVCOKOAJ-MFMCTBQISA-N (1s)-n-[(1r)-6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]-1,2,3,4-tetrahydronaphthalene-1-carboxamide Chemical compound C1([C@H](NC(=O)[C@@H]2C3=CC=CC=C3CCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MFJHCDNVCOKOAJ-MFMCTBQISA-N 0.000 claims 1
- KLNFFSLMHRUYNJ-MUUNZHRXSA-N (3r)-3-(3-cyclopentylpropanoylamino)-n-methyl-n-[1-(2-methylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)CCC2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C)=C1 KLNFFSLMHRUYNJ-MUUNZHRXSA-N 0.000 claims 1
- YPNPQYKFMQOYNH-XMMPIXPASA-N (3r)-3-(cyclobutanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C2CCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YPNPQYKFMQOYNH-XMMPIXPASA-N 0.000 claims 1
- INGCFJWAPQYXRH-HHHXNRCGSA-N (3r)-3-[(2-chloro-3-fluorobenzoyl)-ethylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=C(F)C=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 INGCFJWAPQYXRH-HHHXNRCGSA-N 0.000 claims 1
- ULRQAOVYBQDSPM-HSZRJFAPSA-N (3r)-3-[(2-chloro-3-fluorobenzoyl)amino]-n-methyl-n-(1-pyrimidin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=C(F)C=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=N1 ULRQAOVYBQDSPM-HSZRJFAPSA-N 0.000 claims 1
- JJHJSIRNVKAIOE-HHHXNRCGSA-N (3r)-3-[(2-chloro-4-fluorobenzoyl)-methylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C=3C(=CC(F)=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 JJHJSIRNVKAIOE-HHHXNRCGSA-N 0.000 claims 1
- SHFFLQMLMQOFEY-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C=3C(=CC=CC=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SHFFLQMLMQOFEY-HHHXNRCGSA-N 0.000 claims 1
- PRQUOKHSDZLGHC-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N[C@H]1C2=CC(C(=O)NC3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 PRQUOKHSDZLGHC-RUZDIDTESA-N 0.000 claims 1
- UALIWVBYFZRFOY-AVJYQCBHSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-(3,3-dimethyl-1-pyridin-4-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(C(C1)(C)C)CCN1C1=CC=NC=C1 UALIWVBYFZRFOY-AVJYQCBHSA-N 0.000 claims 1
- SIBIOJLIZOZMMN-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2-methoxypyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC(OC)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=C1 SIBIOJLIZOZMMN-AREMUKBSSA-N 0.000 claims 1
- NGKBHQYAUAHTDT-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(4-chlorophenyl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=C(Cl)C=C1 NGKBHQYAUAHTDT-HHHXNRCGSA-N 0.000 claims 1
- MNXLTHHLNMCHGP-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(4-fluorophenyl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=C(F)C=C1 MNXLTHHLNMCHGP-HHHXNRCGSA-N 0.000 claims 1
- ILUFFEBIERVVMP-LEQGEALCSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-[5-(trifluoromethyl)pyridin-2-yl]pyrrolidin-3-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound N1=CC(C(F)(F)F)=CC=C1N1CC(NC(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)CC1 ILUFFEBIERVVMP-LEQGEALCSA-N 0.000 claims 1
- PEYFLOWKIAMVLS-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-[6-(dimethylamino)pyridin-3-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC(N(C)C)=CC=C1N1CCC(N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)CC1 PEYFLOWKIAMVLS-HHHXNRCGSA-N 0.000 claims 1
- MTQDYONUUYHGQZ-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-cyclopropyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC1=CC=CC=C1C(=O)N[C@H]1C2=CC(C(=O)N(C3CC3)C3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 MTQDYONUUYHGQZ-MUUNZHRXSA-N 0.000 claims 1
- GKSVKGFXVVGAIL-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-ethyl-n-[1-(2-methylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(CC)C(CC1)CCN1C1=CC=NC(C)=C1 GKSVKGFXVVGAIL-MUUNZHRXSA-N 0.000 claims 1
- GHGXIZHEQWZCRJ-XMMPIXPASA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-ethyl-n-[1-(7h-purin-6-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)N(C1CCN(CC1)C=1C=2NC=NC=2N=CN=1)CC)C(=O)C1=CC=CC=C1Cl GHGXIZHEQWZCRJ-XMMPIXPASA-N 0.000 claims 1
- QNJREDLCBGSFNF-XMMPIXPASA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylazetidin-3-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(C1)CN1C1=CC=NC=C1 QNJREDLCBGSFNF-XMMPIXPASA-N 0.000 claims 1
- BWQYLYBBGIZBKP-XMMPIXPASA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-(1-pyrimidin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=N1 BWQYLYBBGIZBKP-XMMPIXPASA-N 0.000 claims 1
- GWLHIHZBZCHSOE-HAPLJMJGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-(4-pyridin-4-yloxycyclohexyl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCC1OC1=CC=NC=C1 GWLHIHZBZCHSOE-HAPLJMJGSA-N 0.000 claims 1
- DIEIDWRRNUEJSL-XMMPIXPASA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(1-methylimidazol-2-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=NC=CN1C DIEIDWRRNUEJSL-XMMPIXPASA-N 0.000 claims 1
- JQRZBXNJSMKJPJ-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(6-methylpyrazin-2-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CN=CC(C)=N1 JQRZBXNJSMKJPJ-RUZDIDTESA-N 0.000 claims 1
- IFHNVZUYDNCGAD-MUUNZHRXSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-propan-2-yl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C(C)C)C(CC1)CCN1C1=CC=NC=C1 IFHNVZUYDNCGAD-MUUNZHRXSA-N 0.000 claims 1
- BTHYHKZIORYJDS-HSZRJFAPSA-N (3r)-3-[(2-fluoro-2-methylpropanoyl)amino]-n-methyl-n-[1-(2-methylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C(C)(C)F)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C)=C1 BTHYHKZIORYJDS-HSZRJFAPSA-N 0.000 claims 1
- FREMCQPIYLMQJZ-GDLZYMKVSA-N (3r)-3-[(2-tert-butylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)C(C)(C)C)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FREMCQPIYLMQJZ-GDLZYMKVSA-N 0.000 claims 1
- XMXVDTUMXKVGHZ-HHHXNRCGSA-N (3r)-3-[[2-(2-chlorophenyl)acetyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)CC=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XMXVDTUMXKVGHZ-HHHXNRCGSA-N 0.000 claims 1
- COCOTXUUHBVHJN-RUZDIDTESA-N (3r)-3-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=C(C=CC=2)C(F)(F)F)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 COCOTXUUHBVHJN-RUZDIDTESA-N 0.000 claims 1
- ZLYBPDJEIZCTAF-AREMUKBSSA-N (3r)-3-benzamido-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C=CC=CC=2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZLYBPDJEIZCTAF-AREMUKBSSA-N 0.000 claims 1
- QKKZMWOLMWFHDB-HHHXNRCGSA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-3-[(2-methylbenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)C)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 QKKZMWOLMWFHDB-HHHXNRCGSA-N 0.000 claims 1
- OWCIQFJSSRTAPJ-XMMPIXPASA-N (3r)-n-methyl-3-(3-methylbutanoylamino)-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)NC(=O)CC(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 OWCIQFJSSRTAPJ-XMMPIXPASA-N 0.000 claims 1
- SOAPFWLNACTRMP-HHHXNRCGSA-N (8r)-8-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C1([C@H](N2C(C3=C(Cl)C=CC=C3C2)=O)CCCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 SOAPFWLNACTRMP-HHHXNRCGSA-N 0.000 claims 1
- UXYRXGFUANQKTA-UHFFFAOYSA-N 1,2-oxazole-3-carboxylic acid Chemical compound OC(=O)C=1C=CON=1 UXYRXGFUANQKTA-UHFFFAOYSA-N 0.000 claims 1
- RMHKREFRDHJBGE-UHFFFAOYSA-N 1-(3-cyclopentylpropanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)CCC3CCCC3)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 RMHKREFRDHJBGE-UHFFFAOYSA-N 0.000 claims 1
- KWJXJZDQWIGSBZ-UHFFFAOYSA-N 1-[(2-chloro-5-fluorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C=3C(=CC=C(F)C=3)Cl)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 KWJXJZDQWIGSBZ-UHFFFAOYSA-N 0.000 claims 1
- XIZQVWFVODWMDZ-UHFFFAOYSA-N 1-[[2-(2-chlorophenyl)-2-methylpropanoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2C(NC(=O)C(C)(C)C=3C(=CC=CC=3)Cl)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 XIZQVWFVODWMDZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002995 2-(trifluoromethyl)benzoyl group Chemical group FC(C1=C(C(=O)*)C=CC=C1)(F)F 0.000 claims 1
- SASQKEAVGFGVRL-UHFFFAOYSA-N 3-(3,3-dimethylbutanoylamino)-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2CCC(NC(=O)CC(C)(C)C)C2=CC(C(=O)N(C2CCN(CC2)C=2C=C3C=CN=CC3=CC=2)C)=C1 SASQKEAVGFGVRL-UHFFFAOYSA-N 0.000 claims 1
- HVYZQKRSSVXTAJ-UHFFFAOYSA-N 3-(3,3-dimethylbutanoylamino)-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CC(C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 HVYZQKRSSVXTAJ-UHFFFAOYSA-N 0.000 claims 1
- DYMSEBCGNCOBDW-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)CCC3CCCC3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 DYMSEBCGNCOBDW-UHFFFAOYSA-N 0.000 claims 1
- JJHHTJWQQQQHNK-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-[1-(5-fluoropyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=NC=NC=C1F JJHHTJWQQQQHNK-UHFFFAOYSA-N 0.000 claims 1
- UFHLVWQGKJDUAZ-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CC2=CC=C(C(=O)NCCC3CCN(CC3)C=3C=CN=CC=3)C=C2C1NC(=O)CCC1CCCC1 UFHLVWQGKJDUAZ-UHFFFAOYSA-N 0.000 claims 1
- YCZWFKSNKIJWLC-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YCZWFKSNKIJWLC-UHFFFAOYSA-N 0.000 claims 1
- JQSRNEFZAPWVSP-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-methyl-n-[1-(2-methylsulfonylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(S(C)(=O)=O)=N1 JQSRNEFZAPWVSP-UHFFFAOYSA-N 0.000 claims 1
- FQPJOQUEWXTDJI-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-methyl-n-[1-(2-pyrrolidin-1-ylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1N1CCCC1 FQPJOQUEWXTDJI-UHFFFAOYSA-N 0.000 claims 1
- BNKDZKLUEGLFKS-UHFFFAOYSA-N 3-(butanoylamino)-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC=CC2=CC(N3CCC(CC3)N(C)C(=O)C3=CC=C4CCC(C4=C3)NC(=O)CCC)=CC=C21 BNKDZKLUEGLFKS-UHFFFAOYSA-N 0.000 claims 1
- STDSANRYQCUQHZ-UHFFFAOYSA-N 3-(butanoylamino)-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(NC(=O)CCC)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 STDSANRYQCUQHZ-UHFFFAOYSA-N 0.000 claims 1
- MZVDRTQAUWLAMS-UHFFFAOYSA-N 3-(cyclohexanecarbonylamino)-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C3CCCCC3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MZVDRTQAUWLAMS-UHFFFAOYSA-N 0.000 claims 1
- ZOVOMKHZTUYFNT-UHFFFAOYSA-N 3-(cyclohexanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C3CCCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZOVOMKHZTUYFNT-UHFFFAOYSA-N 0.000 claims 1
- NYFUJVNQEKNFMG-UHFFFAOYSA-N 3-(cyclopropanecarbonylamino)-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1CC1 NYFUJVNQEKNFMG-UHFFFAOYSA-N 0.000 claims 1
- HYLFYMWANDFMTQ-UHFFFAOYSA-N 3-(cyclopropanecarbonylamino)-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C3CC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 HYLFYMWANDFMTQ-UHFFFAOYSA-N 0.000 claims 1
- JNFOJGYKDVUJFH-UHFFFAOYSA-N 3-[(2,3-dichlorobenzoyl)amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C=3C(=C(Cl)C=CC=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 JNFOJGYKDVUJFH-UHFFFAOYSA-N 0.000 claims 1
- MCMBMBZKDNFIEA-UHFFFAOYSA-N 3-[(2,3-dichlorobenzoyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 MCMBMBZKDNFIEA-UHFFFAOYSA-N 0.000 claims 1
- GQLVKPYNKWVGNP-UHFFFAOYSA-N 3-[(2,3-dichlorophenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC=CC(Cl)=C1Cl GQLVKPYNKWVGNP-UHFFFAOYSA-N 0.000 claims 1
- AVRPPTIQUWJKIS-UHFFFAOYSA-N 3-[(2,3-dichlorophenyl)carbamoylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)NC=3C(=C(Cl)C=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 AVRPPTIQUWJKIS-UHFFFAOYSA-N 0.000 claims 1
- LAKSAXPNIOOEDL-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 LAKSAXPNIOOEDL-UHFFFAOYSA-N 0.000 claims 1
- GNPFVLFYVUPZDC-UHFFFAOYSA-N 3-[(2,4-dichlorophenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC=C(Cl)C=C1Cl GNPFVLFYVUPZDC-UHFFFAOYSA-N 0.000 claims 1
- MVGFQNJJWSOYOZ-UHFFFAOYSA-N 3-[(2,5-dichlorobenzoyl)amino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)C1=CC(Cl)=CC=C1Cl MVGFQNJJWSOYOZ-UHFFFAOYSA-N 0.000 claims 1
- MSXHMZHFHMUVCI-UHFFFAOYSA-N 3-[(2,5-dichlorophenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=CC(Cl)=CC=C1Cl MSXHMZHFHMUVCI-UHFFFAOYSA-N 0.000 claims 1
- JQAUUQVTEKQYON-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=CC=CC=3Cl)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 JQAUUQVTEKQYON-UHFFFAOYSA-N 0.000 claims 1
- HCLHQDATYQRWEC-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)NC1=C(Cl)C=CC=C1Cl HCLHQDATYQRWEC-UHFFFAOYSA-N 0.000 claims 1
- MVFSOOWIDMVUIY-UHFFFAOYSA-N 3-[(2-chloro-5-fluorobenzoyl)amino]-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound FC1=CC=C(Cl)C(C(=O)NC2C3=CC(=CC=C3CC2)C(=O)NCCC2CCN(CC2)C=2C=CN=CC=2)=C1 MVFSOOWIDMVUIY-UHFFFAOYSA-N 0.000 claims 1
- RJRCQAVTZWMVAH-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylbenzoyl)-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound FC=1C=CC(C)=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 RJRCQAVTZWMVAH-UHFFFAOYSA-N 0.000 claims 1
- ACDBYRACSLZQDA-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 ACDBYRACSLZQDA-UHFFFAOYSA-N 0.000 claims 1
- SHFFLQMLMQOFEY-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 SHFFLQMLMQOFEY-UHFFFAOYSA-N 0.000 claims 1
- VCRKZJRUNMAHEM-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-n-[1-(2-cyclopropylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1C1CC1 VCRKZJRUNMAHEM-UHFFFAOYSA-N 0.000 claims 1
- VMDZPGLQUSGFDE-UHFFFAOYSA-N 3-[(2-fluorophenyl)methylsulfonylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CN(C=2C=C3C=CN=CC3=CC=2)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NS(=O)(=O)CC1=CC=CC=C1F VMDZPGLQUSGFDE-UHFFFAOYSA-N 0.000 claims 1
- WYYJGUYTTXXUGW-UHFFFAOYSA-N 3-[(2-methoxyacetyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)COC)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WYYJGUYTTXXUGW-UHFFFAOYSA-N 0.000 claims 1
- NMZAGIWELBEVOP-UHFFFAOYSA-N 3-[(2-methoxyacetyl)amino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C1=C2C(NC(=O)COC)CC(C)(C)C2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NMZAGIWELBEVOP-UHFFFAOYSA-N 0.000 claims 1
- MRWCPOACXDKUCH-UHFFFAOYSA-N 3-[(3,5-dichlorophenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(Cl)=CC(Cl)=CC=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 MRWCPOACXDKUCH-UHFFFAOYSA-N 0.000 claims 1
- MHXQPIPDEDGNGN-UHFFFAOYSA-N 3-[2-(2-chlorophenyl)ethylsulfonylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)CCC=3C(=CC=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 MHXQPIPDEDGNGN-UHFFFAOYSA-N 0.000 claims 1
- WPTLJWGMZOLJJY-UHFFFAOYSA-N 3-[3,3-dimethylbutanoyl(methyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)CC(C)(C)C)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 WPTLJWGMZOLJJY-UHFFFAOYSA-N 0.000 claims 1
- WKKUIRSGYXVTRV-UHFFFAOYSA-N 3-[[2-[2-chloro-6-(trifluoromethyl)phenyl]-2-oxoethyl]amino]-N-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-N-methyl-2,3-dihydro-1H-indene-5-carboxamide Chemical compound ClC1=C(C(=O)CNC2CCC3=CC=C(C=C23)C(=O)N(C)C2CCN(CC2)C2=CC(=NC(=C2)C)C)C(=CC=C1)C(F)(F)F WKKUIRSGYXVTRV-UHFFFAOYSA-N 0.000 claims 1
- MWRIUMYAUHNICN-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)benzoyl]-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC=1C=CC=C(C(F)(F)F)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 MWRIUMYAUHNICN-UHFFFAOYSA-N 0.000 claims 1
- LVWHIABIVOBGER-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LVWHIABIVOBGER-UHFFFAOYSA-N 0.000 claims 1
- ZRJDJRGVXCBSPJ-UHFFFAOYSA-N 3-chloro-n-[3,3-dimethyl-6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-1,2-dihydroinden-1-yl]thiophene-2-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C3=C(C=CS3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZRJDJRGVXCBSPJ-UHFFFAOYSA-N 0.000 claims 1
- VGQNXBRFSMKNGP-UHFFFAOYSA-N 3-chloro-n-[5-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]thiophene-2-carboxamide Chemical compound C=1C=C2C(NC(=O)C3=C(C=CS3)Cl)CCC2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VGQNXBRFSMKNGP-UHFFFAOYSA-N 0.000 claims 1
- PYBGNUCKTVYIGM-UHFFFAOYSA-N 3-chloro-n-[6-[[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-n-methylthiophene-2-carboxamide Chemical compound S1C=CC(Cl)=C1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 PYBGNUCKTVYIGM-UHFFFAOYSA-N 0.000 claims 1
- GOYZJPQPAYRRRT-UHFFFAOYSA-N 3-chloro-n-[6-[[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]thiophene-2-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C3=C(C=CS3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 GOYZJPQPAYRRRT-UHFFFAOYSA-N 0.000 claims 1
- TXDKRVIUZSANKK-UHFFFAOYSA-N 4-(3-cyclopentylpropanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 TXDKRVIUZSANKK-UHFFFAOYSA-N 0.000 claims 1
- HQHMYAMNUGCQJC-UHFFFAOYSA-N 4-[(2,4-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)NC=3C(=CC(Cl)=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HQHMYAMNUGCQJC-UHFFFAOYSA-N 0.000 claims 1
- AHYVVPLZALZMOX-UHFFFAOYSA-N 4-[(2-chloro-5-fluorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=CC=C(F)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 AHYVVPLZALZMOX-UHFFFAOYSA-N 0.000 claims 1
- CHSLSWWQZUFSBV-UHFFFAOYSA-N 4-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NS(=O)(=O)C=3C(=CC=CC=3Cl)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CHSLSWWQZUFSBV-UHFFFAOYSA-N 0.000 claims 1
- BRORSRAKFPIEPN-UHFFFAOYSA-N 8-(3,3-dimethylbutanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)CC(C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BRORSRAKFPIEPN-UHFFFAOYSA-N 0.000 claims 1
- CQRTVBROZRVLNF-UHFFFAOYSA-N 8-(3-cyclopentylpropanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)CCC3CCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 CQRTVBROZRVLNF-UHFFFAOYSA-N 0.000 claims 1
- FAWNOBKCIDHDJW-UHFFFAOYSA-N 8-(cyclohexanecarbonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C3CCCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FAWNOBKCIDHDJW-UHFFFAOYSA-N 0.000 claims 1
- FWJNNEIAKXEYIG-UHFFFAOYSA-N 8-(cyclohexylsulfonylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NS(=O)(=O)C3CCCCC3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FWJNNEIAKXEYIG-UHFFFAOYSA-N 0.000 claims 1
- LMGMGLANMPSULN-UHFFFAOYSA-N 8-[(2,3-dichlorobenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 LMGMGLANMPSULN-UHFFFAOYSA-N 0.000 claims 1
- VYCYKMNXDOJFJY-UHFFFAOYSA-N 8-[(2,4-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C(=CC(Cl)=CC=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VYCYKMNXDOJFJY-UHFFFAOYSA-N 0.000 claims 1
- PJXCQZJJZOCSQM-UHFFFAOYSA-N 8-[(2,6-dimethylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=CC=CC=3C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 PJXCQZJJZOCSQM-UHFFFAOYSA-N 0.000 claims 1
- MWUGCMMXXJELRM-UHFFFAOYSA-N 8-[(2-methoxyacetyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C1=C2C(NC(=O)COC)CCCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 MWUGCMMXXJELRM-UHFFFAOYSA-N 0.000 claims 1
- FDQZOTJMJBPTCE-HHHXNRCGSA-N C1([C@H](NCCC(=O)C2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 Chemical compound C1([C@H](NCCC(=O)C2CCCC2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 FDQZOTJMJBPTCE-HHHXNRCGSA-N 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 1
- 125000005349 heteroarylcycloalkyl group Chemical group 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 claims 1
- MWCJRHAYWMTBBM-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-[[3-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NS(=O)(=O)CC=3C=C(C=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 MWCJRHAYWMTBBM-UHFFFAOYSA-N 0.000 claims 1
- BVJISNBOEBVCAQ-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-[methyl-[[2-(trifluoromethyl)phenyl]methylsulfonyl]amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C)S(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 BVJISNBOEBVCAQ-UHFFFAOYSA-N 0.000 claims 1
- FKGMLYGCPGTSJJ-UHFFFAOYSA-N n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-3-[methyl-[[3-(trifluoromethyl)phenyl]methylsulfonyl]amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(N(C)S(=O)(=O)CC=3C=C(C=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 FKGMLYGCPGTSJJ-UHFFFAOYSA-N 0.000 claims 1
- CWGWKYZBVKPNOB-UHFFFAOYSA-N n-[6-[[1-(2-tert-butylpyrimidin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=NC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C(C)(C)C)=N1 CWGWKYZBVKPNOB-UHFFFAOYSA-N 0.000 claims 1
- PJJYJMFBTTVJMJ-UHFFFAOYSA-N n-[6-[[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3C(NC(=O)C=4C(=NC=CC=4)C(F)(F)F)CCC3=CC=2)=N1 PJJYJMFBTTVJMJ-UHFFFAOYSA-N 0.000 claims 1
- DJPJQMKRSPIJOD-UHFFFAOYSA-N n-[6-[methyl-(1-pyridazin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=NC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NN=C1 DJPJQMKRSPIJOD-UHFFFAOYSA-N 0.000 claims 1
- OGAOIAPVDBMNAX-UHFFFAOYSA-N n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C=NC=NC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 OGAOIAPVDBMNAX-UHFFFAOYSA-N 0.000 claims 1
- PNFYUCOXWLSJGC-UHFFFAOYSA-N n-[6-[methyl-[1-(2-methylsulfonylpyrimidin-4-yl)piperidin-4-yl]carbamoyl]-2,3-dihydro-1h-inden-1-yl]-2-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=NC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(S(C)(=O)=O)=N1 PNFYUCOXWLSJGC-UHFFFAOYSA-N 0.000 claims 1
- IDZVUJNPEHVMAE-UHFFFAOYSA-N n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-4-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NS(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IDZVUJNPEHVMAE-UHFFFAOYSA-N 0.000 claims 1
- IDPCKULAHZYZSM-UHFFFAOYSA-N n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-8-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NS(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IDPCKULAHZYZSM-UHFFFAOYSA-N 0.000 claims 1
- ZNUPMEMTQLKFDP-UHFFFAOYSA-N n-methyl-n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1N=CC=C(C(F)(F)F)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ZNUPMEMTQLKFDP-UHFFFAOYSA-N 0.000 claims 1
- TZHRSIIQPQDPBG-UHFFFAOYSA-N n-methyl-n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]pyrimidine-5-carboxamide Chemical compound C=1N=CN=CC=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 TZHRSIIQPQDPBG-UHFFFAOYSA-N 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 32
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 254
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 192
- 239000000243 solution Substances 0.000 description 161
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 104
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 84
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 83
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
- 238000003786 synthesis reaction Methods 0.000 description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 76
- 230000015572 biosynthetic process Effects 0.000 description 73
- 230000002829 reductive effect Effects 0.000 description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 59
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 57
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 56
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 54
- 229940024606 amino acid Drugs 0.000 description 53
- 239000011780 sodium chloride Substances 0.000 description 51
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 47
- 239000011541 reaction mixture Substances 0.000 description 47
- 229910052938 sodium sulfate Inorganic materials 0.000 description 47
- 235000011152 sodium sulphate Nutrition 0.000 description 47
- 238000006243 chemical reaction Methods 0.000 description 44
- 238000004440 column chromatography Methods 0.000 description 43
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 42
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 42
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 38
- 239000000741 silica gel Substances 0.000 description 36
- 229910002027 silica gel Inorganic materials 0.000 description 36
- 238000004809 thin layer chromatography Methods 0.000 description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 33
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 30
- 150000001412 amines Chemical class 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 28
- 150000001413 amino acids Chemical class 0.000 description 26
- 239000012043 crude product Substances 0.000 description 25
- 238000007792 addition Methods 0.000 description 24
- 239000012074 organic phase Substances 0.000 description 24
- 238000000746 purification Methods 0.000 description 24
- 108020003175 receptors Proteins 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 24
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 23
- 239000012071 phase Substances 0.000 description 23
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 22
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 21
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 20
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- QJWWPTQNLXAJFJ-UHFFFAOYSA-N 1h-indene-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2CC=CC2=C1 QJWWPTQNLXAJFJ-UHFFFAOYSA-N 0.000 description 17
- XRAZLNQNXAFLQZ-UHFFFAOYSA-N n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CNC(=O)C1=CC=C2CCCC2=C1 XRAZLNQNXAFLQZ-UHFFFAOYSA-N 0.000 description 17
- 241000700159 Rattus Species 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000008346 aqueous phase Substances 0.000 description 15
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 15
- 235000019341 magnesium sulphate Nutrition 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- WVMGINRJNBISMA-SNVBAGLBSA-N methyl (3r)-3-amino-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](N)C2=C1 WVMGINRJNBISMA-SNVBAGLBSA-N 0.000 description 14
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- RSENWQHYPMZMBK-HNCPQSOCSA-N methyl (3r)-3-amino-2,3-dihydro-1h-indene-5-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C2CC[C@@H](N)C2=C1 RSENWQHYPMZMBK-HNCPQSOCSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- 229960000583 acetic acid Drugs 0.000 description 11
- 235000019270 ammonium chloride Nutrition 0.000 description 11
- 229960004592 isopropanol Drugs 0.000 description 11
- 229910000027 potassium carbonate Inorganic materials 0.000 description 11
- 235000011181 potassium carbonates Nutrition 0.000 description 11
- QMYMOARPAJVXDF-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C1CCCC2=CC(C(=O)N)=CC=C21 QMYMOARPAJVXDF-UHFFFAOYSA-N 0.000 description 10
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- PMCOWOCKUQWYRL-UHFFFAOYSA-N 2,4-dimethylpyrimidine Chemical compound CC1=CC=NC(C)=N1 PMCOWOCKUQWYRL-UHFFFAOYSA-N 0.000 description 8
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 8
- 229910000024 caesium carbonate Inorganic materials 0.000 description 8
- RSRSIPKNVMHFQY-MRXNPFEDSA-N methyl (3r)-3-[(2-chlorobenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)C(=O)C1=CC=CC=C1Cl RSRSIPKNVMHFQY-MRXNPFEDSA-N 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 8
- PTFJGJNPLJFOTJ-OAHLLOKOSA-N (3r)-3-(4-chloro-3-oxo-1h-isoindol-2-yl)-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound C1C2=CC=CC(Cl)=C2C(=O)N1[C@@H]1CCC2=CC=C(C(=O)O)C=C21 PTFJGJNPLJFOTJ-OAHLLOKOSA-N 0.000 description 7
- ONIKNECPXCLUHT-UHFFFAOYSA-N 2-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1Cl ONIKNECPXCLUHT-UHFFFAOYSA-N 0.000 description 7
- 230000003042 antagnostic effect Effects 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 150000007529 inorganic bases Chemical class 0.000 description 7
- VFTWDTZHSPZVEC-HNCPQSOCSA-N methyl (1r)-1-amino-6-fluoro-2,3-dihydro-1h-indene-5-carboxylate;hydrochloride Chemical compound Cl.C1=C(F)C(C(=O)OC)=CC2=C1[C@H](N)CC2 VFTWDTZHSPZVEC-HNCPQSOCSA-N 0.000 description 7
- NBGPIWZPEVSEAJ-LLVKDONJSA-N methyl (3r)-3-(methylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=C(C(=O)OC)C=C2[C@H](NC)CCC2=C1 NBGPIWZPEVSEAJ-LLVKDONJSA-N 0.000 description 7
- MYYJRUQOMFVEDX-HXUWFJFHSA-N methyl (3r)-3-(naphthalene-1-carbonylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=CC=C2C(C(=O)N[C@@H]3CCC4=CC=C(C=C43)C(=O)OC)=CC=CC2=C1 MYYJRUQOMFVEDX-HXUWFJFHSA-N 0.000 description 7
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 101800004538 Bradykinin Proteins 0.000 description 6
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 6
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 6
- 102100035792 Kininogen-1 Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 239000012298 atmosphere Substances 0.000 description 6
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- XHOUCCWPSDHKDY-UHFFFAOYSA-N methyl 3-(tert-butylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CCC(NC(C)(C)C)C2=C1 XHOUCCWPSDHKDY-UHFFFAOYSA-N 0.000 description 6
- 150000007530 organic bases Chemical class 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- GFMOQFDROXWBAR-OAHLLOKOSA-N (3r)-3-[(2-chlorobenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)O)C(=O)C1=CC=CC=C1Cl GFMOQFDROXWBAR-OAHLLOKOSA-N 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- MGHNDJJPPOAIHK-UHFFFAOYSA-N 1H-inden-1-yl Chemical group C1=CC=C2[CH]C=CC2=C1 MGHNDJJPPOAIHK-UHFFFAOYSA-N 0.000 description 5
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 239000007821 HATU Substances 0.000 description 5
- 101000738546 Homo sapiens Protein PTHB1 Proteins 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 239000005557 antagonist Substances 0.000 description 5
- 229910052786 argon Inorganic materials 0.000 description 5
- 239000003638 chemical reducing agent Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 102000051324 human BBS9 Human genes 0.000 description 5
- WOLRYBGNERNHML-CQSZACIVSA-N methyl (3r)-3-(2-methylpropylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](NCC(C)C)C2=C1 WOLRYBGNERNHML-CQSZACIVSA-N 0.000 description 5
- OZFKCBNSAXXPAM-CQSZACIVSA-N methyl (3r)-3-(2-methylpropylsulfonylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](NS(=O)(=O)CC(C)C)C2=C1 OZFKCBNSAXXPAM-CQSZACIVSA-N 0.000 description 5
- MSJPJDZPBOBCRD-MRXNPFEDSA-N methyl (3r)-3-(4-chloro-3-oxo-1h-isoindol-2-yl)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1C2=CC=CC(Cl)=C2C(=O)N1[C@@H]1CCC2=CC=C(C(=O)OC)C=C21 MSJPJDZPBOBCRD-MRXNPFEDSA-N 0.000 description 5
- YDIGFMQSTVTBKC-HXUWFJFHSA-N methyl (3r)-3-[(2-chlorobenzoyl)-(2-methylpropyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound CC(C)CN([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)C(=O)C1=CC=CC=C1Cl YDIGFMQSTVTBKC-HXUWFJFHSA-N 0.000 description 5
- MIUUKVSKQWPOES-LJQANCHMSA-N methyl (3r)-3-[(2-tert-butylbenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)C(=O)C1=CC=CC=C1C(C)(C)C MIUUKVSKQWPOES-LJQANCHMSA-N 0.000 description 5
- HGGPFIJVIVFMBQ-CYBMUJFWSA-N methyl (3r)-3-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)C(=O)C=1C=C(C)ON=1 HGGPFIJVIVFMBQ-CYBMUJFWSA-N 0.000 description 5
- TYWDEFJBJYEWIP-GOSISDBHSA-N methyl (3r)-3-[3-cyclopentylpropanoyl(methyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound CN([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)C(=O)CCC1CCCC1 TYWDEFJBJYEWIP-GOSISDBHSA-N 0.000 description 5
- LBKLMAHBPUQNLA-HNCPQSOCSA-N methyl (3r)-3-amino-7-fluoro-2,3-dihydro-1h-indene-5-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.FC1=CC(C(=O)OC)=CC2=C1CC[C@H]2N LBKLMAHBPUQNLA-HNCPQSOCSA-N 0.000 description 5
- RSRSIPKNVMHFQY-UHFFFAOYSA-N methyl 3-[(2-chlorobenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C12=CC(C(=O)OC)=CC=C2CCC1NC(=O)C1=CC=CC=C1Cl RSRSIPKNVMHFQY-UHFFFAOYSA-N 0.000 description 5
- 239000012279 sodium borohydride Substances 0.000 description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 5
- USRGGTBTTQICGC-QGZVFWFLSA-N (3r)-3-[3-cyclopentylpropanoyl(methyl)amino]-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound CN([C@H]1C2=CC(=CC=C2CC1)C(O)=O)C(=O)CCC1CCCC1 USRGGTBTTQICGC-QGZVFWFLSA-N 0.000 description 4
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 4
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 4
- 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 4
- GFMOQFDROXWBAR-UHFFFAOYSA-N 3-[(2-chlorobenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound C12=CC(C(=O)O)=CC=C2CCC1NC(=O)C1=CC=CC=C1Cl GFMOQFDROXWBAR-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- VCEHWDBVPZFHAG-POFDKVPJSA-N [des-Arg(9)]-bradykinin Chemical compound NC(N)=NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(O)=O)CCC1 VCEHWDBVPZFHAG-POFDKVPJSA-N 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 239000012346 acetyl chloride Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 125000002015 acyclic group Chemical group 0.000 description 4
- 125000004419 alkynylene group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 125000003725 azepanyl group Chemical group 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- 150000001728 carbonyl compounds Chemical class 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- UOAVOHMMKQRUJN-MRXNPFEDSA-N methyl (1r)-1-[(2-chlorobenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@H]1C2=CC=C(C=C2CC1)C(=O)OC)C(=O)C1=CC=CC=C1Cl UOAVOHMMKQRUJN-MRXNPFEDSA-N 0.000 description 4
- IWSJAHJYMSJWFU-MRXNPFEDSA-N methyl (1r)-1-[(2-chlorobenzoyl)amino]-6-fluoro-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@@H]1CCC=2C=C(C(=CC=21)F)C(=O)OC)C(=O)C1=CC=CC=C1Cl IWSJAHJYMSJWFU-MRXNPFEDSA-N 0.000 description 4
- WFRXIAOCCJDNTB-OAHLLOKOSA-N methyl (1r)-1-[(2-chlorophenyl)sulfonylamino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@H]1C2=CC=C(C=C2CC1)C(=O)OC)S(=O)(=O)C1=CC=CC=C1Cl WFRXIAOCCJDNTB-OAHLLOKOSA-N 0.000 description 4
- UOZGMHAMWDHRQO-HNCPQSOCSA-N methyl (1r)-1-amino-2,3-dihydro-1h-indene-5-carboxylate;hydrochloride Chemical compound Cl.COC(=O)C1=CC=C2[C@H](N)CCC2=C1 UOZGMHAMWDHRQO-HNCPQSOCSA-N 0.000 description 4
- QPKQEYQAYAQPNJ-GFCCVEGCSA-N methyl (3r)-3-(ethylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=C(C(=O)OC)C=C2[C@H](NCC)CCC2=C1 QPKQEYQAYAQPNJ-GFCCVEGCSA-N 0.000 description 4
- GEBKASLAGFRJDP-CYBMUJFWSA-N methyl (3r)-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](NC(=O)OC(C)(C)C)C2=C1 GEBKASLAGFRJDP-CYBMUJFWSA-N 0.000 description 4
- 230000002981 neuropathic effect Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 4
- 230000009278 visceral effect Effects 0.000 description 4
- XDRGSRPRSKWXFM-CYBMUJFWSA-N (3r)-3-(2-methylpropylsulfonylamino)-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2[C@H](NS(=O)(=O)CC(C)C)CCC2=C1 XDRGSRPRSKWXFM-CYBMUJFWSA-N 0.000 description 3
- SYHDYZYWNSYKDP-LJQANCHMSA-N (3r)-3-(naphthalene-1-carbonylamino)-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound C1=CC=C2C(C(=O)N[C@@H]3CCC4=CC=C(C=C43)C(=O)O)=CC=CC2=C1 SYHDYZYWNSYKDP-LJQANCHMSA-N 0.000 description 3
- LJJHAGDPXRSHEM-LJQANCHMSA-N (3r)-3-[(2-chlorobenzoyl)-(2-methylpropyl)amino]-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound CC(C)CN([C@H]1C2=CC(=CC=C2CC1)C(O)=O)C(=O)C1=CC=CC=C1Cl LJJHAGDPXRSHEM-LJQANCHMSA-N 0.000 description 3
- PYLNLQWYYMAPOA-GOSISDBHSA-N (3r)-3-[(2-tert-butylbenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound CC(C)(C)C1=CC=CC=C1C(=O)N[C@H]1C2=CC(C(O)=O)=CC=C2CC1 PYLNLQWYYMAPOA-GOSISDBHSA-N 0.000 description 3
- KSBNGDDPVVKEAI-GFCCVEGCSA-N (3r)-3-[(5-methyl-1,2-oxazole-3-carbonyl)amino]-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound O1C(C)=CC(C(=O)N[C@H]2C3=CC(=CC=C3CC2)C(O)=O)=N1 KSBNGDDPVVKEAI-GFCCVEGCSA-N 0.000 description 3
- SUSOEDGCVYQSCH-CQSZACIVSA-N (4r)-4-(4-chloro-3-oxo-1h-isoindol-2-yl)-8-fluoro-3,4-dihydro-2h-chromene-6-carboxylic acid Chemical compound C1C2=CC=CC(Cl)=C2C(=O)N1[C@@H]1CCOC2=C(F)C=C(C(=O)O)C=C21 SUSOEDGCVYQSCH-CQSZACIVSA-N 0.000 description 3
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 101000695701 Homo sapiens B1 bradykinin receptor Proteins 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 125000006242 amine protecting group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- CQVOMHUJOWJRJD-MRXNPFEDSA-N methyl (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-6-fluoro-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1C2=CC=CC(Cl)=C2C(=O)N1[C@@H]1CCC2=C1C=C(F)C(C(=O)OC)=C2 CQVOMHUJOWJRJD-MRXNPFEDSA-N 0.000 description 3
- GICOTGUAWURDCI-PVQCJRHBSA-N methyl (3r)-3-(3,4-dimethylpentanoylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](NC(=O)CC(C)C(C)C)C2=C1 GICOTGUAWURDCI-PVQCJRHBSA-N 0.000 description 3
- OHXBDYVEXZQILV-OAHLLOKOSA-N methyl (3r)-3-(pyrazolo[1,5-a]pyrimidine-3-carbonylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=NN2C=CC=NC2=C1C(=O)N[C@@H]1CCC2=CC=C(C(=O)OC)C=C21 OHXBDYVEXZQILV-OAHLLOKOSA-N 0.000 description 3
- BGOQYCOCKSQTCP-OAHLLOKOSA-N methyl (3r)-3-[(2-chloro-3-fluorobenzoyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)C(=O)C1=CC=CC(F)=C1Cl BGOQYCOCKSQTCP-OAHLLOKOSA-N 0.000 description 3
- OTQHFHSSWCIQCB-GFCCVEGCSA-N methyl (3r)-3-[(2-fluoro-2-methylpropanoyl)amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](NC(=O)C(C)(C)F)C2=C1 OTQHFHSSWCIQCB-GFCCVEGCSA-N 0.000 description 3
- HLUXBRNELGAODK-MRXNPFEDSA-N methyl (3r)-3-[(4-fluorophenyl)sulfonylamino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound N([C@@H]1CCC2=CC=C(C=C21)C(=O)OC)S(=O)(=O)C1=CC=C(F)C=C1 HLUXBRNELGAODK-MRXNPFEDSA-N 0.000 description 3
- GPHCFHJBDQZIKR-SNVBAGLBSA-N methyl (3r)-3-amino-6-fluoro-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1CC[C@H]2N GPHCFHJBDQZIKR-SNVBAGLBSA-N 0.000 description 3
- NJTSSAZFZFNFPO-UHFFFAOYSA-N methyl 2-(bromomethyl)-6-chlorobenzoate Chemical compound COC(=O)C1=C(Cl)C=CC=C1CBr NJTSSAZFZFNFPO-UHFFFAOYSA-N 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- MOWCIMLOIBGTGG-UHFFFAOYSA-N (1-pyridin-4-ylpiperidin-3-yl)methanamine;dihydrochloride Chemical compound Cl.Cl.C1C(CN)CCCN1C1=CC=NC=C1 MOWCIMLOIBGTGG-UHFFFAOYSA-N 0.000 description 2
- RXDOJDYMUFZQEE-UHFFFAOYSA-N (1-pyridin-4-ylpiperidin-4-yl)methanamine;dihydrochloride Chemical compound Cl.Cl.C1CC(CN)CCN1C1=CC=NC=C1 RXDOJDYMUFZQEE-UHFFFAOYSA-N 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 2
- BCRMPBUSVVTRSK-KAFJHEIMSA-N (3s)-1-(1-cyclopropylpiperidin-4-yl)pyrrolidin-3-amine;trihydrochloride Chemical compound Cl.Cl.Cl.C1[C@@H](N)CCN1C1CCN(C2CC2)CC1 BCRMPBUSVVTRSK-KAFJHEIMSA-N 0.000 description 2
- MAXMUBIIZUKOJF-UHFFFAOYSA-N 1-pyridin-4-ylpiperidin-4-one Chemical compound C1CC(=O)CCN1C1=CC=NC=C1 MAXMUBIIZUKOJF-UHFFFAOYSA-N 0.000 description 2
- XPLSVGOOWYIQTC-UHFFFAOYSA-N 2,2-dimethyl-4-(4-methylpiperazin-1-yl)cyclohexan-1-amine Chemical compound C1CN(C)CCN1C1CC(C)(C)C(N)CC1 XPLSVGOOWYIQTC-UHFFFAOYSA-N 0.000 description 2
- FOJQJDBJBNEHTO-UHFFFAOYSA-N 2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2CCCC2=C1 FOJQJDBJBNEHTO-UHFFFAOYSA-N 0.000 description 2
- UMDLIABIZYDUHP-UHFFFAOYSA-N 2-(1-pyridin-4-ylpiperidin-4-yl)ethanamine Chemical compound C1CC(CCN)CCN1C1=CC=NC=C1 UMDLIABIZYDUHP-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HJLYHXATZHROAL-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-6-carboxamide Chemical compound O1CCCC2=CC(C(=O)N)=CC=C21 HJLYHXATZHROAL-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- YPTSLKZBGOMZSD-UHFFFAOYSA-N 7,7-dimethyl-1,4-dioxaspiro[4.5]decan-8-amine Chemical compound C1CC(N)C(C)(C)CC21OCCO2 YPTSLKZBGOMZSD-UHFFFAOYSA-N 0.000 description 2
- ZVCPUHCJMBMVJA-UHFFFAOYSA-N 8-pyridin-4-yl-1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCN(C=2C=CN=CC=2)CC1 ZVCPUHCJMBMVJA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 108060003359 BDKRB1 Proteins 0.000 description 2
- 102000017916 BDKRB1 Human genes 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 108700042658 GAP-43 Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 2
- 239000002841 Lewis acid Substances 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 101150090155 R gene Proteins 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 230000001270 agonistic effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 2
- RBIAIIOSRGRZPG-UHFFFAOYSA-N benzyl n-(2,2-dimethyl-4-oxocyclohexyl)carbamate Chemical compound CC1(C)CC(=O)CCC1NC(=O)OCC1=CC=CC=C1 RBIAIIOSRGRZPG-UHFFFAOYSA-N 0.000 description 2
- VHSWUNKMNZPZFE-UHFFFAOYSA-N benzyl n-(7,7-dimethyl-1,4-dioxaspiro[4.5]decan-8-yl)carbamate Chemical compound C1CC(NC(=O)OCC=2C=CC=CC=2)C(C)(C)CC21OCCO2 VHSWUNKMNZPZFE-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 150000001649 bromium compounds Chemical class 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001805 chlorine compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000005959 diazepanyl group Chemical group 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 125000005879 dioxolanyl group Chemical group 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000012632 fluorescent imaging Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000007517 lewis acids Chemical class 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- IENHVENZKNEYKT-CYBMUJFWSA-N methyl (1r)-6-fluoro-1-(propan-2-ylamino)-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=C(F)C(C(=O)OC)=CC2=C1[C@H](NC(C)C)CC2 IENHVENZKNEYKT-CYBMUJFWSA-N 0.000 description 2
- LDPVUFYNQPMSOA-OAHLLOKOSA-N methyl (3r)-3-[ethyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound C1=C(C(=O)OC)C=C2[C@H](N(CC)C(=O)OC(C)(C)C)CCC2=C1 LDPVUFYNQPMSOA-OAHLLOKOSA-N 0.000 description 2
- ULPXKCMHQOYJJS-CQSZACIVSA-N methyl (3r)-3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CC[C@@H](N(C)C(=O)OC(C)(C)C)C2=C1 ULPXKCMHQOYJJS-CQSZACIVSA-N 0.000 description 2
- MBNFHJLWRODQRT-CYBMUJFWSA-N methyl (3r)-7-fluoro-3-[(2-methylpropan-2-yl)oxycarbonylamino]-2,3-dihydro-1h-indene-5-carboxylate Chemical compound FC1=CC(C(=O)OC)=CC2=C1CC[C@H]2NC(=O)OC(C)(C)C MBNFHJLWRODQRT-CYBMUJFWSA-N 0.000 description 2
- UCJZSDKGVDIOQR-SBSPUUFOSA-N methyl (4r)-4-amino-3,4-dihydro-2h-chromene-6-carboxylate;hydrochloride Chemical compound Cl.O1CC[C@@H](N)C2=CC(C(=O)OC)=CC=C21 UCJZSDKGVDIOQR-SBSPUUFOSA-N 0.000 description 2
- MYTMBSZOIXTIDU-SECBINFHSA-N methyl (4r)-4-amino-3,4-dihydro-2h-chromene-7-carboxylate Chemical compound N[C@@H]1CCOC2=CC(C(=O)OC)=CC=C21 MYTMBSZOIXTIDU-SECBINFHSA-N 0.000 description 2
- VLUJENWYTCMHBC-UHFFFAOYSA-N methyl 3-hydroxy-2,3-dihydro-1h-indene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CCC(O)C2=C1 VLUJENWYTCMHBC-UHFFFAOYSA-N 0.000 description 2
- YDOOCAKREHMAEB-UHFFFAOYSA-N methyl 3-oxo-1,2-dihydroindene-5-carboxylate Chemical compound COC(=O)C1=CC=C2CCC(=O)C2=C1 YDOOCAKREHMAEB-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- JEVKBVKABVGVBJ-UHFFFAOYSA-N n,n-dibenzyl-2-(1-pyridin-4-ylpiperidin-4-yl)ethanamine Chemical compound C1CN(C=2C=CN=CC=2)CCC1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 JEVKBVKABVGVBJ-UHFFFAOYSA-N 0.000 description 2
- RNGXSQBRBASYFA-UHFFFAOYSA-N n,n-dibenzyl-2-piperidin-4-ylethanamine Chemical compound C1CNCCC1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 RNGXSQBRBASYFA-UHFFFAOYSA-N 0.000 description 2
- BUOGPRWVUKFFQN-UHFFFAOYSA-N n-[(4-methoxyphenyl)methyl]-7,7-dimethyl-1,4-dioxaspiro[4.5]decan-8-amine Chemical compound C1=CC(OC)=CC=C1CNC1C(C)(C)CC2(OCCO2)CC1 BUOGPRWVUKFFQN-UHFFFAOYSA-N 0.000 description 2
- TVWJOMGXJWDIQA-UHFFFAOYSA-N n-methyl-1-pyridin-4-ylpiperidin-4-amine Chemical compound C1CC(NC)CCN1C1=CC=NC=C1 TVWJOMGXJWDIQA-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 2
- 229910000105 potassium hydride Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000010410 reperfusion Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PQEXLIRUMIRSAL-UHFFFAOYSA-N tert-butyl 4-(2-ethoxy-2-oxoethyl)piperidine-1-carboxylate Chemical compound CCOC(=O)CC1CCN(C(=O)OC(C)(C)C)CC1 PQEXLIRUMIRSAL-UHFFFAOYSA-N 0.000 description 2
- NJORMFNJZLXLCN-UHFFFAOYSA-N tert-butyl 4-(2-ethoxy-2-oxoethylidene)piperidine-1-carboxylate Chemical compound CCOC(=O)C=C1CCN(C(=O)OC(C)(C)C)CC1 NJORMFNJZLXLCN-UHFFFAOYSA-N 0.000 description 2
- YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 2
- WSNYPQZNUKSYBI-UHFFFAOYSA-N tert-butyl 4-(2-methylsulfonyloxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCOS(C)(=O)=O)CC1 WSNYPQZNUKSYBI-UHFFFAOYSA-N 0.000 description 2
- NUKQFUYIUNLKBZ-UHFFFAOYSA-N tert-butyl 4-[2-(dibenzylamino)ethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1CCN(CC=1C=CC=CC=1)CC1=CC=CC=C1 NUKQFUYIUNLKBZ-UHFFFAOYSA-N 0.000 description 2
- IVGKRUWVRICRNT-UHFFFAOYSA-N tert-butyl n-[(1-pyridin-4-ylpiperidin-3-yl)methyl]carbamate Chemical compound C1C(CNC(=O)OC(C)(C)C)CCCN1C1=CC=NC=C1 IVGKRUWVRICRNT-UHFFFAOYSA-N 0.000 description 2
- NJRUSULBGRULMH-UHFFFAOYSA-N tert-butyl n-[(1-pyridin-4-ylpiperidin-4-yl)methyl]carbamate Chemical compound C1CC(CNC(=O)OC(C)(C)C)CCN1C1=CC=NC=C1 NJRUSULBGRULMH-UHFFFAOYSA-N 0.000 description 2
- WGDSWCSACGPFNR-CQSZACIVSA-N tert-butyl n-[(1r)-6-bromo-2,3-dihydro-1h-inden-1-yl]-n-ethylcarbamate Chemical compound C1=C(Br)C=C2[C@H](N(CC)C(=O)OC(C)(C)C)CCC2=C1 WGDSWCSACGPFNR-CQSZACIVSA-N 0.000 description 2
- YZEZLDIZHPBHGQ-GFCCVEGCSA-N tert-butyl n-[(1r)-6-bromo-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C1=C(Br)C=C2[C@H](NC(=O)OC(C)(C)C)CCC2=C1 YZEZLDIZHPBHGQ-GFCCVEGCSA-N 0.000 description 2
- ZJFDQRNXGHPZCU-GFCCVEGCSA-N tert-butyl n-[(1r)-6-bromo-4-fluoro-2,3-dihydro-1h-inden-1-yl]carbamate Chemical compound C1=C(Br)C=C(F)C2=C1[C@H](NC(=O)OC(C)(C)C)CC2 ZJFDQRNXGHPZCU-GFCCVEGCSA-N 0.000 description 2
- NKEKVXFZNYTFDZ-ZDUSSCGKSA-N tert-butyl n-[(3s)-1-(1-cyclopropylpiperidin-4-yl)pyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CCN1C1CCN(C2CC2)CC1 NKEKVXFZNYTFDZ-ZDUSSCGKSA-N 0.000 description 2
- 150000003509 tertiary alcohols Chemical class 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 108700026215 vpr Genes Proteins 0.000 description 2
- GJXZRRJHTPWSCE-RUZDIDTESA-N (1r)-1-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-(1-pyridin-2-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=CC=2)N3C(C4=C(Cl)C=CC=C4C3)=O)CC1=CC=2C(=O)N(C)C(CC1)CCN1C1=CC=CC=N1 GJXZRRJHTPWSCE-RUZDIDTESA-N 0.000 description 1
- UTXGQQGDUZPGLC-SBSPUUFOSA-N (1r)-1-amino-6-fluoro-2,3-dihydro-1h-indene-5-carboxylic acid;hydrochloride Chemical compound Cl.OC(=O)C1=C(F)C=C2[C@H](N)CCC2=C1 UTXGQQGDUZPGLC-SBSPUUFOSA-N 0.000 description 1
- DUPHONQIBOZOHL-SECBINFHSA-N (1r)-6-bromo-2,3-dihydro-1h-inden-1-amine Chemical compound C1=C(Br)C=C2[C@H](N)CCC2=C1 DUPHONQIBOZOHL-SECBINFHSA-N 0.000 description 1
- BLCJJZFYWKDROX-SBSPUUFOSA-N (1r)-6-bromo-4-fluoro-2,3-dihydro-1h-inden-1-amine;hydrochloride Chemical compound Cl.C1=C(Br)C=C(F)C2=C1[C@H](N)CC2 BLCJJZFYWKDROX-SBSPUUFOSA-N 0.000 description 1
- YLHIJNUCVQGQLR-AREMUKBSSA-N (3r)-3-(4-chloro-3-oxo-1h-isoindol-2-yl)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](N2C(C3=C(Cl)C=CC=C3C2)=O)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YLHIJNUCVQGQLR-AREMUKBSSA-N 0.000 description 1
- BYYHZRRXRCQVBS-AREMUKBSSA-N (3r)-3-(benzenesulfonamido)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NS(=O)(=O)C=2C=CC=CC=2)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 BYYHZRRXRCQVBS-AREMUKBSSA-N 0.000 description 1
- RXPHVBKQPIRKTO-RUZDIDTESA-N (3r)-3-[(2-chloro-3-fluorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=C(F)C=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 RXPHVBKQPIRKTO-RUZDIDTESA-N 0.000 description 1
- ZQQHSRMGXLHQGT-MUUNZHRXSA-N (3r)-3-[(2-chloro-5-fluorobenzoyl)-ethylamino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=CC=C(F)C=3)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 ZQQHSRMGXLHQGT-MUUNZHRXSA-N 0.000 description 1
- WZMDGIHOKVZCIF-IPLQWOKBSA-N (3r)-3-[(2-chloro-6-fluorobenzoyl)-ethylamino]-n-[4-(2,6-dimethylpyrimidin-4-yl)cyclohexyl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C=3C(=CC=CC=3F)Cl)CC1=CC=C2C(=O)N(C)C(CC1)CCC1C1=CC(C)=NC(C)=N1 WZMDGIHOKVZCIF-IPLQWOKBSA-N 0.000 description 1
- IYVVPPDKQKMOMZ-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-7-fluoro-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C=1C=2)NC(=O)C=3C(=CC=CC=3)Cl)CC=1C(F)=CC=2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 IYVVPPDKQKMOMZ-AREMUKBSSA-N 0.000 description 1
- BOAMFJSZKPNIAK-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2-cyanopyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C#N)=C1 BOAMFJSZKPNIAK-HHHXNRCGSA-N 0.000 description 1
- QNWVVGVVUVKLHM-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(2-methoxy-6-methylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound COC1=NC(C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 QNWVVGVVUVKLHM-RUZDIDTESA-N 0.000 description 1
- RDLBFFFYDCFVCC-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-(3-fluoropyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1F RDLBFFFYDCFVCC-RUZDIDTESA-N 0.000 description 1
- OCEACOIRABQYJZ-AREMUKBSSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-[2-(dimethylamino)-6-methylpyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC(C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 OCEACOIRABQYJZ-AREMUKBSSA-N 0.000 description 1
- CXUXHRVRFNBWSO-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=N1 CXUXHRVRFNBWSO-RUZDIDTESA-N 0.000 description 1
- LUIMRXZHPPAIGB-QMCAYLGFSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-[4-[2-(dimethylamino)pyridin-4-yl]cyclohexyl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC(N(C)C)=CC(C2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](NC(=O)C=4C(=CC=CC=4)Cl)CCC3=CC=2)=C1 LUIMRXZHPPAIGB-QMCAYLGFSA-N 0.000 description 1
- LXCJMEXQHCELIM-UIDYPRJRSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-(2-oxo-1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1=O)CCN1C1=CC=NC=C1 LXCJMEXQHCELIM-UIDYPRJRSA-N 0.000 description 1
- TYXPEZFQADKPQK-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-methylpyridin-4-yl)azetidin-3-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(C1)CN1C1=CC=NC(C)=C1 TYXPEZFQADKPQK-RUZDIDTESA-N 0.000 description 1
- JIPIRWGAZDDHAE-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-methylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC(C)=N1 JIPIRWGAZDDHAE-RUZDIDTESA-N 0.000 description 1
- ISOSULLRJFPUNT-GDLZYMKVSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-pyrrolidin-1-ylpyridin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C(C=1)=CC=NC=1N1CCCC1 ISOSULLRJFPUNT-GDLZYMKVSA-N 0.000 description 1
- WDILGMNJSZYLJC-HHHXNRCGSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(2-pyrrolidin-1-ylpyrimidin-4-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C(N=1)=CC=NC=1N1CCCC1 WDILGMNJSZYLJC-HHHXNRCGSA-N 0.000 description 1
- QSNRIXVQLRTLLG-HSZRJFAPSA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-(3-methyl-1,2,4-thiadiazol-5-yl)piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=NC(C)=NS1 QSNRIXVQLRTLLG-HSZRJFAPSA-N 0.000 description 1
- NGFWRUIOKCVNIN-RUZDIDTESA-N (3r)-3-[(2-chlorobenzoyl)amino]-n-methyl-n-[1-[3-(trifluoromethyl)pyridin-4-yl]piperidin-4-yl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)Cl)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1C(F)(F)F NGFWRUIOKCVNIN-RUZDIDTESA-N 0.000 description 1
- URHJIOJLPNJDIL-ZSTWXAJCSA-N (3r)-3-[3,4-dimethylpentanoyl(ethyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)CC(C)C(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 URHJIOJLPNJDIL-ZSTWXAJCSA-N 0.000 description 1
- BLXZBJNJBFWJFI-HHHXNRCGSA-N (3r)-3-[3-cyclopentylpropanoyl(methyl)amino]-n-[1-(3-fluoropyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)CCC3CCCC3)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1F BLXZBJNJBFWJFI-HHHXNRCGSA-N 0.000 description 1
- FQSVXAPSQSVOEQ-GDLZYMKVSA-N (3r)-3-[3-cyclopentylpropanoyl(methyl)amino]-n-[1-[2-(dimethylamino)pyridin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=NC(N(C)C)=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](N(C)C(=O)CCC4CCCC4)CCC3=CC=2)=C1 FQSVXAPSQSVOEQ-GDLZYMKVSA-N 0.000 description 1
- NZPLNBQROFKUHM-HHHXNRCGSA-N (3r)-3-[3-cyclopentylpropanoyl(methyl)amino]-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3[C@H](N(C)C(=O)CCC4CCCC4)CCC3=CC=2)=N1 NZPLNBQROFKUHM-HHHXNRCGSA-N 0.000 description 1
- PBNYUQIHOXQPNN-HHHXNRCGSA-N (3r)-3-[cyclopentanecarbonyl(ethyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(CC)C(=O)C3CCCC3)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 PBNYUQIHOXQPNN-HHHXNRCGSA-N 0.000 description 1
- PNWXUIJATSGWOI-AREMUKBSSA-N (3r)-3-[cyclopentanecarbonyl(methyl)amino]-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C)C(=O)C3CCCC3)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 PNWXUIJATSGWOI-AREMUKBSSA-N 0.000 description 1
- WTMWGWDIEAECMP-SECBINFHSA-N (3r)-3-amino-6-fluoro-2,3-dihydro-1h-indene-5-carboxylic acid Chemical compound FC1=C(C(O)=O)C=C2[C@H](N)CCC2=C1 WTMWGWDIEAECMP-SECBINFHSA-N 0.000 description 1
- NDDDASDVTMDXLK-AREMUKBSSA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-3-[(2-fluorobenzoyl)amino]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1([C@H](NC(=O)C=2C(=CC=CC=2)F)CCC1=CC=1)=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 NDDDASDVTMDXLK-AREMUKBSSA-N 0.000 description 1
- GHPNFQJHNQNUSX-XMMPIXPASA-N (3r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-3-(2-methylpropylsulfonylamino)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)NS(=O)(=O)CC(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 GHPNFQJHNQNUSX-XMMPIXPASA-N 0.000 description 1
- XBKNGSKZRMIPNO-MUUNZHRXSA-N (3r)-n-[1-[2-(dimethylamino)pyridin-4-yl]piperidin-4-yl]-n-methyl-3-[3-methylbutanoyl(propan-2-yl)amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)CC(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC(N(C)C)=C1 XBKNGSKZRMIPNO-MUUNZHRXSA-N 0.000 description 1
- GWQWBDUEWDAWCW-AREMUKBSSA-N (3r)-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-3-[3-methylbutanoyl(propan-2-yl)amino]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C([C@H](C1=C2)N(C(C)C)C(=O)CC(C)C)CC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC(N(C)C)=N1 GWQWBDUEWDAWCW-AREMUKBSSA-N 0.000 description 1
- BFPGISFGIPVERK-RUZDIDTESA-N (8r)-n-[1-(2,6-dimethylpyrimidin-4-yl)piperidin-4-yl]-n-methyl-8-(3-methylbutanoylamino)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C([C@H](C1=C2)NC(=O)CC(C)C)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=N1 BFPGISFGIPVERK-RUZDIDTESA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000006545 (C1-C9) alkyl group Chemical group 0.000 description 1
- KPKNTUUIEVXMOH-UHFFFAOYSA-N 1,4-dioxa-8-azaspiro[4.5]decane Chemical compound O1CCOC11CCNCC1 KPKNTUUIEVXMOH-UHFFFAOYSA-N 0.000 description 1
- VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 1
- YVDWTMIIEURGAN-UHFFFAOYSA-N 1-(1-methylpiperidin-4-yl)piperidin-4-amine Chemical compound C1CN(C)CCC1N1CCC(N)CC1 YVDWTMIIEURGAN-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- DTUJRJIWGWTNFQ-UHFFFAOYSA-N 1-cyclopropylpiperidin-4-one Chemical compound C1CC(=O)CCN1C1CC1 DTUJRJIWGWTNFQ-UHFFFAOYSA-N 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- VFTFKUDGYRBSAL-UHFFFAOYSA-N 15-crown-5 Chemical compound C1COCCOCCOCCOCCO1 VFTFKUDGYRBSAL-UHFFFAOYSA-N 0.000 description 1
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 1
- LOWAAWMXRXSOPA-UHFFFAOYSA-N 2-(2-bromo-6-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=C(Br)C=CC=C1[N+]([O-])=O LOWAAWMXRXSOPA-UHFFFAOYSA-N 0.000 description 1
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 1
- DIUKLCJZYOPHGW-UHFFFAOYSA-N 2-chloro-3-fluorobenzoyl chloride Chemical compound FC1=CC=CC(C(Cl)=O)=C1Cl DIUKLCJZYOPHGW-UHFFFAOYSA-N 0.000 description 1
- KMVZDSQHLDGKGV-UHFFFAOYSA-N 2-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=CC=C1S(Cl)(=O)=O KMVZDSQHLDGKGV-UHFFFAOYSA-N 0.000 description 1
- NZDOWZQRNZLBOY-UHFFFAOYSA-N 2-fluoro-2-methylpropanoic acid Chemical compound CC(C)(F)C(O)=O NZDOWZQRNZLBOY-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- AYOCKALCSMCLRL-RUZDIDTESA-N 2-methoxy-n-[(1r)-6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]pyridine-3-carboxamide Chemical compound COC1=NC=CC=C1C(=O)N[C@H]1C2=CC(C(=O)N(C)C3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 AYOCKALCSMCLRL-RUZDIDTESA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- NQLNHTOCFWUYQE-UHFFFAOYSA-N 2-methylpropane-1-sulfonyl chloride Chemical compound CC(C)CS(Cl)(=O)=O NQLNHTOCFWUYQE-UHFFFAOYSA-N 0.000 description 1
- OIGXNHYFKZCTCH-UHFFFAOYSA-N 2-methylsulfonylpyrimidine Chemical compound CS(=O)(=O)C1=NC=CC=N1 OIGXNHYFKZCTCH-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- PCXCZMYBFGWKKH-UHFFFAOYSA-N 2-pyrrolidin-1-ylpyrimidine Chemical compound C1CCCN1C1=NC=CC=N1 PCXCZMYBFGWKKH-UHFFFAOYSA-N 0.000 description 1
- ZDFKSZDMHJHQHS-UHFFFAOYSA-N 2-tert-butylbenzoic acid Chemical compound CC(C)(C)C1=CC=CC=C1C(O)=O ZDFKSZDMHJHQHS-UHFFFAOYSA-N 0.000 description 1
- GETAKGOKCSRVLZ-UHFFFAOYSA-N 3,4-dimethyl valeric acid Chemical compound CC(C)C(C)CC(O)=O GETAKGOKCSRVLZ-UHFFFAOYSA-N 0.000 description 1
- HPXAHQNLRVHAPN-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-[1-[2-(dimethylamino)pyrimidin-4-yl]piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound CN(C)C1=NC=CC(N2CCC(CC2)N(C)C(=O)C=2C=C3C(NC(=O)CCC4CCCC4)CCC3=CC=2)=N1 HPXAHQNLRVHAPN-UHFFFAOYSA-N 0.000 description 1
- GOAKXKLXLCNNND-UHFFFAOYSA-N 3-(3-cyclopentylpropanoylamino)-n-methyl-n-[4-(3-methyl-5-oxo-7h-imidazo[1,5-c]imidazol-6-yl)cyclohexyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1CC(N2C(N3C(C)=NC=C3C2)=O)CCC1N(C)C(=O)C(C=C12)=CC=C1CCC2NC(=O)CCC1CCCC1 GOAKXKLXLCNNND-UHFFFAOYSA-N 0.000 description 1
- FEHYTNRPNZADCY-UHFFFAOYSA-N 3-(cyclopropanecarbonylamino)-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)C3CC3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FEHYTNRPNZADCY-UHFFFAOYSA-N 0.000 description 1
- ONTOVKWCWOSSLA-UHFFFAOYSA-N 3-[(2,3-dichlorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=C(Cl)C=CC=3)Cl)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 ONTOVKWCWOSSLA-UHFFFAOYSA-N 0.000 description 1
- FOAUTPUQONVSKK-UHFFFAOYSA-N 3-[(2,5-dichlorobenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(Cl)=CC=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FOAUTPUQONVSKK-UHFFFAOYSA-N 0.000 description 1
- PYCUTHBGGNHSPY-UHFFFAOYSA-N 3-[(2,6-dichlorophenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound ClC=1C=CC=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 PYCUTHBGGNHSPY-UHFFFAOYSA-N 0.000 description 1
- FJJADFDOAXZAJX-UHFFFAOYSA-N 3-[(2,6-dimethylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=CC=3C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FJJADFDOAXZAJX-UHFFFAOYSA-N 0.000 description 1
- PLETVBGXZKRWEA-UHFFFAOYSA-N 3-[(2-chloro-6-fluoro-3-methylbenzoyl)-methylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound FC=1C=CC(C)=C(Cl)C=1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 PLETVBGXZKRWEA-UHFFFAOYSA-N 0.000 description 1
- QBBXBSILNGVPKT-UHFFFAOYSA-N 3-[(2-methoxyacetyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(NC(=O)COC)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 QBBXBSILNGVPKT-UHFFFAOYSA-N 0.000 description 1
- QEAHEHNZWKISLR-UHFFFAOYSA-N 3-[(3-chloro-4-methylphenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C=C(C)C(Cl)=CC=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 QEAHEHNZWKISLR-UHFFFAOYSA-N 0.000 description 1
- TWHOQCWXZTWZMR-UHFFFAOYSA-N 3-[(3-chlorophenyl)carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C=C(Cl)C=CC=3)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 TWHOQCWXZTWZMR-UHFFFAOYSA-N 0.000 description 1
- QVOMQCGPGCMEFY-UHFFFAOYSA-N 3-[(5-chloro-2-methoxyphenyl)carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound COC1=CC=C(Cl)C=C1NC(=O)N(C)C1C2=CC(C(=O)N(C)C3CCN(CC3)C=3C=C(C)N=C(C)C=3)=CC=C2CC1 QVOMQCGPGCMEFY-UHFFFAOYSA-N 0.000 description 1
- NLAUBOYUSAHEJZ-UHFFFAOYSA-N 3-[(5-chloro-2-methoxyphenyl)carbamoylamino]-n-(1-isoquinolin-6-ylpiperidin-4-yl)-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound COC1=CC=C(Cl)C=C1NC(=O)NC1C2=CC(C(=O)N(C)C3CCN(CC3)C=3C=C4C=CN=CC4=CC=3)=CC=C2CC1 NLAUBOYUSAHEJZ-UHFFFAOYSA-N 0.000 description 1
- RQFSVRIEVVCQHY-UHFFFAOYSA-N 3-[[2-chloro-5-(trifluoromethyl)phenyl]carbamoyl-methylamino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C=1C(C(F)(F)F)=CC=C(Cl)C=1NC(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 RQFSVRIEVVCQHY-UHFFFAOYSA-N 0.000 description 1
- KXCZTERJLKWNTG-UHFFFAOYSA-N 3-[[2-chloro-6-(trifluoromethyl)phenyl]sulfonylamino]-n-[2-(1-pyridin-4-ylpiperidin-4-yl)ethyl]-2,3-dihydro-1h-indene-5-carboxamide Chemical compound FC(F)(F)C1=CC=CC(Cl)=C1S(=O)(=O)NC1C2=CC(C(=O)NCCC3CCN(CC3)C=3C=CN=CC=3)=CC=C2CC1 KXCZTERJLKWNTG-UHFFFAOYSA-N 0.000 description 1
- FLXXCMZULMIGFV-UHFFFAOYSA-N 3-[[4-chloro-2-(trifluoromethyl)phenyl]carbamoylamino]-n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NC(=O)NC=3C(=CC(Cl)=CC=3)C(F)(F)F)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 FLXXCMZULMIGFV-UHFFFAOYSA-N 0.000 description 1
- VSGNRXYDUOYGMW-UHFFFAOYSA-N 3-[butanoyl(methyl)amino]-n-[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-n-methyl-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)CCC)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 VSGNRXYDUOYGMW-UHFFFAOYSA-N 0.000 description 1
- NRWHQVVMMCKYQJ-UHFFFAOYSA-N 3-chloro-n-[7-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-1,2,3,4-tetrahydronaphthalen-1-yl]thiophene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C3=C(C=CS3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NRWHQVVMMCKYQJ-UHFFFAOYSA-N 0.000 description 1
- OEHBIUJVMLQXDQ-UHFFFAOYSA-N 3-chloro-n-methyl-n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]thiophene-2-carboxamide Chemical compound S1C=CC(Cl)=C1C(=O)N(C)C(C1=C2)CCC1=CC=C2C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 OEHBIUJVMLQXDQ-UHFFFAOYSA-N 0.000 description 1
- SZQVEGOXJYTLLB-UHFFFAOYSA-N 3-cyclopentylpropanoyl chloride Chemical compound ClC(=O)CCC1CCCC1 SZQVEGOXJYTLLB-UHFFFAOYSA-N 0.000 description 1
- XJLDYKIEURAVBW-UHFFFAOYSA-N 3-decanone Chemical compound CCCCCCCC(=O)CC XJLDYKIEURAVBW-UHFFFAOYSA-N 0.000 description 1
- DPSUTSGXFVAVPE-HSZRJFAPSA-N 3-methoxy-n-[(1r)-6-[methyl-[1-(2-methylpyridin-4-yl)piperidin-4-yl]carbamoyl]-2,3-dihydro-1h-inden-1-yl]-1,2-oxazole-5-carboxamide Chemical compound O1N=C(OC)C=C1C(=O)N[C@H]1C2=CC(C(=O)N(C)C3CCN(CC3)C=3C=C(C)N=CC=3)=CC=C2CC1 DPSUTSGXFVAVPE-HSZRJFAPSA-N 0.000 description 1
- BIABIACQHKYEEB-UHFFFAOYSA-N 3-oxo-1,2-dihydroindene-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2CCC(=O)C2=C1 BIABIACQHKYEEB-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- QSPCOYVUYYFWAU-UHFFFAOYSA-N 4-(2-carboxyethyl)benzoic acid Chemical compound OC(=O)CCC1=CC=C(C(O)=O)C=C1 QSPCOYVUYYFWAU-UHFFFAOYSA-N 0.000 description 1
- NJIRSYUCMKXAGJ-UHFFFAOYSA-N 4-(3,3-dimethylbutanoylamino)-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)CC(C)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 NJIRSYUCMKXAGJ-UHFFFAOYSA-N 0.000 description 1
- RQXBTUQRZYGDST-UHFFFAOYSA-N 4-[(2,6-dimethylbenzoyl)amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3,4-dihydro-2h-chromene-6-carboxamide Chemical compound C=1C=C2OCCC(NC(=O)C=3C(=CC=CC=3C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 RQXBTUQRZYGDST-UHFFFAOYSA-N 0.000 description 1
- BSDGZUDFPKIYQG-UHFFFAOYSA-N 4-bromopyridine Chemical compound BrC1=CC=NC=C1 BSDGZUDFPKIYQG-UHFFFAOYSA-N 0.000 description 1
- SMSVBXDZZQOTGB-UHFFFAOYSA-N 4-bromopyridine;hydrobromide Chemical compound Br.BrC1=CC=NC=C1 SMSVBXDZZQOTGB-UHFFFAOYSA-N 0.000 description 1
- MPZMVUQGXAOJIK-UHFFFAOYSA-N 4-bromopyridine;hydron;chloride Chemical compound Cl.BrC1=CC=NC=C1 MPZMVUQGXAOJIK-UHFFFAOYSA-N 0.000 description 1
- PVMNPAUTCMBOMO-UHFFFAOYSA-N 4-chloropyridine Chemical compound ClC1=CC=NC=C1 PVMNPAUTCMBOMO-UHFFFAOYSA-N 0.000 description 1
- BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- YBIYFJLLJFMDFQ-UHFFFAOYSA-N 4-piperidin-1-ylpyrimidine Chemical compound C1CCCCN1C1=CC=NC=N1 YBIYFJLLJFMDFQ-UHFFFAOYSA-N 0.000 description 1
- BNMPIJWVMVNSRD-UHFFFAOYSA-N 5-methyl-1,2-oxazole-3-carboxylic acid Chemical compound CC1=CC(C(O)=O)=NO1 BNMPIJWVMVNSRD-UHFFFAOYSA-N 0.000 description 1
- DZIBLEREBJNQIF-UHFFFAOYSA-N 7,7-dimethyl-1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)C(C)(C)CC21OCCO2 DZIBLEREBJNQIF-UHFFFAOYSA-N 0.000 description 1
- VSTDREWIASVIIS-UHFFFAOYSA-N 8-[(2,5-dichlorophenyl)carbamoylamino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)NC=3C(=CC=C(Cl)C=3)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 VSTDREWIASVIIS-UHFFFAOYSA-N 0.000 description 1
- YHADEUDGHREBQH-UHFFFAOYSA-N 8-[[2-chloro-3-(trifluoromethyl)benzoyl]amino]-n-methyl-n-(1-pyridin-4-ylpiperidin-4-yl)-5,6,7,8-tetrahydronaphthalene-2-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C(=C(C=CC=3)C(F)(F)F)Cl)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 YHADEUDGHREBQH-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 238000006443 Buchwald-Hartwig cross coupling reaction Methods 0.000 description 1
- JZCMENZONIANHQ-ZVDHGWRTSA-N C[C@@H]1CC(C2=CC=CC=C12)N1C(C2=C(C=CC=C2C1)Cl)=O Chemical compound C[C@@H]1CC(C2=CC=CC=C12)N1C(C2=C(C=CC=C2C1)Cl)=O JZCMENZONIANHQ-ZVDHGWRTSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WUEZLAPNAHPUBE-RFVHGSKJSA-N Cl.CCOC(=O)c1cc2CC[C@@H](N)c2cc1F Chemical compound Cl.CCOC(=O)c1cc2CC[C@@H](N)c2cc1F WUEZLAPNAHPUBE-RFVHGSKJSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000801643 Homo sapiens Retinal-specific phospholipid-transporting ATPase ABCA4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 229930182821 L-proline Natural products 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 102100033617 Retinal-specific phospholipid-transporting ATPase ABCA4 Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 206010041925 Staphylococcal infections Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
- FYJKEHKQUPSJDH-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;potassium Chemical compound [K].C[Si](C)(C)N[Si](C)(C)C FYJKEHKQUPSJDH-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- OQIQSTLJSLGHID-WNWIJWBNSA-N aflatoxin B1 Chemical compound C=1([C@@H]2C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O OQIQSTLJSLGHID-WNWIJWBNSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 150000001543 aryl boronic acids Chemical class 0.000 description 1
- 150000001502 aryl halides Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- XEZSCXSSOBUSJB-UHFFFAOYSA-N benzyl n-[2,2-dimethyl-4-(4-methylpiperazin-1-yl)cyclohexyl]carbamate Chemical compound C1CN(C)CCN1C1CC(C)(C)C(NC(=O)OCC=2C=CC=CC=2)CC1 XEZSCXSSOBUSJB-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000005620 boronic acid group Chemical class 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- ZAEBLFKQMDEPDM-UHFFFAOYSA-N cyclobutyl radical Chemical compound [CH]1CCC1 ZAEBLFKQMDEPDM-UHFFFAOYSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- WACQKHWOTAEEFS-UHFFFAOYSA-N cyclohexane;ethyl acetate Chemical compound CCOC(C)=O.C1CCCCC1 WACQKHWOTAEEFS-UHFFFAOYSA-N 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AAXGWYDSLJUQLN-UHFFFAOYSA-N diphenyl(propyl)phosphane Chemical compound C=1C=CC=CC=1P(CCC)C1=CC=CC=C1 AAXGWYDSLJUQLN-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
- ZOBPQKZMQOTAIG-CYBMUJFWSA-N ethyl (3R)-3-(ethylamino)-2,3-dihydro-1H-indene-5-carboxylate Chemical compound CCN[C@@H]1CCc2ccc(cc12)C(=O)OCC ZOBPQKZMQOTAIG-CYBMUJFWSA-N 0.000 description 1
- WOWCGMIFWRSTHB-LLVKDONJSA-N ethyl (3R)-3-amino-2,3-dihydro-1H-indene-5-carboxylate Chemical compound CCOC(=O)c1ccc2CC[C@@H](N)c2c1 WOWCGMIFWRSTHB-LLVKDONJSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- HPSHEKVARRIWLU-UHFFFAOYSA-M lithium;propane-1-thiolate Chemical compound [Li+].CCC[S-] HPSHEKVARRIWLU-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- MJGFBOZCAJSGQW-UHFFFAOYSA-N mercury sodium Chemical compound [Na].[Hg] MJGFBOZCAJSGQW-UHFFFAOYSA-N 0.000 description 1
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 1
- NZYRFJMNSQGIEI-OAHLLOKOSA-N methyl (4r)-4-(4-chloro-3-oxo-1h-isoindol-2-yl)-8-fluoro-3,4-dihydro-2h-chromene-6-carboxylate Chemical compound C1C2=CC=CC(Cl)=C2C(=O)N1[C@@H]1CCOC2=C(F)C=C(C(=O)OC)C=C21 NZYRFJMNSQGIEI-OAHLLOKOSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- DDLMIXVCCJFHRI-UHFFFAOYSA-N n,1,1-trimethyl-n-(1-pyridin-4-ylpiperidin-4-yl)-3-[[2-(trifluoromethyl)phenyl]methylsulfonylamino]-2,3-dihydroindene-5-carboxamide Chemical compound C=1C=C(C(CC2NS(=O)(=O)CC=3C(=CC=CC=3)C(F)(F)F)(C)C)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 DDLMIXVCCJFHRI-UHFFFAOYSA-N 0.000 description 1
- LAURYIYOSYVBIZ-UHFFFAOYSA-N n,n,4-trimethylpyrimidin-2-amine Chemical compound CN(C)C1=NC=CC(C)=N1 LAURYIYOSYVBIZ-UHFFFAOYSA-N 0.000 description 1
- KWNAQHAMCVSRHE-UHFFFAOYSA-N n-[6-[[1-(2,6-dimethylpyridin-4-yl)piperidin-4-yl]-methylcarbamoyl]-2,3-dihydro-1h-inden-1-yl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=NC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC(C)=NC(C)=C1 KWNAQHAMCVSRHE-UHFFFAOYSA-N 0.000 description 1
- HTBCYXUGRILTRQ-UHFFFAOYSA-N n-[6-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-2,3-dihydro-1h-inden-1-yl]-4-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C=1C=C2CCC(NC(=O)C=3C(=CC=NC=3)C(F)(F)F)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 HTBCYXUGRILTRQ-UHFFFAOYSA-N 0.000 description 1
- IFAVMOPRDITAHI-UHFFFAOYSA-N n-[7-[methyl-(1-pyridin-4-ylpiperidin-4-yl)carbamoyl]-1,2,3,4-tetrahydronaphthalen-1-yl]pyrimidine-5-carboxamide Chemical compound C=1C=C2CCCC(NC(=O)C=3C=NC=NC=3)C2=CC=1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 IFAVMOPRDITAHI-UHFFFAOYSA-N 0.000 description 1
- VUPCEVNNVGQDTL-UHFFFAOYSA-N n-cyclopropyl-1-pyridin-4-ylpiperidin-4-amine Chemical compound C1CC1NC1CCN(C=2C=CN=CC=2)CC1 VUPCEVNNVGQDTL-UHFFFAOYSA-N 0.000 description 1
- VWGYBRUABNUUGR-UHFFFAOYSA-N n-methyl-1-(1-methylpiperidin-4-yl)piperidin-4-amine Chemical compound C1CC(NC)CCN1C1CCN(C)CC1 VWGYBRUABNUUGR-UHFFFAOYSA-N 0.000 description 1
- WNXBUQKVPFLNQK-UHFFFAOYSA-N n-methyl-1-(2-pyridin-4-ylethyl)piperidin-4-amine Chemical compound C1CC(NC)CCN1CCC1=CC=NC=C1 WNXBUQKVPFLNQK-UHFFFAOYSA-N 0.000 description 1
- VMZLTORMMGHBTN-UHFFFAOYSA-N n-methyl-1-(pyridin-4-ylmethyl)piperidin-4-amine Chemical compound C1CC(NC)CCN1CC1=CC=NC=C1 VMZLTORMMGHBTN-UHFFFAOYSA-N 0.000 description 1
- ZOCDRPCVYDIYFM-UHFFFAOYSA-N n-methyl-1-[(2-pyrrolidin-1-ylpyridin-4-yl)methyl]piperidin-4-amine;hydrochloride Chemical compound Cl.C1CC(NC)CCN1CC1=CC=NC(N2CCCC2)=C1 ZOCDRPCVYDIYFM-UHFFFAOYSA-N 0.000 description 1
- QHIXWPOEUOJBOF-UHFFFAOYSA-N n-methyl-1-pyridin-2-ylpiperidin-4-amine Chemical compound C1CC(NC)CCN1C1=CC=CC=N1 QHIXWPOEUOJBOF-UHFFFAOYSA-N 0.000 description 1
- DVNQVINZRDATHF-UHFFFAOYSA-N n-methyl-1-pyridin-4-ylpyrrolidin-3-amine;dihydrochloride Chemical compound Cl.Cl.C1C(NC)CCN1C1=CC=NC=C1 DVNQVINZRDATHF-UHFFFAOYSA-N 0.000 description 1
- GLOJIKSZPWNGPE-UHFFFAOYSA-N n-methyl-3-[methyl(3-methylbutanoyl)amino]-n-(1-pyridin-4-ylpiperidin-4-yl)-2,3-dihydro-1h-indene-5-carboxamide Chemical compound C1=C2C(N(C)C(=O)CC(C)C)CCC2=CC=C1C(=O)N(C)C(CC1)CCN1C1=CC=NC=C1 GLOJIKSZPWNGPE-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RBVFKMBFVHRPCU-UHFFFAOYSA-N n-trimethylsilylhydroxylamine Chemical compound C[Si](C)(C)NO RBVFKMBFVHRPCU-UHFFFAOYSA-N 0.000 description 1
- NSNPSJGHTQIXDO-UHFFFAOYSA-N naphthalene-1-carbonyl chloride Chemical compound C1=CC=C2C(C(=O)Cl)=CC=CC2=C1 NSNPSJGHTQIXDO-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 125000001190 organyl group Chemical group 0.000 description 1
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229910003446 platinum oxide Inorganic materials 0.000 description 1
- 229920001992 poloxamer 407 Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- HNYVPKNVKSTVJO-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound C1=CC=NC2=C(C(=O)O)C=NN21 HNYVPKNVKSTVJO-UHFFFAOYSA-N 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000005956 quaternization reaction Methods 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000012958 reprocessing Methods 0.000 description 1
- 230000036633 rest Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001023 sodium amalgam Inorganic materials 0.000 description 1
- 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
- KHPQHXGYYXYTDN-UHFFFAOYSA-N tert-butyl n-(piperidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCCNC1 KHPQHXGYYXYTDN-UHFFFAOYSA-N 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/68—One oxygen atom attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to substituted benzamide compounds, processes for their preparation, medicaments containing these compounds and the use of substituted benzamide compounds for the preparation of medicaments.
- the bradykinin 1 receptor (B1R) is not or only weakly expressed in most tissues.
- the expression of the B1R is inducible on different cells. For example, in the course of inflammatory reactions, a rapid and pronounced induction of B1R on neuronal cells but also on various peripheral cells such as fibroblasts, endothelial cells, granulocytes, macrophages and lymphocytes. Thus, in the course of inflammatory reactions, there is a switch from a B2R to a B1R dominance on the cells involved.
- cytokines interleukin-1 (IL-1) and tumor necrosis factor alpha (TNFa) are of particular importance in this B1R up-regulation (Passos et al., J. Immunol., 2004, 172, 1839-1847).
- B1 R-expressing cells may subsequently self-secrete pro-inflammatory cytokines such as IL-6 and IL-8 (Hayashi et al., Eur. Respir. J. 2000, 16, 452-458). This leads to the immigration of further inflammatory cells, e.g. neutrophilic granulocytes (Pesquero et al., PNAS 2000, 97, 8140-8145).
- bradykinin B1R system can contribute to the chronicity of disease. This is confirmed by a large number of animal experiments (reviews in Leeb-Lundberg et al., Pharmacol Rev. 2005, 57, 27-77 and Pesquero et al., Biol. Chem. 2006, 387, 119-126). Human expression also shows enhanced expression of the B1 R, e.g. on enterocytes and macrophages in the affected tissue of patients with inflammatory bowel disease (Stadnicki et al., Am J. Physiol Gastrointest ..
- Symptoms such as superficial infections of the skin to septic shock.
- B1 R antagonists in acute and, in particular, chronic inflammatory diseases.
- respiratory diseases bronchial asthma, allergies, COPD / chronic obstructive pulmonary disease, cystic fibrosis, etc.
- inflammatory bowel disease ulcerative colitis, CD / Crohn's disease, etc.
- neurological diseases multiple sclerosis, neurodegeneration, etc.
- inflammation of the skin atopic dermatitis, psoriasis, bacterial infections, etc.
- mucous membranes M. Behcet, pelvitis, prostatitis, etc.
- bradykinin (receptor) system is also involved in the regulation of
- Angiogenesis (potential as an angiogenesis inhibitor in cancer as well as macular degeneration in the eye) and B1 R knockout mice are protected from inducing obesity by a high fat diet (Pesquero et al., Biol. Chem. 2006, 387, 1 19-126). B1 R antagonists are therefore also suitable for the treatment of obesity.
- B1 R antagonists are particularly suitable for the treatment of pain, in particular inflammatory pain and neuropathic pain (Calixto et al., Br. J. Pharmacol 2004, 1-16), here in particular diabetic neuropathy (Gabra et al., Biol. Chem. 2006, 387, 127-143). Furthermore, they are suitable for the treatment of migraine.
- t 1, 2 or 3;
- b 0, 1 or 2;
- c and d are each independently 0, 1 or 2 with the proviso that the cycle has at most 7 ring members;
- X is N (R 9a ) or C (R 9b ) (H);
- D is one of the following radicals D1 or D2
- D1 D2 q is 0 or 1;
- s is 0 or 1;
- r is 1, 2 or 3;
- Qi and Q 2 independently of one another, are each C, CH or N;
- R 1 is d 9-alkyl, aryl, heteroaryl, CH (aryl) 2 , C 3 . 8 cycloalkyl, heterocyclyl, or a bonded via a C ⁇ alkylene, C 2- 6 alkenylene group or C 2-6 alkynylene group aryl, heteroaryl, CH (aryl) 2, C 3-8 cycloalkyl or heterocyclyl;
- R 2 is H, C 1 -e-alkyl, C 3 . 8 cycloalkyl, heterocyclyl, aryl, heteroaryl, or for a Ci -6 - bound alkylene C 3- 8 cycloalkyl, heterocyclyl, aryl or heteroaryl;
- R 5 is 0, 1, 2, 3 or 4 substituents which are independently selected from the group consisting of F, Cl, CF 3l OCF 3, C -6 alkyl, and 0-d -6 alkyl and / or two adjacent substituents R 5 form a fused aryl, heteroaryl or de-cycloalkyl and / or two substituents R s attached to a carbon atom form a 3, 4 or 5 membered saturated carbocycle unsubstituted or attached to one or more of its carbon ring members one or more substituents independently selected from the group consisting of F, CF 3 and C 1-6 alkyl substituted;
- R 6 is 0, 1, 2 or 3 substituents independently selected from the group consisting of F, Cl, Br, CF 3 , OCF 3 , OH, C 1-6 alkyl, C 3-8 cycloalkyl , 0-C 1-6 -alkyl, N0 2 , NH 2 , N (H) (C 1-6 -alkyl) and N (C 1-6 -alkyl) 2 and / or two adjacent substituents R 6, an annulated aryl , Heteroaryl or C 4 . 8 -cycloalkyl form;
- R 7 is H, Ci-e-alkyl, C3-8 cycloalkyl, heterocyclyl, aryl or heteroaryl, or a C -6 alkylene group bonded via a C 3-8 cycloalkyl, heterocyclyl, aryl or heteroaryl,
- R is H, de-alkyl, C 3-8 -cycloalkyl, aryl, heteroaryl, or C 3- e -cycloalkyl, aryl or heteroaryl bonded via a d -3 -alkylene group;
- R 13 is C 1-6 alkyl, aryl, heteroaryl, CH (aryl) 2 , C 3 . 8 cycloalkyl, heterocyclyl, or a bonded via a C 1-6 alkylene group, C 2- 6 alkenylene group, or C 2- 6-alkynylene aryl, heteroaryl, C 3-8 cycloalkyl or heterocyclyl;
- R 14 is H, C 1-6 alkyl, C 3-8 cycloalkyl, aryl, heteroaryl, or a via a C -3 - bound alkylene C 3-8 cycloalkyl, aryl or heteroaryl;
- R 15 and R 16 are each H, C 1-4 -alkyl, C 3-8 -cycloalkyl, aryl or heteroaryl, or
- R 17 and R 18 are each independently H, C 1-6 alkyl or C 3 . 8 -cycloalkyl, or
- R 17 and R 18 together with the nitrogen atom connecting them form a heterocycle which is unsubstituted or at one or more, for example 1, 2 or 3, of its
- Carbon ring members having one or more, for example 1, 2, 3 or 4,
- R 23 are de-alkyl, C 3- 8 cycloalkyl, aryl, heteroaryl or a Ci -3 alkylene group bonded via a C 3-8 - cycloalkyl, aryl or heteroaryl;
- R 19 is H, de-alkyl, C 3-8 -cycloalkyl, heterocyclyl, aryl, heteroaryl or C 2-6 -alkylene-NR 17 R 18 or a heterocyclyl bonded via a d-6-alkylene group, C 3-8 Cycloalkyl, aryl or heteroaryl;
- R 20 and R 2 independently of one another, are each H, de-alkyl or C 3-8 -cycloalkyl, or
- R 20 and R 21 together with the nitrogen atom connecting them form a heterocycle which is unsubstituted or at one or more, for example 1, 2 or 3, of its
- Carbon ring members having one or more, for example 1, 2, 3 or 4
- Heteroaryl in each case unsubstituted or singly or multiply with the same or
- d-4-alkyl d -6 -alkyl, d -3 -alkylene, d. 6- alkylene, C 2-6 -alkylene, C 2-6 -alkenylene and C 2 . 6 alkynyls, each branched or unbranched; in the form of the free connection; the tautomers; the N-oxides; the racemate; of the
- halogen preferably stands for the radicals F, Cl, Br and I, in particular for the radicals F and Cl.
- C 1-9 -alkyl for the purposes of this invention comprises acyclic saturated hydrocarbon radicals having 1, 2, 3 , 4, 5, 6, 7, 8 or 9 C atoms or 1, 2, 3, 4, 5 or 6 C atoms or 1, 2, 3 or 4 C atoms or 1, 2 or 3 C atoms which may be branched or straight-chain (unbranched) and unsubstituted or mono- or polysubstituted, for example 2-, 3-, 4- or 5-fold, with the same or different radicals.
- the alkyl radicals may be selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, iso-pentyl, neo-pentyl and hexyl.
- Particularly preferred alkyl radicals can be selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl and tert-butyl.
- C 3-8 -cycloalkyl For the purposes of this invention, the term "C 3-8 -cycloalkyl", “C 4 . 8 -cycloalkyl "or” C 3- 6 cycloalkyl "cyclic saturated hydrocarbons having 3, 4, 5, 6, 7 or 8, including 4, 5, 6, 7 or 8 or 3, 4, 5 or 6 Carbon atoms which may be unsubstituted or monosubstituted or polysubstituted, for example, by 2, 3, 4 or 5, identical or different radicals on one or more ring members and, if the cycloalkyl radicals have at least 4 carbon atoms, may also be substituted by further saturated, partially unsaturated or aromatic or heteroaromatic ring systems may be condensed, which in turn may be unsubstituted or monosubstituted or polysubstituted, for example, with 2, 3, 4 or 5, identical or different radicals ..
- C 3 -e- cycloalkyl may be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl
- a cycloalkyl radical condensed with a phenyl radical tetrahydronaphthalene (tetrahydronaphthyl) called.
- heterocyclyl includes saturated or unsaturated (but not aromatic)
- Cycloalkyls having four to seven ring members in which one, two or three carbon atoms are replaced by a heteroatom each independently selected from the group S, N or O, wherein the ring members unsubstituted or mono- or polysubstituted could be.
- the bonding of the heterocyclyl to the general structure above can take place via any and possible ring member of the heterocyclyl radical.
- Heterocyclyl radicals can also be condensed with further saturated, (partially) unsaturated or aromatic or heteroaromatic ring systems, which in turn may be unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times.
- heterocyclyl radicals from the group azetidinyl, oxetanyl, azepanyl, dioxanyl, dioxolanyl, morpholinyl, pyranyl, pyrrolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyrazolinonyl, dihydroindenyl, tetrahydropyranyl, chromanyl or
- Thiomorpholinyl Particularly preferred are heterocyclyl radicals from the group azetidinyl, oxetanyl, azepanyl, dioxanyl, dioxolanyl, morpholinyl, pyranyl, pyrrolidinyl, piperazinyl, piperidinyl, pyrazolidinyl, pyrazolinonyl or thiomorpholinyl.
- aryl in the context of this invention means aromatic hydrocarbons, in particular phenyls and naphthyls.
- the aryl radicals can also be condensed with further saturated, (partially) unsaturated or aromatic ring systems.
- Each aryl radical can be unsubstituted or monosubstituted or polysubstituted, for example 2, 3, 4 or 5 times, substituted, where the aryl substituents can be identical or different and in any desired and possible position of the aryl.
- aryl may be selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl, which may each be unsubstituted or mono- or polysubstituted, for example with 2, 3, 4 or 5 radicals.
- heteroaryl in the context of the present invention is a 5-, 6- or 7-membered cyclic aromatic radical which has at least 1, optionally also 2, 3, 4 or 5
- heteroatoms wherein the heteroatoms may be the same or different and the
- Heteroaryl unsubstituted or mono- or polysubstituted may be substituted with identical or different radicals.
- the substituents may be attached in any and possible position of the heteroaryl.
- the heterocycle may also be part of a bicyclic or polycyclic, in particular a mono-, bi- or tricyclic system, which may then be more than 7-membered in total, preferably up to 14-membered.
- Preferred heteroatoms are independently selected from the group consisting of N, O and S.
- the heteroaryl radical can be selected from the group consisting of pyrrolyl, indolyl, furyl (furanyl), benzofuranyl,
- Benzotriazolyl benzodioxolanyl, benzodioxanyl, benzooxazolyl, benzooxadiazolyl,
- the heteroaryl radical can be selected from the group consisting of isooxazolyl, oxazolyl, pyridazinyl, pyrazinyl, thienyl, imidazoyl, thiazolyl, triazolyl, pyridinyl and pyrimidinyl.
- d -3 -alkylene group for the purposes of the present invention comprises acyclic saturated hydrocarbon radicals having 1, 2 or 3 C atoms, 1, 2 , 3, 4, 5 or 6 C atoms or 2, 3, 4, 5 or 6 C atoms which are branched or straight-chain (unbranched) and unsubstituted or mono- or polysubstituted, for example 2-, 3-, 4 or 5-fold, may be substituted with the same or different radicals and linking a corresponding radical with the parent general structure.
- the alkylene groups may be selected from the group consisting of -CH 2 -, -CH 2 -CH 2 -, -CH (CH 3 ) -, -CH 2 -CH 2 -CH 2 -, -CH (CH 3 ) -CH 2 -, -CH (CH 2 CH 3 ) -, -CH 2 - (CH 2 ) 2 -CH 2 -, -CH (CH 3 ) -CH 2 -CH 2 -, -CH 2 -CH ( CH 3 ) -CH 2 -, -CH (CH 3 ) - CH (CH 3 ) -, -CH (CH 2 CH 3 ) -CH 2 -, -C (CH 3 ) 2 -CH 2 -, -CH ( CH 2 CH 3 ) -, -C (CH 3 ) 2 -CH 2 -, -CH ( CH 2 CH 3 ) -, -C (CH 3 ) (CH 2 CH 3 ) -
- the alkylene groups may be selected from the group consisting of -CH 2 -, -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -.
- C 2-6 alkenylene group for the purposes of the present invention comprises acyclic, mono- or polyunsaturated, for example 2-, 3- or 4-membered, unsaturated
- Hydrocarbon radicals having 2, 3, 4, 5 or 6 carbon atoms which are branched or straight-chained Hydrocarbon radicals having 2, 3, 4, 5 or 6 carbon atoms which are branched or straight-chained
- C 2-6 -alkynylene group for the purposes of the invention comprises acyclic, mono- or poly-substituted, for example 2-, 3- or 4-membered, unsaturated hydrocarbon radicals having 2, 3, 4, 5 or 6 carbon atoms which are branched - or straight-chain (unbranched) and unsubstituted or one or more times, for example 2-, 3-, 4- or 5-fold, with the same or
- the alkynylene groups may be substituted by different radicals and linking a corresponding radical with the parent general structure.
- the alkynylene groups have at least one CsC triple bond.
- Ci -3 alkylene group, a Ci -6 alkylene group C 2-6 alkylene "C. 2 6 alkenylene or C 2- 6-alkynylene group aryl or heteroaryl bonded" in the context of the present Invention that the Ci. 3- alkylene groups, C alkylene groups, C 2-6 alkylene groups, C 2-6 alkenylene groups, C 2 . 6 alkynylene groups and aryl or
- Heteroaryl have the meanings defined above and the aryl or heteroaryl via a C 1-3 alkylene, C 1-6 alkylene, C 2-6 alkylene, C 2 . 6 alkenylene group or C 2 - $ - alkynylene group is bound to the parent general structure.
- Examples include benzyl, phenethyl and phenylpropyl.
- C 3-8 -cycloalkyl and heterocyclyl bonded via a C 1-3 -alkylene group, C 1-6 -alkylene group, C 2-6 -alkylene group, C 2-6 -alkenylene group or C 2-6 -alkynylene group means in the sense of the present invention, that the C 1-3 -alkylene group, C 1-6 -alkylene group, C 2-6 -alkylene group, C 2 .
- 6 alkenylene, C 2-6 alkynylene, C 3-8 - cycloalkyl, and heterocyclyl are as defined above and C 3-8 cycloalkyl and heterocyclyl via a C -3 alkylene, Ci-e-alkylene group, C 2- 6 -alkylene group, C 2-6 -alkenylene group or C 2-6 -alkynylene group is bonded to the general structure above.
- alkyl In the context of “alkyl”, “alkylene”, “alkenylene”, “alkynylene”, “cycloalkyl” and
- Heterocyclyl is understood by the term “substituted” in the sense of this invention
- the radicals which either on different or on the same atoms multiply, for example two or three times, for example, three times on the same carbon atom as in the case of CF 3 or CH 2 CF 3 or at different positions as in the
- it is intended here to include the substitution of one or more hydrogen radicals by F, CN, CF 3 , NH 2 , N (CH 3 ) 2 , OH, phenyl, 0-CF 3 or 0-C 1-6 -alkyl.
- NH-de-alkyl NH-Ci-6-alkylene-OH, N (Ci -6 alkyl) 2, N (C 1-6 alkylene-OH) 2, NH-aryl, N (aryl 1) 2, N (Ci-6-alkyl) aryl 1, pyrrolinyl, Pyrroldinyl, piperazinyl, N-methyl-piperazinyl, morpholinyl, azetidinyl, piperidinyl, thiazolinyl, azepanyl, diazepanyl, (C 1-3 alkylene) -azetidinyl, (C 1- 3 - alkylene) -Pyrrolinyl, (Ci -3 alkylene) piperidinyl, (C 3 alkylene) -morpholinyl, (C 1-3 alkylene) -.
- alkyl, C3-6 cycloalkyl, 0-C 3 6 cycloalkyl, pyrrolidinyl, imidazolyl, benzyloxy, phenoxy, phenyl, naphthyl, pyridinyl, pyrimidinyl, -C 1-3 - alkylene-aryl 1, benzyl, thienyl, furyl or a Ci -6 alkylene group bonded OCF 3, OH, O-C 1-6 -alkyl, SH, SC 1-6 -alkyl, C 3-6 -cycloalkyl, O-C 3-6 -cycloalkyl, NR 20 R 21 , C ( O) - NR 20 R 21 , phenyl, pyridyl or pyrimidyl, wherein aryl 1 is phenyl, thiazolyl, thienyl or pyridinyl, on one or different atoms, wherein the abovementioned substituents
- Substituents can be substituted.
- the multiple substitution of aryl and heteroaryl can be made with the same or different substituents.
- NH-de-alkyl NH-C 1-6 -alkylene-OH, N (d 6 -alkyl) 2 , N (C 1-6 -alkylene-OH) 2 , NH-aryl 1 , N (aryl 1 ) 2, N (Ci -6 alkyl) aryl 1, pyrrolinyl, Pyrroldinyl, piperazinyl, N-methyl-piperazinyl, morpholinyl, azetidinyl, piperidinyl, thiazolinyl, azepanyl, diazepanyl, (C 1-3 alkylene) -azetidinyl, (C 1-3 - alkylene) -Pyrrolinyl, (d 3 alkylene) piperidinyl, (Ci -3 alkylene) -morpholinyl, (C 1-3 alkylene) -.
- 6- alkyl OCF 3 , CF 3 , -O-CH 2 -O-, -O-CH 2 - CH 2 -O-, -O-C (CH 3 ) 2 -CH 2 -, de-alkyl, C 3-6 -cycloalkyl, 0-C 3-6 -cycloalkyl, pyrrolidinyl,
- Imidazolyl, benzyloxy, phenoxy, phenyl, naphthyl, pyridinyl, pyrimidinyl, -d. 3- alkylene-aryl- 1 , benzyl, thienyl, furyl or for a via a d -6- alkylene-bound OCF 3 , OH, 0-C 1-6 -alkyl, SH, Sd.6-alkyl, C 3-6 Cycloalkyl, O-C 3-6 -cycloalkyl, NR 20 R 21 , C ( O) -NR 20 R 21 , phenyl, pyridyl or pyrimidyl, wherein aryl 1 is phenyl, thiazolyl, thienyl or pyridinyl.
- substituents for aryl and heteroaryl can be selected from the group consisting of -O-C 1-3 -alkyl, unsubstituted d -6- alkyl, F, Cl, CN, CF 3 , 0CF 3 , OH, NH 2 , NR 2 ° R 21 , phenyl, naphthyl, thiazolyl, thienyl and pyridinyl, in particular from the group consisting of tert-butyl, F, Cl, CN, CF 3 , CH 3 ; OCH 3 , OCF 3 , NH 2 and NR 20 R 21 .
- Substitution pattern also the symbol " ⁇ " used, which group is not bound to a particular atom within the chemical structural formula, in contrast to the representation of a bond to a particular atom (R a is here exemplified by a substituent R with a by the variable "a "numbering shown).
- the symbol used in formulas denotes a linkage of a corresponding remainder to the respective overall general structure.
- groups such as or (C 1 - alkyl) 2, in which the two C1-4 alkyl groups may be identical or different, such as in N (CH 3) 2 or N (CH 3) (C 2 H 5).
- physiologically tolerated salt preferably means salts of the compounds according to the invention with inorganic or organic acids which are physiologically compatible - in particular when used on humans and / or mammals, for example salts of hydrochloric acid (hydrochlorides).
- this term also means compounds which are obtained by quaternization of a nitrogen atom present in the structure (for example pyridyl, N-methylpiperidinyl). Such compounds can be obtained for example by alkylation to generate the corresponding cation with counterions such as CI " and F " .
- a is 0 or 1 and t is 1 or 2.
- the partial structure (Ac) is one of the partial structures (Ac 1), (Ac 2), (Ac 5) or (Ac 6).
- the partial structure D1 is selected from the group consisting of
- the radical R 1 is preferably in the compounds of the invention for Ci. 9- alkyl, CH (phenyl) 2 , C 3 . 8 -cycloalkyl, heterocyclyl, phenyl, naphthyl, tetrahydronaphthyl,
- 3 alkylene group bonded phenyl, C 3-6 cycloalkyl or C 4- 6-heterocyclyl very particularly preferably represents Ci -6 alkyl, CH (phenyl) 2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyranyl, oxetanyl, tetrahydrofuranyl, Piperidinyl, phenyl, naphthyl, tetrahydronaphthyl, pyridinyl, pyrimidinyl, pyrazolo [1, 5-a] pyrimidinyl, dihydroindenyl, chromanyl, isoquinolinyl, oxazolyl, isoxazolyl or phenyl bonded via a C 1 2 0 of the 3-alkylene group, cyclopropyl, cyclobutyl , Cyclopentyl, cyclohexy
- the radical R 1 in the compounds according to the invention is dg-alkyl, CH (phenyl) 2 , C 3-8 -cycloalkyl, heterocyclyl, phenyl, naphthyl, tetrahydronaphthyl, chromanyl, indolyl, benzofuranyl, benzothiophenyl (benzothienyl) , Benzooxazolyl, benzooxadiazolyl, pyrrolyl, furanyl, thienyl, oxazolyl, isoxazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazolo [1, 5-a] pyrimidinyl, pyrazinyl, imidazothiazolyl, carbazolyl, dibenzofuranyl, dibenzothiophenyl (dibenzothienyl) or a via a C 1 -3
- the radical R 1 may in particular denote d -6- alkyl, cyclopropyl, cyclobutyl, cyclopentyl,
- Tetrahydrofuranyl piperidinyl, phenyl, naphthyl, tetrahydronaphthyl, pyridinyl, pyrimidinyl,
- alkyl, alkylene, and cycloalkyl groups are each unsubstituted or monosubstituted or polysubstituted, for example 2-, 3-, 4- or 5-fold, identical or different, wherein the substituents are independently selected in particular from the group consisting of C 1 -C 3 -alkyl, F, Cl, CF 3 , OCF 3 , OH,
- Thienyl and pyridinyl themselves are each unsubstituted or monosubstituted or polysubstituted, for example, 2-, 3-, 4- or 5-fold, same or different, wherein the
- Substituents are independently selected in particular from the group consisting of C 1-4 alkyl, C 1 -C 3 alkyl, F, Cl, CF 3 , OCF 3 and OH.
- the radical R 1 can be, in particular, d -6 -alkyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetrahydropyranyl, oxetanyl, tetrahydrofuranyl, piperidinyl, phenyl, naphthyl, tetrahydronaphthyl, pyridinyl, pyrimidinyl, pyrazolo [1, 5 a] pyrimidinyl, thienyl, oxazolyl, isoxazolyl or a bonded via a Ci, 2 0 of the 3-alkylene phenyl, cyclopropyl, cyclobutyl, cyclopentyl
- radical R 1 can be selected from the group consisting of
- R can in particular also for C -9 alkyl, C 3- 6 cycloalkyl or heterocyclyl or bonded via a C 1-6 alkylene C 3-6 - cycloalkyl, or Heterocyclyl, wherein Ci -6- alkyl unsubstituted or mono- or polysubstituted, for example, 2-, 3-, 4- or 5-fold, may be substituted, in particular with radicals selected from the group consisting of F, CF 3 , OCF 3 , OH and methoxy and wherein C 3-6 -cycloalkyl and heterocyclyl may be optionally fused with phenyl and
- unsubstituted or mono- or polysubstituted for example 2-, 3-, 4- or 5-fold, may be substituted, in particular with radicals selected from the group consisting of F, CF 3 , OCF 3 , OH and methoxy.
- the compounds according to the invention have the substructure D1-1, in which
- R 1 is phenyl, pyridyl, preferably 3-pyridyl, oxazolyl or isoxazolyl, each of these radicals each being unsubstituted or monosubstituted or polysubstituted, for example 2-, 3-, 4- or 5-fold, identical or different, the substituents are independently selected in particular from the group consisting of 0-C 1-3 alkyl, d. e-alkyl, F, Cl, CN, CF 3 , 0CF 3 , and OH, preferably from the group consisting of O-CH 3 , CH 3 , F, Cl, and CF 3 , or
- R is C 1-6 alkyl, C 3-6 cycloalkyl, C 4-6 heterocyclyl, or a bonded via a C 1-3 alkylene group or C 3-6 cycloalkyl C 4 -6-heterocyclyl, wherein the abovementioned alkyl, alkylene, cycloalkyl and heterocyclyl groups are each unsubstituted or monosubstituted or polysubstituted, for example, 2-, 3-, 4- or 5-fold, identical or different, wherein the substituents are independently selected particularly from the group consisting of 0-Ci -3 alkyl, C 1-4 alkyl, F, Cl, CF 3, OCF 3 and OH, or compounds of the invention have the partial structure D1-2 in which
- R 1 is C 1 -e-alkyl, C 3-6 -cycloalkyl, C 4 - 6 -heterocyclyl, or a C 3 bonded via a C 1-3 -alkylene group. 6 -cycloalkyl or C 4-6 -heterocyclyl, wherein the abovementioned
- Alkyl, alkylene, cycloalkyl and heterocyclyl groups are each unsubstituted or monosubstituted or polysubstituted, for example, 2-, 3-, 4- or 5-fold, identical or different, wherein the substituents are independently selected in particular from
- a group consisting of 0-C 1-3 -alkyl, C-alkyl, F, Cl, CF 3 , OCF 3 , and OH or the compounds according to the invention have the substructure D2-1 in which R is 1 or 2 substituents which are selected independently of one another from the group consisting of F, Cl, CF 3l and CH 3 .
- the radical R 2 in the compounds according to the invention is preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, CH 2 -CF 3 , cyclopropyl,
- R 5 may be 0, 1, 2, 3 or 4 substituents which are independently selected from the group consisting of F, CF 3, OCF 3 and Ci -6 alkyl.
- R 5 can be absent or stand for 1, 2, 3 or 4 methyl groups.
- R 5 can be 0, 1, 2, 3 or 4 substituents which are selected independently of one another from the group consisting of F, CF 3 and OCF 3 , in particular fluorine.
- R 5 may represent 0 substituents, ie be absent.
- R 6 1 in likewise preferred embodiments of R 6 1 can be used for 0, are 2 or 3 substituents independently selected from the group consisting of F, Cl, CF 3, OCF 3, OH, Ci- 6 alkyl and Od-6- alkyl.
- R 6 can be absent or stand for 1, 2 or 3 fluorine substituents.
- R 6 may represent 0 substituents, ie be absent.
- the radical R 10 in the compounds according to the invention is preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, CH 2 -CF 3 , cyclopropyl,
- Further preferred embodiments of the compounds according to the invention are those in which the partial structure D2 is selected from the group consisting of
- R 300 is 0, 1, 2, 3 or 4 substituents independently of one another selected from the group consisting of F, Cl, Br, I, CF 3 , O-CF 3 , C 1-4 -alkyl and O-4 alkyl;
- R 310 is 0, 1, 2 or 3 substituents independently of one another selected from the group consisting of F, Cl, Br, I, CF 3 , 0-CF 3 , C 1-4 -alkyl and 0-C 1 4- alkyl;
- R 320 is a substituent selected from the group consisting of H, F, Cl, Br, I, CF 3 , O-CF 3 and C 1-6 -alkyl;
- R 330 is a substituent selected from the group consisting of H, C 1-6 alkyl, aryl, CH 2 -aryl and heteroaryl; r1 stands for 1 or 2 and
- r2 stands for 1 or 2.
- D 2 is a radical selected from the group consisting of
- R 300 is a substituent selected from the group consisting of H, F, Cl, Br, I, CF 3 , -O-CF 3 , C 1-4 alkyl and 0-C 1-4 alkyl;
- R 3 0 represents a substituent selected from the group consisting of H, F, Cl, Br, I, CF 3 , -O-CF 3 , C 1-4 alkyl and 0-C 1-4 alkyl ;
- R 320 is a substituent selected from the group consisting of H, F, Cl, Br, I, CF 3 , -O-CF 3 and C 1-4 alkyl and
- R 330 is a substituent selected from the group consisting of H, C 1-4 alkyl, aryl, CH 2 -aryl and heteroaryl.
- D 2 is a radical selected from the group consisting of
- radical D 2 in the compounds according to the invention may be the following radical:
- the radical R 7 is preferably H, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, CH 2 -CF 3 , cyclopropyl,
- Cyclobutyl, cyclopentyl or cyclohexyl particularly preferred for H, methyl, ethyl, iso-propyl, iso-butyl, tert-butyl or cyclopropyl.
- the radical R 7 is H or methyl.
- b 0.
- b is 2.
- b is 0 or 2, preferably 0.
- X is N (R 9a ).
- X is C (R 9b ) H.
- the substructure (Cy) is selected from the list of the abovementioned radicals (Cy 1) to (Cy 22) and R 9a or R 9b are pyridinyl or pyrimidyl and where the pyridyl and Pyrimidyl are each unsubstituted or monosubstituted or polysubstituted, for example, 2-, 3-, or 4-fold, same or different, wherein the substituents are independently selected from the group consisting of azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, N-methylpiperazinyl , Pyridinyl, cyclopropyl, 0-Ci.
- radicals which have an NR 9a grouping ie (Cy 1) to (Cy 8) and (Cy 19) to (Cy 22).
- residues having an N-R moiety i. (Cy 1) to (Cy 8) and (Cy 19) to (Cy 22).
- a group or a cyclopropyl or cyclobutyl radical which is unsubstituted or attached to one or more several of its carbon ring members with one or more substituents
- R 9a is CHR 15 R 16 , aryl, heteroaryl or a via a Ci. 3- alkylene-bonded CHR 15 R 16 , aryl or heteroaryl,
- R 20 and R 2 together with the nitrogen atom connecting them, form a heterocycle which is unsubstituted or independently selected from 1, 2, 3 or 4 substituents selected from the group consisting of F, Cl, Br, I, CF 3 , C 1-4 -alkyl , OC ⁇ alkyl, OH, OCF 3 , SH,
- R 27 is d-4-alkyl, C 3-6 -cycloalkyl, aryl, heteroaryl or a bonded via a Ci -3 alkylene C. 3 6 - cycloalkyl, aryl or heteroaryl; in which
- Aryl is phenyl or naphthyl
- Heteroaryl in each case, pyridinyl, triazinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, quinazolinyl, purinyl, thiazolyl, thiadiazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thienyl, pyrrolyl, tetrazolyl, oxadiazolyl or oxathiazolyl, particularly preferably in each case for pyridinyl , Triazinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, quinazolinyl, thiazolyl, thiadiazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thien
- methyl, isopropyl, tert-butyl, F, Cl, CF 3 , OCF 3 , methoxy, OH, S ( O) 2 -CH 3 , NH 2 , NH (CH 3 ), N ( CH 3 ) 2 , pyrrolidinyl, piperidinyl, cyclopropyl, CN,
- R 17 and R 18 are each independently H, C 1-4 alkyl or C 3-6 cycloalkyl, or
- Heteroaryl in each case represents pyridinyl, triazinyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinolinyl, isoquinolinyl, quinazolinyl, thiazolyl, thiadiazolyl, imidazolyl, triazolyl, oxazolyl, isoxazolyl, thienyl, pyrrolyl, tetrazolyl, oxadiazolyl, oxathiazolyl, preferably for pyridinyl,
- b is 0, 1 or 2;
- 01 is O, 1, 2 or 3;
- R 8 is 0, 1 or 2 methyl groups
- R 101 is 0, 1, 2 or 3 substituents independently of one another selected from the group consisting of methyl, ethyl, isopropyl, tert-butyl, F, Cl, CF 3 , OCF 3 ,
- R 102 is a substituent selected from the group consisting of H, methyl, ethyl, n -propyl, isopropyl, n -butyl, iso -butyl, sec -butyl, tert -butyl, CH 2 -CF 3 , Cyclopropyl and cyclobutyl.
- R 9a is unsubstituted or mono- or polysubstituted heteroaryl
- R is C 1-6 -alkyl, C 4 -C 6 -cycloalkyl or C -C 6 -heterocyclyl or a C 4 -C 6 -cycloalkyl or C 4 -C 6 bonded via a C 1 , 2 or 3-alkylene group Heterocyclyl and wherein R 2 is H, methyl, ethyl, n-propyl, isopropyl, isobutyl, tert-butyl or cyclopropyl,
- R 1 is d -6- alkyl, C -C 6 -cycloalkyl or C 4 -C 6 -heterocyclyl or a C 4 -C 6 -cycloalkyl bound via a C 1 , 2 or 3-alkylene group or C 4 -C 6 -heterocyclyl and in which R 2 is H, methyl, ethyl, n-propyl, isopropyl, isobutyl, tert-butyl or cyclopropyl,
- R 2 is H, methyl, ethyl, n-propyl, iso-propyl, iso-butyl, tert-butyl or cyclopropyl, and R 502 is 0, 1 or 2 substituents each independently selected from the group consisting of F, Cl, methyl, methoxy and CF 3 ;
- R 2 is H, methyl, ethyl, n-propyl, iso-propyl, iso-butyl, tert-butyl or cyclopropyl
- R 503 is 0, 1 or 2 substituents each independently selected from the group consisting of F, Cl, methyl, methoxy, and CF 3 ;
- R 2 is H, methyl, ethyl, n-propyl, iso-propyl, iso-butyl, tert-butyl or cyclopropyl, and R 504 is 0, 1 or 2 substituents each independently selected are selected from the group consisting of F, Cl, methyl, methoxy and CF 3 ;
- c and d are each independently 0, 1 or 2 with the proviso that the cycle has at most 7 ring members;
- R 1 is de-alkyl, C3-8 cycloalkyl, heterocyclyl, phenyl, or a via a C -3 - bound alkylene C 3-8 cycloalkyl or heterocyclyl;
- R 2 is H, methyl, ethyl, n -propyl, iso-propyl, iso -butyl, tert -butyl or cyclopropyl;
- R 6 is H or F;
- R 7 is H, methyl, ethyl, n-propyl, iso-propyl, iso-butyl, tert-butyl or cyclopropyl, preferably methyl;
- R 8 is 1, 2, 3 or 4 substituents independently selected from the group consisting of H and methyl;
- R 9a is pyridyl or pyrimidyl
- R 10 is H, methyl, ethyl, n-propyl, iso-propyl, iso-butyl, tert-butyl or cyclopropyl, preferably methyl;
- R 300 is 0, 1 or 2 substituents independently selected from the group consisting of F, Cl, CF 3 and methyl; wherein the abovementioned alkyl, alkylene, cycloalkyl and heterocyclyl groups are each unsubstituted or monosubstituted or polysubstituted, for example, 2-, 3-, 4- or 5-fold, identical or different, wherein the substituents are independently selected from the group consisting of C 1 -C 3 -alkyl, F, Cl, CF 3 , OCF 3 , OH, 0O, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, phenoxy, naphthyl, thienyl and pyridinyl, preferably from the group consisting of C 1 -C 3 -alkyl, F, Cl, CF 3 , OCF 3 , OH, cyclopropyl, cyclobutyl, cycl
- the compounds according to the invention can be selected from the group consisting of
- H-1 1 (1 R) -1- (4-chloro-3-oxo-1,2-dihydro-isoindol-2-yl) -N-methyl-N- (1-pyridin-4-yl-piperidine 4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-12 (3R) -3- (4-Chloro-3-oxo-1,2-dihydroisoindol-2-yl) -N-methyl-N- (1-pyridin-4-yl-piperidine-4- yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-52 (1R) -1- (4-chloro-3-oxo-1,2-dihydro-isoindol-2-yl) -N-methyl-N - [[1- (2-methyl-pyridine-4 -yl) -piperidin-4-yl] -methyl] -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-53 (1R) -1- (4-chloro-3-oxo-1, 2-dihydro-isoindol-2-yl) -N-methyl-N- [1 - [(2-pyrrolidin-1-yl-pyridin-4-yl) -methyl] -piperidin-4-yl] -2,3 -dihydro-1H-indene-5-carboxylic acid amide
- H-66 (3R) -3 - [(2-chloro-benzoyl) -amino] -N-methyl-N- [2- (1-pyridin-4-yl-piperidin-4-yl) -ethyl] -2, 3-dihydro-1H-indene-5-carboxylic acid amide
- H-67 (3R) -3 - [(2-tert-butylbenzoyl) amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- H-81 (4R) -4 - [(2-Chloro-benzoyl) -amino] -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] -8-fluoro N-methyl-3,4-dihydro-2H-chromen-6-carboxylic acid amide
- H-82 (3R) -3- (2,3-dihydro-1H-indene-1-carbonylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-103 (3R) -3 - [(2-Chlorobenzoyl) amino] -N-methyl-N - [(1S, 3R) -3- (4-methylpiperazin-1-yl) cyclohexyl] - 2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-104 (3R) -3 - [[(2-chlorophenyl) sulfonyl] amino] -N-methyl-N - [(1S, 3R) -3- (4-methylpiperazin-1-yl) cyclohexyl] 2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-120 (3R) -N- [1- (2-Dimethylamino-pyrimidin-4-yl) -piperidin-4-yl] -3- [isopropyl- (3-methyl-butanoyl) -amino] -N-methyl 2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-122 (3R) -3 - [(2-chloro-benzoyl) -amino] -N-methyl-N- [1 - (2-methyl-pyrimidine -4-yl) - piperidin-4-yl] -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-139 (3R) -3 - [(2-Chloro-benzoyl) amino] -N- [1- (2-isopropyl-6-methylpyrimidin-4-yl) -piperidin-4-yl] -N- Methyl 2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-140 (3R) -3 - [(2-Chloro-benzoyl) amino] -N-methyl-N- [1- (2-oxo 2-pyrrolidin-1-yl-ethyl) -piperidin-4-yl] -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-145 (3R) -3 - [(2-Chloro-benzoyl) -ethyl-amino] -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] -N -methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-146 (3R) -3 - [(2-Chlorobenzoyl) amino] -N-methyl-N- (1-pyridin-4-ylazetidin-3-yl) -2,3-dihydro-1H -inde-5-carboxylic acid amide
- H-151 (1 R) -1 - [(2-Chloro-benzoyl) amino] -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] -6-fluoro N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-152 (1R) -1 - [(2-chloro-benzoyl) -amino] -6-fluoro-N-methyl-N - [1- (6-methyl-pyrimidin-4-yl) -piperidin-4-yl] -2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-163 (3R) -3 - [(2-Chloro-6-fluoro-benzoyl) -amino] -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] - N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-164 (3R) -3 - [(2-chloro-3-fluoro-benzoyl) amino] -N-methyl-N- ( 1-pyrimidin-4-yl-piperidine
- H-165 (3R) -3 - [(2-Chloro-4-fluoro-benzoyl) -amino] -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] - N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-166 (3R) -3 - [(2-chloro-benzoyl) -isopropyl-amino] -N- [1- (2- isopropyl-6-methyl-pyrimidin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-184 (3R) -3 - [(2-Chloro-benzoyl) -amino] -N- [4- (2-dimethylamino-pyridin-4-yl) -cyclohexyl] -N-methyl-2,3-dihydro- 1 H-indene-5-carboxylic acid amide
- H-185 (3R) -3- (3-cyclopentyl-propanoyl-methyl-amino) -N- [1- (2-dimethylaminopyridin-4-yl) -piperidine-4 -yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-186 (3R) -3- (3-Cyclopentyl-propanoyl-methyl-amino) -N- [1- (2-dimethylamino-pyrimidin-4-yl) -piperidin-4-yl] -N-
- H-230 (3R) -3- (cyclopentanecarbonyl-methyl-amino) -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] -N-methyl-2,3 -dihydro-1H-indene-5-carboxylic acid amide
- H-231 (3R) -3 - [(2-cyclopentyl-acetyl) -methyl-amino] -N- [1- (2,6-dimethyl-pyrimidine-4 - yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- H-232 (3R) -3- (3,4-dimethyl-pentanoyl-methyl) amino) -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl] -N-methyl-2,
- H-236 (8R) -8 - [(2-chloro-benzoyl) -amino] -N- [1- (2-dimethylamino-pyrimidin-4-yl) -piperidin-4-yl] -N-methyl-5, 6,7,8-tetrahydro-naphthalene-2-carboxylic acid amide
- H-237 (8R) -8 - [(2-chloro-benzoyl) -amino] -N- [1- (2-dimethylamino-6-methyl-pyrimidine 4-yl) piperidin-4-yl] -N-methyl-5,6,7,8-tetrahydronaphthalene-2-carboxylic acid amide
- H-238 (3R) -3 - [(2-cyclopentyl-acetyl) -amino ] -N- [1- (2,6-dimethyl-pyrimidin-4-yl) -piperidin-4-yl]
- CCJH-10 N- [7- [methyl- (1-pyridin-4-yl-piperidin-4-yl) -carbamoyl] -1,3,3,4-tetrahydronaphthalene-1-yl] -4- trifluoromethyl) -pyridine-3-carboxylic acid amide
- CC_H-14 (cyclohexanecarbonylamino) -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- CC_H-16 8 [[[2-Chloro-6- (trifluoromethyl) phenyl] sulfonyl] amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -5,6 , 7,8-tetrahydro-naphthalene-2-carboxylic acid amide
- CC_H-17 3 [[2-chloro-6- (trifluoromethyl) benzoyl] amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2, 3-dihydro-indene-5-carboxylic acid amide
- CC_H-18 3- (3-cyclopentyl-propanoylamino) -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidine
- CC_H-33 4 - [(2-Chloro-benzoyl) amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3,4-dihydro-2H-chromen-6-ene carboxylic acid amide
- CC_H-35 4 [(2,3-dichloro-benzoyl) amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3,4-dihydro-2H-chromene 6-carboxylic acid amide
- H-36 3 [(2-Chloro-5-fluoro-benzoyl) -amino] -N- [2- (1-pyridin-4-yl-piperidin-4-yl) -ethyl] -
- CC_H-55 N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-3 - [[[2- (trifluoromethyl) -phenyl] -methylsulfonyl] -amino] -2,3-dihydro- 1 H-indene-5-carboxylic acid amide
- CC_H-56 N-methyl-N- (1-pyridin-4-yl ⁇ iperidin-4-yl) -4 - [[[2- (trifluoromethyl) -phenyl] -methylsulfonyl] amino] -3,4-dihydro-2H-chromen-6-carboxylic acid amide
- CC_H-58 1- (Cyclohexanecarbonylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-59 3- (3-Cyclopentyl-propanoylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- CC_H-64 1 [(2-chloro-5-fluoro-benzoyl) -amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- CC_H-65 1- (3-Cyclopentyl-propanoylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- CC_H-69 3- (Cyclohexanecarbonyl-methyl-amino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-70 3- (3-Cyclopentyl-propanoyl-methyl-amino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene 5-carboxylic acid amide
- CC_H-78 3- (3-Cyclopentyl-propanoylamino) -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-83 3 - [(2,3-dichloro-benzoyl) -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl 2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-84 3- (3-Cyclopentyl-propanoyl-methyl-amino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3 -dihydro-1H-indene-5-carboxylic acid amide
- CC_H-100 1 - [[2- (2-chlorophenyl) -2-methyl-propanoyl] amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3- di-ydro-1H-indene-5-carboxylic acid amide
- CC_H-102 8 [[2- (2-chlorophenyl) -2-methyl-propanoyl] -amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -5,6, 7,8-tetrahydro-naphthalene-2-carboxylic acid amide
- CC_H-103 3 [[2- (2-chlorophenyl) -2-methyl-propanoyl] amino] -N- [2- (1-pyridin-4-yl] piperidine
- CC_H-104 3 [[(2-Chloro-phenyl) -methyl-carbamoyl] -amino] -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3-dihydro-1H -inde-5-carboxylic acid amide
- CC_H-1 13 N-Methyl-1- (3-methylbutanoylamino) -N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-123 3- (cyclohexanecarbonylamino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -
- CC_H-132 3- (3-Methylbutanoylamino) -N- [2- (1-pyridin-4-yl-piperidin-4-yl) -ethyl] -2,3-dihydro-1H-indene-5 carboxylic acid amide
- CC_H-134 3 [[[2-Chloro-6- (trifluoromethyl) -phenyl] sulfonyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidine-4 -yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-141 N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3 - [[[2- (trifluoromethyl) -phenyl] -methylsulfonyl] -amino] -2,3-dihydro- 1 H-indene-5-carboxylic acid amide
- CC_H-142 3 [[(2-Chloro-phenyl) -methyl-carbamoyl] -amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl- 2,3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-143 1 - [[[2-chloro-6- (trifluoromethyl) phenyl] sulfonyl] amino] -N-methyl-N- (1-pyridine -4-yl-piperidin
- CC_H-205 3- (Cyclopropanecarbonylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-206 3- (3,3-Dimethylbutanoylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5 carboxylic acid amide,
- CCJH-21 1 3- (Cyclohexanecarbonyl-methyl-amino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-212 3- (Cyclopropanecarbonyl-methyl-amino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide .
- CC_H-213 3- (3,3-Dimethyl-butanoyl-methylamino) -N-methyl-N- (1-pyridin-4-yl-piperidine
- CC_H-214 3 [(2-methoxy-acetyl) -metyl-amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- CC_H-215 3- (acetylmethylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-
- CC_H-217 3 [[(2-Chloro-phenyl) -carbamoyl] -methyl-amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-1 H-indene-5-carboxylic acid amide,
- CC_H-220 3 [[(2,3-dichloro-phenyl) -carbamoyl] -methyl-amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3 -dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-221 3 [[(2,5-dichloro-phenyl) -carbamoyl] -methyl-amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3 -dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-226 3- (Cyclopropanecarbonylamino) -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-indene-5-carboxylic acid amide,
- CC_H-227 3- (3,3-Dimethyl-butanoylamino) -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-indene-5 -carboxylic acid amide,
- CC_H-228 3 [(2-methoxy-acetyl) -amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -
- CC_H-229 3-acetylamino-N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-indene-5-carboxylic acid amide,
- CC_H-231 3 [[2-chloro-3- (trifluoromethyl) benzoyl] amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2, 3-dihydro-indene-5-carboxylic acid amide,
- CCJH-236 3 [[(2,5-dichloro-phenyl) -carbamoyl] -amino] -N, 1,1-tris-diethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2, 3-dihydro-indene-5-carboxylic acid amide,
- CC_H-237 3 [[(3,5-dichloro-phenyl) -carbamoyl] -amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2, 3-dihydro-indene-5-carboxylic acid amide,
- CC_H-238 3 - [[(2,4-dichlorophenyl) -carbamoyl] amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3- dihydro-indene-5-carboxylic acid amide,
- CC_H-239 3 [[[2-Chloro-5- (trifluoromethyl) -phenyl] -carbamoyl] -amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl ) -2,3-dihydro-indene-5-carboxylic acid amide, CC_H-240 3 - [[[4-chloro-2- (trifluoromethyl) -phenyl] -carbamoyl] -amino] -N, 1,1-trimethyl-N - (1-pyridin-4-yl-piperidin-4-yl) -2,3-dihydro-indene-5-carboxylic acid amide, CC_H-241 3 - [[(3-chloro-4-methyl-phenyl) -carbamoyl ] amino] -N, 1,1-trimethyl-N- (1-pyridin
- CC_H-245 3 [[(2-Chlorophenyl) -metyl-carbamoyl] -amino] -N, 1,1-trimethyl-N- (1-pyridin-4-yl-piperidin-4-yl) -2,3 dihydro-indene-5-carboxylic acid amide,
- CC_H-274 4- (Cyclopropanecarbonylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3,4-dihydro-2H-chromen-6-carboxylic acid amide,
- CC_H-275 4- (3,3-Dimethyl-butanoylamino) -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3,4-dihydro-2H-chromen-6-carboxylic acid amide,
- CC_H-277 4-Acetylamino-N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3,4-dihydro-2H-chromen-6-carboxylic acid amide,
- CC_H-283 4 - [[(2,5-dichloro-phenyl) -carbamoyl] -amino] -N-methyl-N- (1-pyridin-4-yl-piperidin-4-yl) -3,4-dihydro- 2H-chromene-6-carboxylic acid amide,
- CC_H-294 3 [(2-chloro-5-fluoro-benzoyl) -amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl- 2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-302 N- [1- (2,6-Dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-3 - [[[2- (trifluoromethyl) -phenyl] -methylsulfonyl] -amino ] -2,3-dihydro-1H-indene-5-carboxylic acid amide, CC_H-303 3 - [[2-chloro-3- (trifluoromethyl) benzoyl] amino] -N- [1- (2,6- dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-304 3 [[(2-chlorophenyl) -carbamoyl] amino] -N- [1- (2,6-dimethylpyridin-4-yl) -piperidin-4-yl] -N-methyl-2, 3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-305 3 [[(3-chlorophenyl) carbamoyl] amino] - N - [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2, 3-dihydro-1H-indene-5-carboxylic acid amide
- CC_H-306 3 [[(2,6-dichloro-phenyl) -carbamoyl] -amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N- methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-313 3 [[(3-Chloro-4-methyl-phenyl) -carbamoyl] -amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] - N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide, CC_H-314 3 - [[(3-chloro-4-fluoro-phenyl) -carbamoyl] -amino] -N- [1- ( 2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-317 3 [[(2,4-dichlorophenyl) -methyl-carbamoyl] -amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N- methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide, CC_H-318N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl- 3- (3-methylbutanoylamino) -2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-320 3- (3-Cyclopentyl-propanoylamino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1 H-indene-5-carboxylic acid amide,
- CC_H-328 3 [(2,5-dichloro-benzoyl) -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl 2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-329 3- [t 2 -chloro-6- (trifluoromethyl) -benzoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] - N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-330 3- (Cyclohexanecarbonyl-methyl-amino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-di-dehydro 1 H-indene-5-carboxylic acid amide,
- CC_H-331 3- (Cyclopropanecarbonyl-methyl-amino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1 H-indene-5-carboxylic acid amide,
- CC_H-332 3- (3,3-Dimethyl-butanoyl-methylamino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2 , 3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-334 3- (Acetylmethylamino) -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1 H-indene-5-carboxylic acid amide,
- CC_H-335 3 [[(2-Chloro-6-methyl-phenyl) -sulfonyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl ] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-336 3 [[(2-Chloro-phenyl) -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethylpyridin-4-yl) -piperidin-4-yl] -N-methyl 2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-338 3 [[(2,6-dichloro-phenyl) -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide, CC_H-339 3 - [[(2,3-dichloro-phenyl) -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridine]
- CC_H-344 3 - [[[4-chloro-2- (trifluoromethyl) -phenyl] -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidine] 4-yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-345 3 - [[(3-Chloro-4-methyl-phenyl) -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidine-4- yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-346 3 [[(3-Chloro-4-fluoro-phenyl) -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidine-4- yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-348 3 [[(5-Chloro-2-methoxy-phenyl) -carbamoyl] -methyl-amino] -N- [1- (2,6-dimethyl-pyridin-4-yl) -piperidine-4- yl] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-354 3- (3-Cyclopentyl-propanoyl-methyl-amino) -N- [1- (2,6-dimethylpyridin-4-yl) -piperidin-4-yl] -N-methyl-2,3 -dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-358 3 - [(2-chloro-6-fluoro-3-methylbenzoyl) amino] -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3- dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-362 3- (3,3-dimethylbutanoylamino) -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-
- CC_H-374 3 [[(5-chloro-2-methoxy-phenyl) -carbamoyl] -amino] -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3- dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-376 3 - [[(2,4-dichlorophenyl) -methyl-carbamoyl] -amino] -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3-dihydro- 1H-indene-5-carboxylic acid amide,
- CC_H-381 3- (3-Cyclopentyl-propanoylamino) -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide .
- CC_H-382 3 - [(ethylsulfonyl) amino] -N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-383 N- (1-isoquinolin-6-yl-piperidin-4-yl) -N-methyl-3 - [[[3- (trifluoromethyl) -phenyl] -methylsulfonyl] -amino] -2,3-dihydro-1 H-indene-5-carboxylic acid amide, CC_H-384 3 - [[(2-fluorophenyl) methylsulfonyl] amino] -N- (1-isoquinolin-6-yl-piperidin-4-yl) -
- CC_H-613 3- (3-cyclopentyl-propanoylamino) -N-methyl-N- [1- (2-methylsulfonyl-pyrimidine
- CC_H-615 4- [4 - [[3- (3-cyclopentyl-propanoylamino) -2,3-dihydro-1H-indene-5-carbonyl] -methyl-amino] -piperidin-1-yl] -N, N-dimethyl-pyridine-2-carboxylic acid amide, CC_H-616 N- [1- (2-tert-butyl-pyrimidin-4-yl) -piperidin-4-yl] -3 - [(2-chloro-benzoyl) amino] -N-methyl-2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-620 3- (3-Cyclopentyl-propanoylamino) -N-methyl-N- [1- (2-pyrrolidin-1-yl-pyrimidine
- CC_H-624 N- [1- (2-tert-Butyl-pyrimidin-4-yl) -piperidin-4-yl] -3- (3-cyclopentyl-propanoylamino) -N-methyl-2,3-dihydro-1H -inde-5-carboxylic acid amide, CC_H-626 3- (3-Cyclopentyl-propanoylamino) -N-methyl-N- [4- (5-methyl-3-oxo-1,2-dihydro-imidazo [5,1-e] -imidazol-2-yl ) -cyclohexyl] -2,3-dihydro-1H-indene-5-carboxylic acid amide,
- CC_H-629 3- (3-Cyclopentyl-propanoylamino) -N- [1- (2-dimethylamino-pyrimidin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H- indene-5-carboxylic acid amide,
- CC_H-630 3- (3-Cyclopentyl-propanoylamino) -N- [1- (2-cyclopropyl-pyrimidin-4-yl) -piperidin-4-yl] -N-methyl-2,3-dihydro-1H- indene-5-carboxylic acid amide,
- CC_H-632 3- (3-Cyclopentyl-propanoylamino) -N- [1- (5-fluoro-pyrimidin-4-yl) -piperidin-4-yl] -
- CC_H-633 3 - [(2-Chlorobenzoyl) amino] -N-methyl-N- (1-pyridazin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5 -carboxylic acid amide and
- CC_H-634 3- (3-Cyclopentyl-propanoylamino) -N-methyl-N- (1-pyridazin-4-yl-piperidin-4-yl) -2,3-dihydro-1H-indene-5-carboxylic acid amide , in the form of free compounds; the tautomers; the N-oxides; the racemate; of the
- the compounds according to the invention have an antagonistic effect both on the human B1R receptor (hB1R) and on the B1R receptor of the rat (rB1R).
- the compounds according to the invention have an inhibition of at least 15%, 25%, 50% in the FLIPR assay at a concentration of 10 ⁇ at the human B1R receptor and / or at the B1R receptor of the rat. 70%, 80% or 90% up.
- the agonistic or antagonistic effect of substances can on the bradykinin receptor 1 (B1R) of the species human and rat using ectopically expressing cell lines (CHO K1 cells) and with the aid of a Ca 2+ -sensitive dye (Fluo-4) in the Fluorescent Imaging Plate Reader (FLIPR).
- B1R bradykinin receptor 1
- FLIPR Fluorescent Imaging Plate Reader
- the indication in% activation is based on the Ca 2+ signal after addition of Lys-Des-Arg 9 -bradykinin (0.5 nM), or des-Arg 9 -bradykinin (100 nM).
- Antagonists lead to a suppression of Ca 2+ influx after the addition of the agonist. Indicated are% inhibition compared to the maximum achievable inhibition.
- the substances according to the invention act, for example, on the im
- Another object of the invention are therefore medicaments containing at least one compound of the invention, and optionally suitable additives and / or auxiliaries and / or optionally other active ingredients.
- the medicaments according to the invention optionally contain suitable additives and / or adjuvants, as well
- Carrier materials, fillers, solvents, diluents, dyes and / or binders can be administered as liquid dosage forms in the form of injection solutions, drops or juices, as semi-solid dosage forms in the form of granules, tablets, pellets, patches, capsules, patches / spray patches or aerosols ,
- excipients etc. as well as the amounts to be used depend on whether the drug is oral, peroral, parenteral, intravenous, intraperitoneal, intradermal, intramuscular, nasal, buccal, rectal or topical, for example on the skin, mucous membranes or in the eyes, to be applied.
- preparations in the form of tablets, dragees, capsules, granules, drops, juices and syrups are suitable; for parenteral, topical and inhalative administration, solutions, suspensions, Constituable dry preparations and sprays.
- Substituted compounds according to the invention in a depot, in dissolved form or in a plaster, optionally with the addition of main-promoting agents, are suitable percutaneous agents
- Substituted compounds according to the invention may also be present in parenteral
- the amount of drug to be administered to the patient varies depending on the weight of the patient, the mode of administration, the indication and the severity of the disease. Usually 0.00005 to 50 mg / kg, in particular 0.01 to 5 mg / kg of at least one compound according to the invention are administered.
- a substituted compound according to the invention present is optionally present as a pure diastereomer and / or enantiomer, as a racemate or as a non-equimolar or equimolar mixture of the diastereomers and / or enantiomers.
- the person skilled in suitable methods for the separation of stereoisomers are known.
- substituted compounds according to the invention can be used in particular for the preparation of a medicament for the treatment of pain, in particular of acute, visceral, neuropathic or chronic pain or inflammatory pain.
- Another object of the invention is therefore the use of at least one substituted compound according to the invention for the manufacture of a medicament for the treatment of pain, in particular of acute, visceral, neuropathic or chronic pain.
- a specific embodiment of the present invention is the use of at least one of the substituted compounds of the invention for the manufacture of a medicament for the treatment of inflammatory pain.
- the invention also provides the use of at least one substituted compound according to the invention for the treatment of pain, in particular of acute, visceral, neuropathic or chronic pain or inflammatory pain.
- Another object of the invention is the use of at least one substituted according to the invention for the manufacture of a medicament for the treatment of diabetes, respiratory diseases, for example bronchial asthma, allergies, COPD / chronic obstructive pulmonary disease or cystic fibrosis; inflammatory bowel disease, for example, ulcerative colitis or CD / Crohn's disease;
- neurological diseases for example multiple sclerosis, neurodegenerative diseases, fibrotic diseases, inflammation of the skin, for example atopic dermatitis, psoriasis or bacterial infections; rheumatic diseases,
- rheumatoid arthritis or osteoarthritis for example rheumatoid arthritis or osteoarthritis; septic shock;
- Reperfusion syndrome for example after heart attack or stroke, obesity; and as an angiogenesis inhibitor.
- the invention also provides the use of at least one substituted compound according to the invention for the treatment of one of the aforementioned indications.
- a substituted compound used is present as a pure diastereomer and / or enantiomer, as a racemate or as a non-equimolar or equimolar mixture of the diastereomers and / or enantiomers.
- Another object of the invention is a method for the treatment, in particular in one of the aforementioned indications, of a non-human mammal or human, which requires a treatment of the corresponding indication, by administering a therapeutically effective dose of a substituted compound or a medicament according to the invention.
- Another object of the invention is a method for the treatment of pain, in particular one of the aforementioned types of pain, a non-human mammal or human, or a treatment, in particular pain, especially of acute, visceral, neuropathic or chronic pain or
- Inflammatory pain is required by administering a therapeutically effective dose of a substituted compound of the invention or a pharmaceutical composition of the invention.
- Another object of the invention is a process for the preparation of
- Aryl zinc compounds e.g. after (Ref No. 5) Takahashi, Hideki; Inagaki, Shinya; Nishihara, Yasushi; Shibata, Takanori; Takagi, Kentaro; Organic Letters; Vol. 8; (2006); p. 3037-3040, from aldehydes e.g. after (Ref No. 6) Kotake, Yoshihiko; lijima, Atsumi; Yoshimatsu, Kentaro; Tamai, Naoko; Ozawa, Yoichi; et al .; Journal of Medicinal Chemistry; Vol. 37; (1994); p. 1616-1624, from arylboronic acids e.g. after (Ref No. 7) Horiguchi, Hakaru; Tsurugi, Hayato;
- ester derivatives of (I) are obtained by these methods, which are then converted to the step (j) in the acids (I).
- Acids of the general formula (II) can be prepared by methods known from the literature, e.g. by oxidation (Ref No. 10) Matveeva, E. D .; Podrugina, T.A .; Zefirova, O. N .; Alekseyev, A. S .; Bachurin, S. O .; Pellicciari, R .; Zefirov, N.S .; Russian Journal of Organic Chemistry; vol. 38; (2002); p. 1764-1768, by carbonyl insertion (Ref. No. 11) WO2005 / 95387 (A1) and (Ref No. 12) Takeuchi, Ryo; Yasue, Hiroyuki; Journal of Organic Chemistry; Vol.
- step (d) acids of the general formula (II) are prepared by a literature method (see (a) Protecting Groups, Philip J. Kocienski, Thieme, Stuttgart, 3rd Revised Edition (14 February 2005) (b) Protective Groups in Organic Synthesis, Theodora W. Greene and Peter GM Wuts, Wiley &Sons; 4th Edition (October 30, 2006)) into an ester preferably selected from the group consisting of methyl, ethyl, isopropyl and tert-butyl esters of the general formula (III), transferred.
- step (e) ketones of the general formula (III) are dissolved in at least one solvent, preferably selected from the group consisting of water, dichloromethane,
- At least one inorganic base preferably selected from the group consisting of potassium hydride, potassium carbonate, sodium carbonate, cesium carbonate, sodium hydroxide, and sodium acetate, or an organic base, preferably selected from the group consisting of triethylamine, diisopropylethylamine and pyridine, at temperatures of preferably -15 ° C to 100 ° C to give compounds of general formula (IV).
- step (f) hydroxylamines of the general formula (IV) in at least one
- Solvent preferably selected from the group consisting of dichloromethane, chloroform, dimethylformamide, diethyl ether, dioxane, tetrahydrofuran, water, methanol, ethanol and isopropanol with at least one reducing agent preferably selected from the group consisting of lithium aluminum hydride, sodium borohydride, lithium borohydride, sodium, sodium amalgam and zinc optionally in the presence of at least one acid or Lewis acid, preferably selected from the group consisting of hydrochloric acid, sulfuric acid, acetic acid and titanium tetrachloride at temperatures of preferably -15 ° C to 100 ° C to give compounds having the general formula (VI).
- at least one reducing agent preferably selected from the group consisting of lithium aluminum hydride, sodium borohydride, lithium borohydride, sodium, sodium amalgam and zinc optionally in the presence of at least one acid or Lewis acid, preferably selected from the group consisting of hydrochloric acid, sulfuric acid, acetic acid and titanium
- hydroxylamines of the general formula (IV) in step (f) may also be present in at least one solvent, preferably selected from the group consisting of chloroform, ethyl acetate, dimethylformamide, diethyl ether, dioxane, tetrahydrofuran,
- at least one catalyst preferably selected from the group consisting of rhodium on carbon, palladium on carbon, palladium black, Raney nickel and platinum oxide
- at least one acid Preferably selected from the group consisting of hydrochloric acid, sulfuric acid and acetic acid at temperatures of preferably 0 ° C to 50 ° C are converted to compounds having the general formula (VI).
- Step (k) are obtained, wherein Pg preferably Boc corresponds.
- Pg preferably Boc corresponds.
- Tetra hydrofu ran dimethyl sulfoxide, methanol and ethanol or mixtures of these
- step (g) amines of the general formula (VI) are prepared by a literature method (see (a) Protecting Groups, Philip J. Kocienski, Thieme, Stuttgart, 3rd Revised Edition (14 February 2005) (b) Protective Groups in Organic Synthesis, Theodora W. Greene and Peter GM Wuts, Wiley &Sons; 4th Edition (October 30, 2006)) with appropriate protecting groups (Pg), preferably selected from the group consisting of tert-butyloxycarbonyl (Boc) and benzylcarbamate (Cbz) Mistake.
- Pg protecting groups
- step (h) are amines of general formula (VI) or (XII), in at least one solvent, preferably selected from the group consisting of dichloromethane, acetonitrile, dimethylformamide, diethyl ether, dioxane, tetrahydrofuran, methanol, Ethanol and isopropanol with acid chlorides or sulfonyl chlorides, in the presence of at least one inorganic base, preferably selected from the group consisting of
- Potassium carbonate and cesium carbonate or an organic base, preferably selected from the group consisting of triethylamine, diisopropylethylamine and pyridine and optionally with the addition of 4- (dimethylamino) pyridine or 1-hydroxybenzotriazole, at temperatures of preferably -15 ° C to 50 ° C. converted into compounds of the general formula (VII) or (IX).
- step (h) instead of the carboxylic acid chlorides and the corresponding carboxylic acids are used.
- R'OH wherein R 'has the meaning given above, are used in at least one
- Solvent preferably selected from the group consisting of dichloromethane,
- Cesium carbonate or an organic base, preferably selected from the group consisting of triethylamine, diisopropylethylamine and pyridine and optionally with the addition of 4- (dimethylamino) pyridine or 1-hydroxybenzotriazole to give compounds having the general formula (VII) or (IX) ,
- Cyclic amidic systems are synthesized in step (h) in analogy to rules known from the literature, e.g. (Ref 14) Bioorganic & Medicinal Chemistry Letters 17 (2007) 428-433 and (ref 15) Bioorganic & Medicinal Chemistry Letters 17 (2007) 424-427.
- the step (h) can be carried out in two steps.
- first the amines of the general forms (VI) or (XII) are converted into the corresponding alkylated amines before the second step is carried out analogously to the above-described methods 1) or 2) for the step (h).
- the alkylated amines are either by
- Reaction of the amines of the general forms (VI) or (XII) with aldehydes or ketones in at least one organic solvent preferably from the group consisting of diethyl ether, tetrahydrofuran, methanol, ethanol, dichloroethane, dichloromethane and toluene, with the addition of at least a reducing agent, preferably from the group consisting of borane-pyridine complex, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride and triethylsilane optionally in the presence of at least one acid, preferably selected from the group consisting of formic acid, acetic acid, hydrochloric acid and trifluoroacetic acid at temperatures of preferably -70 ° C to 100 ° C, or by reacting the amines of the general forms (VI) or (XII) with halides, preferably bromides or iodides, or sulfonates, preferably mesy
- At least one suitable base preferably sodium hydride or
- Potassium carbonate in at least one organic solvent, preferably from the group consisting of THF, DMSO and DMF at temperatures of preferably -70 ° C to 100 ° C.
- step (i) compounds of the general formula (V) or (VII) are dissolved in at least one solvent, preferably selected from the group consisting of water,
- Dimetylformamide, dioxane and dimethyl sulfoxide with an inorganic base preferably selected from the group consisting of lithium hydroxide, sodium hydroxide, potassium hydroxide, Kaliumtertbutanolat, lithium propanethiolate and sodium phenylselenolat, optionally with the addition of HMPA or lithium chloride or with a Lewis acid, preferably selected from the group consisting of trimethylsilyl chloride, boron tribromide and
- Aluminum trichloride optionally with the addition of thiols, sodium iodide or lithium chloride, reacted at temperatures of preferably 0 ° C to 100 ° C to give compounds of general formula (VIII) or (X).
- step () compounds of the general formula (X) or (VIII) in at least one solvent, preferably selected from the group consisting of
- step (k) the amine protecting groups (Pg) are prepared from molecules of the general formula (XI) by a method known from the literature (see (a) Protecting Groups, Philip J. Kocienski, Thieme, Stuttgart, 3rd Revised Edition (February 14, 2005) (b) Protective Groups in Organic Synthesis, Theodora W. Greene and Peter GM Wuts, Wiley &Sons; 4th Edition (30.
- step (k) the compounds of general formula (XI) in at least one solvent, preferably selected from the group consisting of water, methanol, ethanol, isopropanol, diethyl ether, tetrahydrofuran, acetonitrile, dioxane, Dimetylformamid and dimethyl sulfoxide with an acid, preferably selected from the group consisting of trifluoroacetic acid, sulfuric acid and hydrochloric acid or acetyl chloride / methanol at temperatures of preferably 0 ° C to 80 ° C to
- step (o) the amine protecting groups (Pg) (preferably Boc, Cbz, Bn, PMB) are prepared from the corresponding compounds by a method known from the literature (see (a) Protecting Groups, Philip J. Kocienski, Thieme, Stuttgart, 3rd Revised Edition (February 14, 2005) (b) Protective Groups in Organic Synthesis, Theodora W. Greene and Peter GM Wuts, Wiley &Sons; 4th Edition (October 30, 2006)).
- Pg amine protecting groups
- step (o) the corresponding compounds are in at least one solvent, preferably selected from the group consisting of water, methanol, ethanol, isopropanol, diethyl ether, tetrahydrofuran, acetonitrile, dioxane, dimethylformamide and dimethyl sulfoxide with an acid , preferably selected from the group consisting of trifluoroacetic acid, sulfuric acid and hydrochloric acid or
- Acetyl chloride / methanol reacted at temperatures of preferably 0 ° C to 80 ° C to the corresponding deprotected compounds.
- step (I) compounds of general formula (XIII) in at least one
- Solvent preferably selected from the group consisting of ethanol, methanol, n-butanol, iso-propanol, 2-butanone, DMSO, diethyl ether, water, benzene, toluene, THF, DCM, acetonitrile, acetone, DMF and pentane with boronic acids, iodide , Bromide, chloride or mesylate compounds, optionally with the addition of at least one base, preferably selected from the group consisting of potassium hydroxide, sodium hydroxide,
- potassium carbonate optionally in aqueous or alcoholic solution, potassium carbonate,
- Sodium ethoxide, sodium tert-butoxide and diisopropylethylamine optionally with the addition of an adjuvant, preferably selected from the group consisting of 18-crown-6, 15-crown-5, terabutylammonium bromide or sulphate,
- Benzyltriethyiammonium chloride, 1-n-butyl-3-methylimidazolium tetrafluoroborate and DMAP optionally with the use of a catalyst, preferably selected from the group consisting of Pd (pyclohexyl 3 ) 2 Cl 2 , Pd 2 (dba) 3l Ni (OAc) 2 , Cu (OAc ) 2 , optionally using a ligand, preferably selected from the group consisting of P (o-tolyl) 3 , P (1, 1'-bis (diphenylphosphino) ferrocene, 2,2'-bipyridine, P (tri-o-tolylphosphine) 3 to Implemented compounds of general formula (XIV).
- a catalyst preferably selected from the group consisting of Pd (pyclohexyl 3 ) 2 Cl 2 , Pd 2 (dba) 3l Ni (OAc) 2 , Cu (OAc ) 2
- compounds of the general formula (XIV) are obtained by reacting compounds of the general formula (XIII) with iodide, bromide, chloride or mesylate compounds under Buchwald-Hartwig conditions.
- step (m) will be compounds of general formula (XIII) with aldehydes of the general formula R b CHO, or ketones of the general formula R b COR ° wherein R b and R c have the abovementioned meanings, in at least one organic
- Solvent preferably from the group consisting of diethyl ether, tetrahydrofuran, methanol, ethanol, dichloroethane, dichloromethane and toluene, with the addition of at least one reducing agent, preferably from the group consisting of borane-pyridine complex, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride and triethylsilane, optionally in the presence at least one acid, preferably selected from the group consisting of formic acid, acetic acid, hydrochloric acid and trifluoroacetic acid at temperatures of preferably -70 ° C to 100 ° C to give compounds of general formula (XVI).
- at least one reducing agent preferably from the group consisting of borane-pyridine complex, sodium borohydride, sodium triacetoxyborohydride, sodium cyanoborohydride and triethylsilane
- at least one acid preferably selected from the group consisting of formic acid, ace
- step (n) amines of the general formula (XIII), in at least one
- Solvents preferably selected from the group consisting of dichloromethane, acetonitrile, dimethylformamide, diethyl ether, dioxane, tetrahydrofuran, methanol, ethanol and isopropanol with acid chlorides R d COCI, or sulfonyl chlorides R d S0 2 CI, or isocyanates R d NCO wherein R d has the abovementioned meaning, in the presence of at least one inorganic base, preferably selected from the group consisting of
- Potassium carbonate and cesium carbonate or an organic base, preferably selected from the group consisting of triethylamine, diisopropylethylamine and pyridine and optionally with the addition of 4- (dimethylamino) pyridine or 1-hydroxybenzotriazole, at temperatures of preferably -15 ° C to 50 ° C. converted into compounds of general formula (XVIII).
- step (n) instead of the carboxylic acid chlorides and the
- R d C0 2 H, wherein R d has the meaning given above, in at least one
- Solvent preferably selected from the group consisting of dichloromethane,
- Cesium carbonate, or an organic base preferably selected from the group consisting of triethylamine, diisopropylethylamine and pyridine and optionally with the addition of 4- (dimethylamino) pyridine or 1-hydroxybenzotriazole to give compounds of general formula (XVIII).
- step (p) compounds of the general formula (XX) with amines of the general formula R e NHR f in which R e and R f have the abovementioned meanings, in at least one organic solvent, preferably from the group consisting of diethyl ether, tetrahydrofuran, Methanol, ethanol, dichloroethane, dichloromethane and toluene, with the addition of at least one reducing agent, preferably from the group consisting of borane-pyridine complex, sodium borohydride, sodium triacetoxyborohydride,
- step (q) will be compounds of general formula (XX) in at least one organic solvent, preferably from the group consisting of diethyl ether, tetrahydrofuran, methanol, ethanol, dichloroethane, dichloromethane and toluene, with the addition of at least one reducing agent, preferably from the group consisting of
- Sodium cyanoborohydride, diborane, and triethylsilane Selectride ® optionally in the presence of at least one acid, preferably selected from the group consisting of formic acid, acetic acid, hydrochloric acid and trifluoroacetic acid at temperatures of preferably -25 ° C to 100 ° C to give compounds of the general formula (XXIII) implemented.
- step (r) compounds of general formula (XXIII) are converted to compounds of general formula (XXIV) by introduction of a suitable leaving group, such as, for example, halogen or mesylate, and subsequent reaction with alcohols.
- a suitable leaving group such as, for example, halogen or mesylate
- Trifluoromethylsulfonyl chloride Trifluoromethylsulfonyl chloride, tolylsulfonyl chloride and at least one base, preferably selected from the group consisting of cesium carbonate, calcium carbonate,
- Potassium carbonate, triethylamine, diisopropylethylamine and pyridine are converted at temperatures of preferably 0 ° C to 80 ° C in the corresponding mesylates.
- These are in at least one solvent, preferably selected from the group consisting of dichloromethane, dioxane, diethyl ether, tetrahydrofuran, acetonitrile, toluene and
- step (r) compounds of the general formula (XXIV) in a
- Mitsunobu reaction can be prepared from compounds of general formula (XXIV).
- stage (r) can be carried out analogously to stage (t).
- step (s) the carbonyl compounds (XX) with organometallics, typically Li or Mg organyls (Grignard) in solvents such as toluene, benzene, hexane, pentane, THF or diethyl ether, optionally with the addition of, for example CeCl 3 to the tertiary alcohols (XXVI) implemented.
- organometallics typically Li or Mg organyls (Grignard) in solvents such as toluene, benzene, hexane, pentane, THF or diethyl ether, optionally with the addition of, for example CeCl 3 to the tertiary alcohols (XXVI) implemented.
- step (u) compounds of the general formula (XXVI) in at least one solvent, preferably selected from the group consisting of methanol, ethanol, isopropanol, dichloromethane, dioxane, diethyl ether, dimethyl sulfoxide, tetrahydrofuran, acetonitrile and dimethylformamide in the presence of at least one acid, preferably selected from the group consisting of formic acid, acetic acid, hydrochloric acid,
- the agonistic or antagonistic action of substances may be due to bradykinin
- Receptor 1 (B1 R) of the human and rat species can be determined by the following assay.
- the intracellular Ca 2+ increase after administration of a B1 R agonist by means of a Ca + -sensitive dye (type Fluo-4, Molecular Probes Europe BV, Leiden Netherlands) in the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices, Sunnyvale, USA) and / or Novostar (BMG Labtech GmbH, Offenburg, Germany).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11761012.1A EP2619178A1 (fr) | 2010-09-22 | 2011-09-21 | Composés de benzamide substitués |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10010200 | 2010-09-22 | ||
PCT/EP2011/004732 WO2012038081A1 (fr) | 2010-09-22 | 2011-09-21 | Composés de benzamide substitués |
EP11761012.1A EP2619178A1 (fr) | 2010-09-22 | 2011-09-21 | Composés de benzamide substitués |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2619178A1 true EP2619178A1 (fr) | 2013-07-31 |
Family
ID=43770597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11761012.1A Withdrawn EP2619178A1 (fr) | 2010-09-22 | 2011-09-21 | Composés de benzamide substitués |
Country Status (18)
Country | Link |
---|---|
US (1) | US8680159B2 (fr) |
EP (1) | EP2619178A1 (fr) |
JP (1) | JP2013540750A (fr) |
KR (1) | KR20140000682A (fr) |
CN (1) | CN103097354A (fr) |
AR (1) | AR083167A1 (fr) |
AU (1) | AU2011304666A1 (fr) |
BR (1) | BR112013008667A2 (fr) |
CA (1) | CA2811796A1 (fr) |
CL (1) | CL2013000787A1 (fr) |
CO (1) | CO6700838A2 (fr) |
EA (1) | EA201300388A1 (fr) |
EC (1) | ECSP13012519A (fr) |
IL (1) | IL225350A0 (fr) |
MX (1) | MX2013003309A (fr) |
PE (1) | PE20131350A1 (fr) |
TW (1) | TW201217312A (fr) |
WO (1) | WO2012038081A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
US9034874B2 (en) * | 2012-07-20 | 2015-05-19 | Novartis Ag | Carbamate/urea derivatives |
CN110128406B (zh) * | 2013-04-12 | 2021-08-27 | 制药有限责任公司 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
WO2014186704A2 (fr) * | 2013-05-17 | 2014-11-20 | N30 Pharmaceuticals, Inc. | Nouveaux composés permettant le traitement de la fibrose kystique |
AU2014367781B2 (en) * | 2013-12-19 | 2019-07-04 | Eisai R&D Management Co., Ltd. | Therapeutic and/or preventive agent comprising 1-indansulfamide derivative for pain |
EP3085700B1 (fr) | 2013-12-20 | 2018-10-31 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Nouveau composé pipéridine carboxamide, procédé de préparation et utilisation associée |
KR102662215B1 (ko) | 2014-11-06 | 2024-05-02 | 비알 - 알&디 인베스트먼츠, 에스.에이. | 치환된 피라졸로(1,5-a)피리미딘 및 의학적 장애의 치료에서의 그의 용도 |
US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US20180185368A1 (en) | 2014-11-06 | 2018-07-05 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
CN105175272A (zh) * | 2015-08-31 | 2015-12-23 | 吴玲 | 制备r-5-溴-1-氨基茚满的方法 |
MX2018012208A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
MX2018012211A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirazol[1,5-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
MX2018012207A (es) | 2016-04-06 | 2019-03-28 | Lysosomal Therapeutics Inc | Compuestos de pirrol[1,2-a]pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos. |
WO2017192931A1 (fr) | 2016-05-05 | 2017-11-09 | Lysosomal Therapeutics Inc. | Imidazo[1,2-a]pyridines substituées, imidazo[1,2-a]pyrazines substituées, composés apparentés et leur utilisation dans le traitement de troubles médicaux |
SG11201809693SA (en) | 2016-05-05 | 2018-11-29 | Lysosomal Therapeutics Inc | SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS |
CN106279114B (zh) * | 2016-08-04 | 2019-01-29 | 东南大学 | 一种Taladegib的合成方法 |
JOP20190156B1 (ar) * | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
EP3366683A1 (fr) * | 2017-02-28 | 2018-08-29 | Acousia Therapeutics GmbH | Amides, acetamides et ureas cycliques pour ouvris les voies de calcium |
EP3762379A1 (fr) | 2018-03-07 | 2021-01-13 | Bayer Aktiengesellschaft | Identification et utilisation d'inhibiteurs d'erk5 |
CN114933568A (zh) * | 2022-05-24 | 2022-08-23 | 抚州润泰药业有限公司 | 一种4,6-二甲基-2-甲磺酰基嘧啶的制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1109544A4 (fr) * | 1998-09-01 | 2004-10-27 | Bristol Myers Squibb Co | Inhibiteurs de canaux potassium et leur methode d'utilisation |
KR20060036399A (ko) * | 2003-06-20 | 2006-04-28 | 암젠 인코포레이티드 | 피페라진 유도체 및 사용 방법 |
US20090253908A1 (en) | 2004-03-11 | 2009-10-08 | Glaxo Group Limited | Novel m3 muscarinic acetylchoine receptor antagonists |
MXPA06010904A (es) | 2004-03-24 | 2007-06-11 | Abbott Lab | Inhibidores de pirazol cinasa triciclicos. |
US20070032475A1 (en) * | 2005-04-15 | 2007-02-08 | Ye Xiaocong M | Novel compounds useful for bradykinin B1 receptor antagonism |
WO2007101007A2 (fr) | 2006-02-23 | 2007-09-07 | Neurogen Corporation | Heterocycles sulfonyl aryliques |
WO2007140383A2 (fr) | 2006-05-30 | 2007-12-06 | Neurogen Corporation | Sulfonamides spirocycliques et composés apparentés |
NZ575566A (en) | 2006-09-29 | 2011-05-27 | Gruenenthal Chemie | Substituted sulfonamide derivatives |
CA2666406A1 (fr) | 2006-10-16 | 2008-04-24 | Gruenenthal Gmbh | Derives de sulfonamide substitues en tant que modulateurs du recepteur de bradykinine-1 |
TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
-
2011
- 2011-09-20 TW TW100133690A patent/TW201217312A/zh unknown
- 2011-09-21 PE PE2013000618A patent/PE20131350A1/es not_active Application Discontinuation
- 2011-09-21 EA EA201300388A patent/EA201300388A1/ru unknown
- 2011-09-21 BR BR112013008667A patent/BR112013008667A2/pt not_active Application Discontinuation
- 2011-09-21 WO PCT/EP2011/004732 patent/WO2012038081A1/fr active Application Filing
- 2011-09-21 MX MX2013003309A patent/MX2013003309A/es not_active Application Discontinuation
- 2011-09-21 AU AU2011304666A patent/AU2011304666A1/en not_active Abandoned
- 2011-09-21 KR KR1020137010060A patent/KR20140000682A/ko not_active Application Discontinuation
- 2011-09-21 JP JP2013529577A patent/JP2013540750A/ja not_active Withdrawn
- 2011-09-21 CA CA2811796A patent/CA2811796A1/fr not_active Abandoned
- 2011-09-21 CN CN2011800453665A patent/CN103097354A/zh active Pending
- 2011-09-21 EP EP11761012.1A patent/EP2619178A1/fr not_active Withdrawn
- 2011-09-22 US US13/240,598 patent/US8680159B2/en not_active Expired - Fee Related
- 2011-09-23 AR ARP110103474A patent/AR083167A1/es unknown
-
2013
- 2013-03-20 IL IL225350A patent/IL225350A0/en unknown
- 2013-03-21 CL CL2013000787A patent/CL2013000787A1/es unknown
- 2013-03-21 EC ECSP13012519 patent/ECSP13012519A/es unknown
- 2013-03-22 CO CO13057218A patent/CO6700838A2/es unknown
Non-Patent Citations (1)
Title |
---|
See references of WO2012038081A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN103097354A (zh) | 2013-05-08 |
MX2013003309A (es) | 2013-04-29 |
US20120071461A1 (en) | 2012-03-22 |
CA2811796A1 (fr) | 2012-03-29 |
CL2013000787A1 (es) | 2013-09-23 |
US8680159B2 (en) | 2014-03-25 |
CO6700838A2 (es) | 2013-06-28 |
AU2011304666A1 (en) | 2013-05-02 |
IL225350A0 (en) | 2013-06-27 |
JP2013540750A (ja) | 2013-11-07 |
AR083167A1 (es) | 2013-02-06 |
EA201300388A1 (ru) | 2014-01-30 |
ECSP13012519A (es) | 2013-05-31 |
KR20140000682A (ko) | 2014-01-03 |
TW201217312A (en) | 2012-05-01 |
PE20131350A1 (es) | 2013-12-08 |
BR112013008667A2 (pt) | 2016-06-21 |
WO2012038081A1 (fr) | 2012-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2619178A1 (fr) | Composés de benzamide substitués | |
EP2066659B1 (fr) | Dérivés de sulfonamides substitués | |
US6521621B1 (en) | 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives | |
EP2356101B1 (fr) | Dérivés de pyrimidine- et de triazine-sulfonamide en tant que inhibiteurs du récepteur bradykinin (b1r) pour le traitement de la douleur | |
US9334269B2 (en) | Carboxamides as inhibitors of voltage-gated sodium channels | |
EP2393812B1 (fr) | Spiroamides substitués en tant que modulateurs du b1r | |
WO2010022055A2 (fr) | Inhibiteurs de canaux sodiques sensibles au potentiel | |
WO2010099938A1 (fr) | Tétrahydroazolopyrazines sulfonylées et leur utilisation en tant que produits médicamenteux | |
EP2350003A1 (fr) | Disulfonamides substitués en tant que modulateurs de bri | |
CN105814058B (zh) | 用作tnf活性调节剂的三唑并哒嗪衍生物 | |
JP2014516059A (ja) | 新規Syk阻害剤としての置換ピリドピラジン | |
JP2011509961A (ja) | 置換スルホンアミド誘導体 | |
CN105814043A (zh) | 用作tnf活性调节剂的三唑并吡啶衍生物 | |
JP2013508350A (ja) | ガンマ−セクレターゼモジュレーターとしての新規なヘテロアリールイミダゾールおよびヘテロアリールトリアゾール | |
DE60130910T2 (de) | Enamin-derivate als zell-adhäsionsmoleküle | |
WO2009124733A1 (fr) | Dérivés de sulfonamide substitués | |
WO2009071691A2 (fr) | Dérivés oxindoliques et leur utilisation comme médicament | |
EP2393803A1 (fr) | Composés d'indol substitués en tant que modulateurs du récepteur 1 de la bradykinine | |
JP2004505110A (ja) | 3位置換イソキノリン−1−イル誘導体 | |
JP2011516515A (ja) | 置換スルホンアミド誘導体 | |
EP2857388A1 (fr) | Azoles contenant du sulfone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130309 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1188443 Country of ref document: HK |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150401 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1188443 Country of ref document: HK |